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Chapter 1 Introduction 
 
The topic of this thesis is epilepsy in childhood. For those who are not familiar with this disorder a 
short overview will be presented of epilepsy and its possible causes. In addition, some insight of 
how many patients suffer from epilepsy and which persons are at higher risk for developing 
epilepsy will be given. One should bear in mind that epilepsy is not a single condition, but a diverse 
family of disorders, having in common an abnormally increased predisposition to seizures [1]. This 
diversity will be highlighted, as well as the consequences of having epilepsy. Next, some topics of 
international epilepsy research are presented and finally the motives for the Dutch study of epilepsy 
in childhood will be explained, followed by an overview of the study. 
 
Epilepsy is a well-known neurological disorder that is characterized by epileptic seizures. 
According to the latest definition, a person has to have at least one epileptic seizure in association 
with an enduring disturbance of the brain capable of giving rise to other seizures [1]. During a 
seizure an electrical imbalance in the brain prohibits normal functioning, and mostly causes absent 
or lowered consciousness and involuntary movements. Some patients may experience strange 
sensations, like seeing or hearing things that are not there. The majority of seizures last for about 30 
seconds to 20 minutes, and most seizures stop spontaneously. Sometimes a seizure or successive 
seizures without the return of consciousness in-between can last for at least half an hour, in which 
case we speak of a status epilepticus. Any major seizure lasting more than five minutes is a 
threatening situation and needs to be stopped to prevent damage to the brain, heart or other organs. 
 
Unlike most other illnesses and disorders, there are many causes for epilepsy. Acquired brain 
injuries which can be traumatic (accidents, physical trauma) or non-traumatic (tumor, stroke, 
infection, hypoxia) are one of the main causes. Further, one can have a genetic predisposition or a 
hereditary genetic abnormality causing specific types of epilepsy. Abnormal brain chemistry on the 
level of neurotransmitter and ion channel functioning, as well as congenital structural abnormalities 
in the brain can cause seizures, but also external factors - like alcohol, drugs, or metabolic 
disturbances, e.g. hypoglycemia or hypocalcaemia. In the latter case, we don’t speak of epilepsy, as 
mostly there is no enduring disturbance of the brain once these external factors are eliminated. 
 
We can categorize the causes of epilepsy (in other words: ‘etiology’) into idiopathic, cryptogenic 
and remote symptomatic [2]. An idiopathic etiology means that there is no underlying cause other 
than a possible hereditary predisposition. The term cryptogenic is used when the cause is presumed 
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to be symptomatic but is unknown.  A remote symptomatic etiology is the consequence of a known 
or suspected disorder of the central nervous system. This classification was proposed in the starting 
years of the Dutch study of Epilepsy in Childhood. In 2011, new terminology and concepts to 
classify etiology and epilepsies were recommended and are still under discussion [3]. 
 
Epilepsy can develop at all ages. In the Netherlands the incidence of epilepsy in 2007 was 0.52 per 
1000 males (95% CI: 0.37-0.73) and 0.46 per 1000 females (95% CI: 0.32-0.67). The point 
prevalence on January 1
st
 in that year was 7.0 per 1000 males (95% CI: 5.32-9.22) and 6.82 per 
1000 females (95% CI: 5.17-9.01) [4]. These data were based on general practitioner registrations. 
Figure 1.1 and Figure 1.2 present the incidence and prevalence of epilepsy per age-group and 
gender. These show that the incidence and prevalence are increased in childhood and in the elderly. 
In childhood, this mostly results from genetic, neurological or developmental defects and 
hypoxemia during pregnancy or delivery causing early onset of seizures. In elderly people epilepsy 
mostly results from cerebrovascular disease, primary neurodegenerative disorders, brain tumors and 
traumatic head injury [5].  
 
Figure 1.1: Incidence of epilepsy in 2007 
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Figure 1.2: Prevalence of epilepsy in 2007 
 
 
 
During childhood and adolescence, the brain is still developing and this makes childhood-onset 
epilepsy different from adult-onset epilepsy. In general, there are many types of epilepsy and 
syndromes with a diverse manifestation and course during time. Some types of epilepsy start during 
childhood such as benign Rolandic epilepsy or childhood absence epilepsy and stop before patients 
have become adults. Many other types of epilepsy start during childhood too, but most of them 
continue in adulthood. Juvenile myoclonic epilepsy for example starts between the ages 8 to 20 
years. Patients with this type of epilepsy have a lifelong risk of seizures but seizures are mostly 
well-controlled by antiepileptic drugs and by avoidance of precipitants such as lack of sleep or 
alcohol. More severe types of epilepsy are e.g. West, Dravet’s or Ohtahara syndrome, which all 
begin during infancy. In case of West syndrome the prognosis depends on the underlying cause 
which is in many cases tuberous sclerosis. Most of these patients will have mental retardation and 
continuing seizures and for some this syndrome will evolve into Lennox-Gastaut syndrome with 
multiple seizure types (mostly drop attacks) which not always respond to treatment. Dravet’s 
syndrome starts in children with a normal development. At onset most seizures are associated with 
fever. Later, most seizures are prolonged with a risk of status epilepticus, seizure frequency 
increases and more seizure types occur. Patients do not respond well to treatment and suffer from 
additional complications such as autism spectrum disorders, orthopedic or movement disorders, and 
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infections. The prognosis of patients with the syndrome of Ohtahara is very poor, with half of the 
infants dying before the age of two. Those surviving are severely mentally handicapped. 
 
Treatment of epilepsy is primarily focused on the prevention of seizures or in case this is not 
possible on the reduction of seizure frequency and severity. Several epilepsy types require specific 
treatment strategies. This calls for an accurate diagnosis and classification (mostly based on the 
description of the seizures and results of diagnostic investigations, such as EEG, CT-scan, or MRI) 
followed by an appropriate treatment.  
 
Beside the short-term physical consequences of having a seizure such as confusion, headache, or 
myalgia, patients with epilepsy are confronted with long-term consequences they have to deal with. 
The facts that they are suddenly facing a neurological disorder, have unpredictable seizures that 
influence their daily life, and need to take medication with a high chance of side-effects, may 
become very frustrating. In addition, the fear for new seizures and dying may be overwhelming. 
Beside this, epilepsy not only reduces the opportunity of getting a driver’s license, it also may have 
great impact on social well-being, the chance to make friends, find a partner, have kids, but also on 
cognitive development, education and employment. All these aspects influence a patient’s well-
being, self-esteem and quality of life and should be recognized and dealt with by the treating 
physician and other caregivers involved, such as the epilepsy nurse.  
 
The wide scale of epilepsy types and syndromes during the early years of life, together with all 
aspects of epilepsy mentioned above, make childhood-onset epilepsy an inexhaustible source for 
scientific research. Worldwide, there have been several cohort studies focusing on aspects, such as 
long-term medical prognosis of epilepsy, the risk of status epilepticus, the development of 
intractability, possible increased mortality, educational or social prognosis, and quality of life 
(Table 1.1). Another area of research is that focusing on alternative or additional treatment 
strategies for patients with epilepsy not responding to antiepileptic drugs (epilepsy surgery, 
ketogenic diet, and nervus vagus stimulation).  
 
Despite all research efforts, a lot of questions remained unanswered or the results found needed 
further confirmation. Worldwide in the years 80, for example, there was dispute on the treatment 
strategy of children with only one seizure, or when to safely stop treatment in children after 
remission. Some even reported that delaying AED-treatment might lead to an accelerating seizure 
pattern of epilepsy with a higher risk of becoming intractable [6].  
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In treatment decisions there has to be a balance between the intended prevention of seizures with 
anti-epileptic drugs and the risk of possibly severe side effects of these drugs. Exposing children to 
unnecessary treatment has to be avoided. On the other hand, stopping medication too early may 
increase the risk for recurrent seizures. It was evident at that time that more research was needed to 
solve these treatment dilemmas in children with epilepsy.  
 
The central theme in these dilemmas was predictability. Would it be possible to predict early in the 
course of the disease which children will have a favorable prognosis, permitting a more relaxed 
policy regarding starting and stopping of medication, or would it be possible to predict which 
children have a poor prognosis, probably requiring more aggressive treatment, including for 
example early referral for epilepsy surgery. In addition, there was a need for information about 
factors determining the favorable or poor prognosis of childhood-onset epilepsy, either alone or in 
combination. 
 
To answer these questions a large cohort study was needed to follow children with newly diagnosed 
epilepsy. Worldwide there were not many large cohort studies prospectively following children 
since their diagnosis of epilepsy. That's why the Dutch Study of Epilepsy in Childhood was started 
in which children who attended hospital with new-onset epilepsy were consecutively recruited 
between 1988 and 1992. In contrast to research in specialized Dutch epilepsy centers (mostly 
treating the more severe cases), this prospective cohort study was the first large study conducted in 
regular and academic hospitals in the Netherlands, and had the advantage of observing the course, 
outcome and treatment effects of ‘more average’ epilepsy in children in detail almost from the time 
of onset. The aim of the study and methods are further described in the next paragraph. 
 
The Dutch Study of Epilepsy in Childhood: 
 
Neurologists and pediatric neurologists of two university hospitals, one general and one children’s 
hospital in the western region of the Netherlands agreed to prospectively study children with at least 
one unprovoked epileptic seizure or a status epilepticus from the time of diagnosis. The objective of 
the study was four-fold and subjects could participate in more than one of the substudies:  
1. Worldwide, treatment policies differ after one unprovoked epileptic seizure. In some 
countries treatment is initiated after one seizure, while in other countries they have a wait-
and-see policy. As many children have only one epileptic seizure during lifetime, treating 
them all would mean that many of them would be treated unnecessarily and would be 
exposed to the at times severe side effects of medication. In our country a wait-and-see 
policy was standard. We followed untreated children with only one epileptic seizure to study 
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the risk of a new seizure and its possible predictors (First Seizure study). A low risk of 
recurrence would justify the no-treatment policy after a first epileptic seizure, while a high 
risk would justify treatment of all patients. Further, in this study special attention was given 
to the accuracy and reliability of the diagnosis of a first epileptic seizure and the long-term 
outcome [34, 37, 38]. These first two aspects, which are mostly neglected in other studies, 
are important as the differential diagnoses of a single paroxysmal event are numerous and 
labeling a patient as having an epileptic seizure, while in fact is was not, or vice versa, may 
have great impact on both patient and family. Finally, children who entered the study with a 
status epilepticus - defined as a seizure with a duration of at least 30 minutes or recurrent 
seizures lasting a total of more than 30 minutes without regaining consciousness in between 
- were followed separately to study their long-term outcome [35]. Analyzing causes for 
status epilepticus, risk factors, recurrence rate and outcome including mortality after a status 
epilepticus may help to improve the immediate and long-term care for these children with 
epilepsy. 
2. When children with epilepsy using anti-epileptic drugs reach remission, the question is how 
long a patient has to be seizure free before discontinuation of treatment is considered. Two 
studies (one from our country) showed that 75-80% of the children in whom medication was 
discontinued after two years reached a remission [91, 92]. Remarkably, in the study from 
Leiden, 90% of the children had a treatment response time - i.e. the interval between the 
start of medication and the beginning of the remission period - of less than two months [91]. 
Based on this, we hypothesized that a short treatment response time - and not so much the 
duration of remission - increases the chance of staying in remission after treatment 
discontinuation. In our study, children having a six-month remission period starting within 
two months after the beginning of treatment were regarded as fast-responders. They were 
randomized for either six or twelve months of treatment (Short Treatment study). We 
investigated whether a shorter treatment-duration in this group was possible without 
increasing the risk of recurrences [39]. 
3. Of all the children with epilepsy some have an inherent good prognosis, while others 
develop a chronic and therapy-resistant type of epilepsy. The question is if the first group 
needs to be exposed to the now and then severe side effects of anti-epileptic drugs, while in 
the second group the question is whether early intensive treatment might prevent therapy-
resistance. Some investigators found that the intervals between successive untreated tonic-
clonic seizures decreased, suggesting that there is an accelerating disease process in which 
seizures beget seizures, although in a later prospective study the decreasing pattern could not 
be affirmed [44]. Whether to delay or start treatment is a dilemma for the treating physician 
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in each individual patient. It would be valuable if a physician could accurately predict the 
long-term outcome of a patient in an early stage of the disease. In the Prognosis study 
which was part of the Dutch Study of Epilepsy we developed models to predict the two-year 
outcome based on information available at enrollment or on information that came available 
during the first six months of follow-up [41]. In a later stage we tested these models in a 
newly recruited cohort of children with epilepsy [93]. Further we studied the risk of 
mortality by comparing the death rate of our cohort with that of similar age-groups of the 
Dutch population in the same period [48]. 
4. The central nervous system interacts with the immune system and it might be possible that 
the immune system is involved in the pathogenesis of some types of epilepsy. Children with 
epilepsy might have abnormal serum immunoglobulin concentrations before treatment is 
started or at a later stage, in which case it is possible that these concentrations are caused by 
the use of some specific anti-epileptic drugs. Furthermore, it is possible that the serum 
immunoglobulin concentrations of children with a worse prognosis differ from those with a 
better prognosis. To investigate these aspects, serum samples of 282 unselected children of 
our cohort were taken before the start of medication and during the use of anti-epileptic 
drugs (Immunology study) [47].   
 
This prospective cohort study - known as the Dutch Study of Epilepsy in Childhood -, was 
approved by the ethical committees of the participating hospitals and was financially supported by 
the Dutch National Epilepsy Fund (grants no. A72, A85, A86), and by the Princess Irene Fund 
Arnhem. 
 
In 1988 we recruited all children aged one month to 16 years who attended hospital because of one 
or more epileptic episodes, had not been treated earlier for this, nor were referred from another 
hospital. Written informed consent was given by all parents and children of 12 years or older, not 
intellectually handicapped. All children were discussed in a panel of three neurologists. This panel 
had to decide whether the event or events were indeed of epileptic nature. Further, they had to 
classify the epileptic seizure and if possible - mostly in case of more seizures - the type of epilepsy 
and etiology. The discussions were based on the description of the episode of an eyewitness, and on 
the results of the EEGs or CT-scan if performed for the final classification. Two years after 
enrollment or after the start of medication all children were discussed again to see if the original 
diagnosis and classifications were still correct. Furthermore, they were classified using the ILAE 
classification that was not yet available at enrollment [94]. Children with a questionable diagnosis 
at enrollment were followed for one year to see if new events with a definite epileptic nature would 
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occur. In that case they were discussed again and included. After four years, enrollment stopped in 
1992. Figure 1.3 shows a flowchart of the included children. The recruitment rate of the original 
study approximated 75% of the expected annual incidence in the referral area of the participating 
hospitals. 
 
After the diagnosis was made all children were regularly seen with intervals of three to six months. 
At each visit a form was completed with questions about the date and type of seizures, medication 
changes, and complaints, if applicable. Further, results of additional investigations like blood-
plasma concentrations, liver functions, EEGs or CT-scans could be added.  
 
After the first five years with regular visits and contacts with patients, the follow-up of our cohort 
stopped. Later we decided to contact the cohort again, and between 2004 and 2006 we sent a 
questionnaire with items concerning epilepsy to 453 subjects with a five-year follow-up (Appendix 
1). Questions included dates of last seizure, use of medication, dates of discontinuation of 
medication, health perception, other affections, disorders or restrictions due to epilepsy. We were 
also interested in the living arrangements of the subjects, and in addition their educational and 
occupational achievement. After some reminders and telephone contacts, 413 subjects returned their 
completed questionnaire. The response rate based on the original 494 subjects was 84%. 
 
The main objective of the present thesis is to study the course and long-term outcome of childhood-
onset epilepsy in terms of remission, intractability and mortality, as well as socioeconomic status. 
The second objective was to develop statistical models to be able to predict outcome for an 
individual person. By extending the follow-up of the original cohort, beside the long-term outcome, 
the consequences of epilepsy other than having seizures could be investigated.  
 
Subjects in this cohort with a fast response to medication were randomized for either six months or 
twelve months of treatment (Short Treatment study). The objective of this trial was to investigate 
whether the duration of treatment could be reduced in fast responders without increasing the risk of 
new seizures. Their outcome at four years after randomization is described in Chapter 2. 
 
Of the original cohort, 453 subjects had a follow-up of five years. The course of their epilepsy 
during these years is described in Chapter 3 (Prognosis study). In addition, we present two models 
predicting the individual prognosis at five years of follow-up. One model is based on variables 
present at enrollment and the other on a combination of these variables and those derived during the 
first six months of follow-up.  
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Figure 1.3: Flowchart of 881 enrolled children with a possible first seizure or epilepsy 
 
  
 
 
 
About 10 years after the five-year follow-up, the 453 subjects mentioned above received a 
questionnaire for further research. Their course of epilepsy in terms of seizures and remission 
during a follow-up of almost 15 years is outlined in Chapter 4. This chapter also describes the 
mortality rate of the cohort during these years. Further, a combination of variables best predicting 
intractability is presented. Chapter 5 describes the health aspects, restrictions, living arrangements, 
and socioeconomic status of the subjects as compared with age-peers of the Dutch population.  
 
In our cohort, 9% of the subjects were intractable in the last year of follow-up, defined as having 
seizures in the last year of follow-up with remission periods of less than three months despite the 
use of adequate treatment. Because intractability is still a controversial issue in epilepsy, with 
different definitions used by several authors, we tried to depict the occurrence of intractability 
during the first five years of follow-up, time of onset, duration, and further course during the 
extended follow-up and made a comparison with intractability in the final year. We also tried to 
find explanations for the onset and discontinuation of intractability. The results of this investigation 
are presented in Chapter 6.  
Page | 20  
 
  
Page | 21  
 
Chapter 2 Four-year outcome after early withdrawal of antiepileptic drugs 
in childhood epilepsy 
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INTRODUCTION 
 
Withdrawal of antiepileptic drugs is often considered in children with epilepsy who have remained 
seizure free for at least 2 years. While early withdrawal may prevent unnecessarily prolonged 
treatment, it may increase the risk of recurrence and a poor response to renewed treatment
1
; 
however, there are few data on the long-term outcome after recurrence.
2-6
 
In an earlier prospective trial of early withdrawal (6 or 12 months) of antiepileptic drugs in children, 
the recurrence rate at 2 years after randomization was similar (49% versus 48%) in the two groups.
4
 
Here, we extended the follow-up to 4 years to determine which factors influence outcome and to 
develop a model to identify children who may benefit from early withdrawal.  
 
METHODS  
 
The design and results of the 2-year follow-up study have been reported elsewhere.
4
 Briefly, 
children aged between 1 month and 16 years with two or more unprovoked seizures or one status 
epilepticus who became seizure free within 2 months after starting treatment and remained so for 6 
months were randomized to medication withdrawal at that time (6-month group) or after another 6 
months of treatment (12-month group). 
The first recurrence after randomization determined the recurrence rate and included recurrences 
occurring in the 12-month group before the planned withdrawal. We defined terminal remission as 
the interval between the last seizure and the last day of follow-up at 4 years after randomization 
(TR4). Outcome was excellent if a TR4 of at least 2 years was reached without medication during 
these 2 years. 
Risk of recurrence was calculated using survival techniques and multiple logistic regression 
analysis. Missing values were derived by imputation. The goodness of fit of the final model was 
determined by the Pearson χ2 test. Bootstrapping techniques were used to test the internal validity of 
the model and to correct for over optimism. Regression coefficients were multiplied by the 
shrinkage factor (0.89) calculated from B = 10,000 bootstrap samples. A risk score (z) was derived 
and the chance of an excellent outcome was calculated using the formula: p (excellent) = 1/(1 + e
-z
). 
 
RESULTS  
 
We assessed the recurrence rate in 161 children and the 4-year outcome in 154 children; seven 
children with a limited follow-up after randomization were excluded (Figure 2.1).  
  
Figure 2.1: Study design, number of children analyzed, and the occurrence of first 
recurrences, medication use, and 4-year outcome in a randomized, prospective trial of 
children with newly diagnosed childhood epilepsy.  
 
 
 
 
*Patients continued antiepileptic drug (AED) because a recurrence occurred during tapering or 
before the planned discontinuation of the AED.  
#Discontinuation of AED before end of follow-up: 4 years after randomization. 
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Mean age at onset in the 154 children was 6.5 years (median 6.5 years); 76 (49.4%) were boys 
(Table E-1 on the Neurology Web site at www.neurology.org or in Appendix 2). 
Four years after randomization, 55% of the 161 children had a recurrence (Figure 2.2): 59% of the 
6-month group and 51% of the 12-month group (95% confidence interval [CI] of the difference: 
 -16% to 32%).  
 
Figure 2.2: Probability of remaining seizure free after immediate or delayed withdrawal of 
antiepileptic drug (AED) treatment in children with newly diagnosed epilepsy after 6 months 
of seizure freedom.  
 
 
Months after randomization 0 6 12 18 24 36 48 
At risk in 12-month group 83 72 55 44 43 41 36 
At risk in 6-month group 78 72 47 41 40 35 31 
 
 
Kaplan–Meier curves: lower curve = 6-month group (n = 78), upper curve = 12-month group (n = 
83). Xs in curves represent censored children. Test statistics (log-rank) for equality of the two 
survival distributions was 1.83 (df = 1, p = 0.1756). 
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Recurrence rates were equal at 2 years of follow-up, but the 6-month group had relatively more late 
recurrences. If only the children who had no seizures during the first 2 years after randomization 
were considered, the 6-month group had a recurrence rate at 4 years of 20% vs 7% in the 12-month 
group: (95% CI of the difference: -4 to 29%). Similar results were obtained if recurrence rates were 
calculated from the time medication was stopped instead of randomization. 
Seventy-eight of the 154 (51%) children had an excellent outcome (44% without and 7% after a 
recurrence); 33 (21%) had a TR4 of 2 years or more with medication during at least a part of these 2 
years; 23 (15%) had a TR4 of less than 1 year (Figure 2.1). Differences between the 6-month and 
the 12-month groups were not significant. Of the 55 children who restarted medication, 14 (25%) 
experienced seizure recurrence. Adverse events or death did not occur during the study period. Two 
children experienced a status epilepticus after withdrawal (one in each group). One child continued 
to have seizures despite restarting medication, whereas the other remained seizure free. 
 In the univariate analyses, duration of initial treatment was not significantly associated with 
outcome, whereas age at onset, number of seizures before start of medication, seizure and epilepsy 
type, etiology, EEG findings, and postictal signs before study inclusion were (Table E-1 on the 
Neurology Web site at www.neurology.org or in Appendix 2). These variables, except for number 
of seizures and epilepsy type, remained in the final predictive model (Table E-2 on the Neurology 
Web site at www.neurology.org or in Appendix 2). The sensitivity (69.2%) and specificity (76.3%) 
were highest at a cutoff p value of 0.63 (positive predictive value = 75.0%; negative predictive 
value = 70.7%). p Values above the cutoff point indicate an excellent outcome. Receiver operating 
characteristics revealed an area under the curve of 0.78. The model correctly classified 10 of the 12 
children (83%) with a predicted chance of a good outcome of <25%, 67 of the 100 (67%) with a 
predicted chance of a good outcome of 25 to 75%, and 35 of the 42 (83%) with a predicted chance 
of a good outcome of >75%. Overall, the model correctly classified 72.7% of the children. The 
chance of an excellent outcome for various combinations of predictive factors is given in Table 2.1. 
 
DISCUSSION  
 
We extended the follow-up period of our earlier clinical trial of early withdrawal of medication in 
children with epilepsy with a rapid response to antiepileptic drugs.
4
 In that study, the rate of 
recurrence at 2 years was similar between groups in which medication was withdrawn after 6 or 12 
months. In the current study, recurrence rates at 4 years after randomization were not significantly 
different (59% versus 51%), but the 6-month group had relatively more recurrences during the last 2 
years of follow-up. The relatively longer follow-up period of the 6-month group after medication 
withdrawal did not explain this difference. However, we cannot exclude that the shorter treatment  
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Table 2.1: Calculated chances (%) of an excellent outcome in  
children with epilepsy who respond to treatment within 2 months  
after start of AEDs and remain seizure free for 6 months 
 
 Age at onset, y 
Seizures  <6 ≥6 
Absence (chance, %)  87 78 
No absence (chance, %)   
     Normal EEG (no post-ictal signs)   
         Idiopathic  87 78 
         Non-idiopathic  78 66 
     Normal EEG (post-ictal signs)   
         Idiopathic  60 44 
         Non-idiopathic  45 30 
     Abnormal EEG (no post-ictal signs)   
         Idiopathic  63 48 
         Non-idiopathic  48 34 
     Abnormal EEG (post-ictal signs)   
         Idiopathic  28 17 
         Non-idiopathic  18 10 
All combinations of variables based on the predictive multivariate 
model are shown. Confidence intervals after shrinkage cannot 
be calculated but will be wide for most estimates. 
 
 
was responsible for these late recurrences. The overall recurrence rate of 55% at 4 years after 
randomization is higher than that of other studies, probably because of patient selection. While most 
withdrawal studies included only children who had been seizure free for 2 years, thereby excluding 
children with a poorer prognosis, we included such children. 
Outcome after early withdrawal was excellent in 51% of the children. These children had a terminal 
remission of at least 2 years without medication, and hence unnecessary treatment was prevented 
for 12 to 18 months. There were no adverse effects. However, 15% of children had a TR4 shorter 
than 1 year and 25% did not become seizure free after restarting medication. Failure of renewed 
treatment may be a serious risk of early withdrawal, but our results are comparable with those of 
other studies of withdrawal after at least 2 years of treatment.
2,3,6
 Moreover, children on continuous 
medication may also have recurrences during longer follow-up.
7
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We found that age at onset younger than 6 years, idiopathic etiology, having only absences, lack of 
postictal signs, and normal EEG findings were significant predictors of an excellent outcome, as 
reported previously
1-3,8-10
 and are comparable with indicators for good outcome of childhood 
epilepsy in general.
7
 Thus, it may be more appropriate to consider in which patients medication can 
be stopped safely than when medication can be stopped. Our model had a fair validity in predicting 
which children would have an excellent outcome, but the clinical validity of the model should be 
tested further. 
We did not compare early withdrawal with the standard withdrawal protocol (2-year seizure-free 
interval) and hence cannot comment on the possible (dis)advantages of early withdrawal. While we 
cannot recommend early withdrawal in all children with a rapid response to antiepileptic 
medication, our findings suggest that early withdrawal should be considered in a large proportion of 
such children. Our predictive model discriminated between children with a good versus poor chance 
of attaining an excellent outcome. 
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ABSTRACT 
 
Knowing the prognosis of epilepsy will undoubtedly influence the treatment strategy. This study 
aimed to define the prospects of newly diagnosed childhood epilepsy, assess the dynamics of its 
course, identify relevant variables and develop models to assess the individual prognosis. Four 
hundred and fifty-three children with newly diagnosed epilepsy were followed for 5 years. Terminal 
remission at 5 years (TR5) was compared with terminal remission at 2 years (TR2) and with the 
longest remission during follow-up. Variables defined at intake and at 6 months of follow-up were 
analyzed for their prognostic relevance. In multivariate analyses, combinations of variables were 
tested to develop reliable models for the calculation of the individual prognosis. Data on treatment, 
course during follow-up and epilepsy syndromes were also studied. Three hundred and forty-five 
children (76%) had a TR5 >1 year, 290 (64%) >2 years and 65 (14%) had not had any seizure 
during the entire follow-up. Out of 108 children (24%) with TR5 <1 year, 27 were actually 
intractable at 5 years. Medication was started in 388 children (86%). In 227 of these (59%), anti-
epileptic drugs (AEDs) could be withdrawn. A TR5 >1 year was attained by 46% on one AED, on 
the second AED by 19%, and by 9% on all additional AED regimes. Almost 60% of the children 
treated with a second or additional AED regime had aTR5>1 year. Variables predicting the outcome 
at intake were etiology, history of febrile seizures and age. For intake and 6-month variables 
combined, sex, etiology, postictal signs, history of febrile seizures and TR at 6 months were 
significant. The model derived from intake variables only predicted TR5 <1 year correctly in 36% 
and TR5 >1 year in 85% (sensitivity 0.65, specificity 0.64). The corresponding values for the model 
derived from intake and 6-month variables were 43 and 88% (sensitivity 0.69, specificity 0.71). The 
course of the epilepsy was constantly favorable in 51%, steadily poor in 17%, improving in 25% 
and deteriorating in 6%. Intractability was in part only a temporary phenomenon. The outcome at 5 
years in this cohort of children with newly diagnosed epilepsy was favorable in 76%; 64% were off 
medication at that time. Almost a third of the children had a fluctuating course; improvement was 
clearly more common than deterioration. After failure of the first AED, treatment can still be 
successful. Models predicting the outcome have fewer misclassifications when predicting a long 
terminal remission than when predicting continuing seizures. 
 
Abbreviations  
AED = anti-epileptic drug; CI = confidence interval; DSEC = Dutch Study of Epilepsy in 
childhood; LR = longest remission during a defined period of follow-up; OR = odds ratio; RC = 
regression coefficient; ROC = receiver operant characteristic; TR = length of terminal remission 
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existing at moment of evaluation; TR2 = terminal remission existing at 2 years; TR5 = terminal 
remission existing at 5 years. 
 
INTRODUCTION 
 
The prognosis of childhood epilepsy has important epidemiological and clinical implications. 
Assessment of the risk profile of an individual patient may be used to tailor the treatment strategy. 
Not initiating anti-epileptic drug (AED) treatment after a first unprovoked seizure is now an 
evidence-based established practice (Hirtz et al., 2003). Conversely, decisions whether and, if so, 
when to start treatment in children with epilepsy are not based on firm clinical evidence since trials 
comparing different treatment strategies are lacking. Randomized studies to explore the way in 
which AEDs influence the natural course of epilepsy are usually considered unethical. The only 
exception so far is the Multicenter Study of Early Epilepsy and Single Seizures (MESS) trial, 
conducted in the UK, of which results will be available shortly. Although in recent years the 
opinion that AEDs only suppress seizures and have no influence on the course of the disease 
(Shinnar and Berg, 1996) has gained momentum, some authors have maintained that early vigorous 
treatment is essential to prevent intractability (Reynolds et al., 1983). The possibility of a self-
perpetuating mechanism of untreated epileptic seizures (Gowers, 1881; Reynolds et al., 1983; 
opposed by van Donselaar et al., 1997) is in contrast with the results of large cohort studies 
indicating that about 60% of children with newly diagnosed epilepsy have a good prognosis 
(Camfield et al., 1993; Sillanpää et al., 1998). To resolve the controversy, it remains essential to 
gather entirely, prospective follow-up data in large cohorts of patients of all ages with different 
types of epilepsy, look for evidence adding to the already available knowledge, and develop 
instruments to assess the prognosis of an individual patient. This might ultimately provide a sound 
medical and ethical basis for trials addressing the issue more directly.  
The Dutch Study of Epilepsy in Childhood (DSEC) provides some of the answers needed. We 
prospectively studied a cohort of children with newly diagnosed epilepsy, determined their 
outcomes, and identified factors associated with good and poor seizure outcomes. We also studied 
the dynamics of the course of the epilepsy and addressed the question of when and how to define 
intractability. Another goal was to identify children with newly diagnosed epilepsy who might 
benefit from immediate and vigorous treatment because of their poor prognosis, or in whom 
treatment could possibly be withheld or at least postponed because of the inherently favorable 
prognosis. In this paper, we present the data of the 5-year follow-up of the cohort, following up on 
our analysis of the 2-year outcome (Arts et al., 1999). 
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METHODS  
 
Composition of the cohort  
The design of the study and the results of the 2-year follow-up have been described previously (Arts 
et al., 1999). A hospital-based cohort (n = 466) of children aged 1 month to 15 years with newly 
diagnosed epilepsy (defined as two or more unprovoked seizures within a 1-year period) was 
recruited after informed consent of the parents. Four Dutch hospitals participated: two University 
hospitals (Rotterdam and Leiden), one children’s hospital and one general hospital (both in The 
Hague). The cohort comprised about 75% of the expected incidence in their referral areas. The 
attending pediatric neurologist completed an extensive questionnaire on the description of the 
event(s), possible provoking factors, previous medical history and the family history. Confirmation 
of the diagnosis of epilepsy by a committee of three pediatric neurologists, using predefined 
diagnostic criteria, was required for inclusion. The etiology was classified according to the 
definitions of the International League Against Epilepsy (ILAE; Commission on Epidemiology and 
Prognosis of the International League Against Epilepsy, 1993) as idiopathic, cryptogenic or remote 
symptomatic. The etiology of children with mental retardation was classified as remote 
symptomatic. Children with acute symptomatic seizures only were excluded. Epilepsy types and 
syndromes were classified according to the International Classification of Epilepsies and Epileptic 
Syndromes (ICES; Commission on Classification and Terminology of the International League 
Against Epilepsy, 1989). This was done at 2 years of follow-up, because the ICES had not yet been 
published when we started the study. 
 
Follow-up and outcome 
The follow-up of the original cohort (n = 466) was extended until 5 years after intake. We chose a 
fixed duration of follow-up for all children (instead of a variable length) to facilitate outcome 
comparisons at fixed intervals (6 months, 2 years, 5 years) and to examine the course of the 
epilepsy of all children during the entire follow-up. 
Eight children died during the 5-year follow-up (Callenbach et al., 2001). They were not included in 
the present analyses. Five children (1.1%) were lost. Eventually, 453 patients remained for the 
analyses at 5 years. 
We defined outcome as terminal remission (TR): the time from the last seizure to the moment of 
evaluation (i.e. 2 and 5 years after study entry). The TR at 5 years (TR5) was trichotomized (<1 
year, 1–2 years, >2 years).We defined intractability at 2 and 5 years as a TR <1 year and longest 
remission (LR) <3 months during the last year of observation despite adequate treatment 
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(Huttenlocher and Hapke, 1990; Berg et al., 2001; A. Berg, personal communication). Adequate 
treatment was defined as the optimal use of at least two AEDs, either alone or in combination. 
The course during the follow-up was compared with TR5 in two ways. First, we compared TR5 
with TR2. Next, we studied the duration of the LR during the entire 5-year follow-up in relation to 
the occurrence of seizure(s) during the last year of follow-up (TR5 <1 year). 
 
Treatment 
Treatment decisions were made by each child’s treating pediatric neurologist. In children who 
needed AED treatment, we tried at least two first-choice AEDs in monotherapy (mostly sodium 
valproate and carbamazepine) before using a polytherapy regimen. In children who experienced 
long-term remission, we usually withdrew the AED(s) after 2 years without seizures. However, our 
cohort also contained 161 children in whom medication was withdrawn much earlier, selected on 
the basis of a rapid and complete response to AED therapy (Peters et al., 1998). 
 
Determinants 
A priori-defined variables, including EEG, were collected at intake and at 6 months of follow-up 
(Table 3.1). These possible determinants were analyzed for their relevance for the outcome at 2 
years (Arts et al., 1999) and 5 years after intake (see below). In the univariate analysis, age at intake 
was categorized in five groups (0–3, 3–6, 6–9, 9–12 and 12–16 years of age) to show more detail. In 
the multivariate analyses, age as a continuous variable was analyzed both on linear and transformed 
scales to determine which scale best predicted the outcome. Since none of these was satisfactory, 
age was dichotomized (below and above 6 years of age). This also reduced the number of dummy 
variables.  
The temporal seizure pattern before intake (Table 3.1) was studied as a possible determinant on the 
basis of a report by Shorvon (1984). We identified the following patterns: continuous (intervals 
between seizures <1 week); intermittent (intervals between seizures >1 week); multiple bursts 
(clusters of seizures within one week with >1 week between the clusters); status epilepticus (seizure 
with duration of >30 min); solitary burst (one cluster of seizures within a period of at most 1 week). 
 
Statistical analyses 
The correlation of intake and 6-month follow-up determinants with outcome (defined as TR5 less 
than or more than 1 year) was analyzed with a modelling strategy (Harrell et al., 1996). When 
variables had missing values (e.g. family history), these were derived using imputation. Variables 
with many missing values (e.g. CT) were not considered in the multivariate analyses. After a stable 
model had been established, all second-order interaction terms of each determinant remaining in the  
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model were tested. Significant interaction terms were added to the model. The goodness of fit of the 
models was determined by Pearson’s χ2 test. Bootstrapping techniques were used to determine the 
internal validity of the final models.  
For each group that we analyzed, we developed a model with intake variables only and a model 
with intake and 6-month variables combined. 
From the odds ratios of the variables contributing to these models, regression coefficients (RC) can 
be derived. For each individual patient, the RCs of the applicable variables and a constant for the 
model can be summated to obtain the individual’s sum score. From the sum score, the predicted 
probability of a poor outcome can be calculated using the formula P = 1/1+e
-Z
, in which Z is sum 
score/–100. The area under the receiver operant characteristic (ROC) curve (giving the relation 
between the sensitivity and the specificity of the predictions) is a measure of the ability of the 
model to discriminate between patients with and without a poor outcome. The value of P with the 
best combination of sensitivity and specificity is the probability cut-off. Any value of P above the 
cut-off predicts TR5 <1 year; any value below P predicts the opposite. Since P can be plotted 
against Z and, therefore, also against the sum score, one can use the sum score for the determination 
of the individual’s prognosis. The cut-off value of P directly yields a cut-off value of Z and the sum 
score. Using the individual’s value of the sum score (below or above the cut-off) facilitates the use 
of the model in daily clinical practice.  
 
RESULTS 
 
Outcome 
Of the 453 children, 345 (76%) attained a TR5 of at least one year, 290 (64%) of at least 2 years 
and 248 (55%) had not had any seizure since the 2-year outcome evaluation (Figure 3.1). The 
moment of entering TR5 (i.e. the day of the last seizure during the 5-year follow-up) is presented as 
a Kaplan-Meier survival curve in Figure 3.2. It shows that half of the cohort had reached terminal 
remission after 18.5 months of follow-up.  
Sixty-five children (14%) were completely seizure free since the intake (Figure 3.1). In the 
univariate analyses, a number of significant variables distinguished this group from the 388 children 
with seizures after intake. They had had fewer seizures before intake, more often of a generalized 
tonic-clonic nature. Their EEG showed less often epileptiform discharges and they less often had 
symptomatic epilepsy. Their seizure pattern had more often been intermittent or a single burst and 
less often continuous.  
Twenty-seven (6%) out of 108 children (24%) with a TR5 of less than one year fulfilled our criteria 
for intractability. Of these, seven children had symptomatic partial and seven others cryptogenic 
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partial epilepsy; five had cryptogenic generalized and one symptomatic generalized epilepsy. Three 
had been classified as idiopathic generalized epilepsy with (mainly) absences, and four as idiopathic 
generalized epilepsy with (mainly) generalized tonic-clonic seizures. 
 
Figure 3.1: Outcome of 453 children with newly diagnosed epilepsy at 5 years of follow-up 
 
 
 
 
Figure 3.2: Moment (time in months) of the last seizure before entering the terminal remission 
existing at 5 years of follow-up for 453 children in the cohort. Kaplan–Meier survival curve 
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Treatment 
Sixty-five children (14%) were not treated with AEDs. Most of these suffered from sporadic 
generalized tonic-clonic seizures. Of the 65 untreated children, 61 (94%) achieved a TR5 >1 year, 
and 53 (82%) > 2 years. 
Medication was prescribed to 388 (86%) children. Of these, 206 (53%) received only one AED and 
182 (47%) two or more (up to nine) AEDs or AED regimens (Figure 3.3). Of the 388 treated 
children, 46% attained a TR5 >1 year on one AED, 19% reached this end-point on two AED 
regimes and 9% on three or more. 
Medication was withdrawn in 227 (59% of 388 treated) patients of whom 13 had a TR5 less than 
one year and 214 a TR5 of >1 year. At 5 years of follow-up, 161 (36% of 453) patients were still 
using AEDs (TR5 <1 year: 91; TR5 >1 year: 70). 
 
Figure 3.3: Number of anti-epileptic drug (AED) regimens during 5 years of follow-up in the 
entire cohort and in each of two 5-year outcome categories, all expressed as percentage of the 
entire cohort (n = 453) 
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Predictive variables 
The determinants of seizure outcome at 5 years were largely identical to those found in the 2-year 
analysis (Table 3.1). 
 
Table 3.1: Univariate analysis 
 
 Number 
of 
children 
% with 
TR2 <1 
year 
% with 
TR5 <1 
year 
OR for TR5 <1 
year  
(95% CI’s) 
                       INTAKE 
Overall 453 43 24  
Sex     
    - Male 221  42 22 1.00 
    - Female 232  44 26 1.26 (0.81, 1.94) 
Age at intake (years)     
    - 0 – 3  145 48 28 1.00 
    - 3 – 6  90 46 30 1.13 (0.63, 2.01) 
    - 6 – 9  99 39 15 0.47 (0.24, 0.91)* 
    - 9 – 12 73 34 18 0.57 (0.28, 1.15) 
    - 12 – 16  46 41 28 1.03 (0.49, 2.17) 
No. of seizures before intake    
 
    - < 25 285  42 22 1.00 
    - > 25 168 44 26 1.23 (0.79, 1.91) 
Seizure type     
    - Generalized tonic-clonic 272 38 22 1.00 
    - Complex partial 49 51 35 1.88 (0.97, 3.63) 
    - Simple partial 29 69  17 0.74 (0.27, 2.02) 
    - Absences 59 32 19 0.81 (0.40, 1.66) 
    - Infantile spasms, myoclonic/ 
      atonic seizures, etc. 
44 57 34 1.83 (0.92, 3.65) 
Type of epilepsy    *** 
    - Generalized idiopathic 193 32 16 1.00 
    - Generalized cryptogenic 31 52 42 3.92 (1.70, 9.06)*** 
    - Generalized  symptomatic 32 47  28 2.13 (0.89, 5.08) 
    - Partial idiopathic 28 39 0  0.00 
    - Partial cryptogenic 86  48 34 2.76 (1.51, 5.07)*** 
    - Partial symptomatic 67 63 39 3.45 (1.80, 6.59)*** 
    - Unclassifiable 16 38 6 0.36 (0.05, 2.87) 
Etiology    *** 
    - Idiopathic 232 33 14 1.00 
    - Remote symptomatic 126 56 33 2.91 (1.70, 4.98)*** 
    - Cryptogenic 95 48 36 3.36 (1.89, 5.98)*** 
Pre-existing neurological signs     
    - Absent 396 41 22 1.00 
    - Present 57 54 33 1.72 (0.94, 3.15) 
Postictal signs     
    - Absent 407 42 22 1.00 
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 Number 
of 
children 
% with 
TR2 <1 
year 
% with 
TR5 <1 
year 
OR for TR5 <1 
year  
(95% CI’s) 
    - Present 46 52 39 2.26 (1.19, 4.30)* 
History of febrile convulsions     
    - No 406 42 23 1.00 
    - Yes 47 51 32 1.58 (0.82, 3.04) 
Family history     
    - Negative 395 44 24 1.00 
    - Positive 58 31 24 1.02 (0.53, 1.94) 
Standard intake EEG     
    - Normal 111 36 20 1.00 
    - Epileptiform  267 45 25 1.32 (0.76, 2.27) 
    - Other abnormalities 69 45 28 1.54 (0.76, 3.13) 
CT scan     
    - Normal 245 40 24 1.00 
    - Abnormal 67 61 34 1.69 (0.94, 3.03) 
    - Not obtained 141 38 19 0.76 (0.46, 1.28) 
Temporal seizure pattern
 
    
    - Continuous
 
189 41 25 1.00 
    - Intermittent 162 43 19 0.71 (0.43, 1.20) 
    - Multiple bursts 17 59 47 2.69 (0.97, 7.45)* 
    - Solitary status epilepticus 24 46 33 1.51 (0.61, 3.77) 
    - Solitary burst 61 39 23 0.90 (0.45, 1.78) 
 
       6 MONTHS AFTER INTAKE 
No. of seizures within 6 months    
 
    - < 25 288 40 21 1.00 
    - > 25 165 47 27 1.56 (1.00, 2.43)* 
3-month remission ever in 6 months     
    - No 123 67 42 1.00 
    - Yes 330 34 17 0.28 (0.17, 0.45)*** 
6-month EEG     
    - Normal 122 32 17 1.00 
    - Epileptiform 110 55 32 2.24 (1.20, 4.21)** 
    - Other abnormalities 58 43 24 1.53 (0.71, 3.30) 
    - Not obtained 163 42 23 1.46 (0.81, 2.66) 
TR at 6 months     
    - 6 months 141 28 13 1.00 
    - 2 to 6 months 171 38 17 1.46 (0.77, 2.74) 
    - 0 to 2 months 141 51 43 5.23 (2.77, 9.89)*** 
 
The table shows the distribution of the possible determinants collected at intake and after 6 months, 
percentages of children with a TR2 and TR5 <1 year and odds ratios for TR5 <1 year for each value of 
the intake and 6-month variables compared with the reference value of that variable, scored as 1.00. 
OR = odds ratio; CI = confidence interval. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Few variables showed substantial changes in outcome when the TRs at 2 and 5 years were 
compared. Most conspicuously, patients with simple partial seizures had a significantly worse 
outcome at 2 years in comparison with patients with generalized tonic–clonic seizures, but at 5 
years of follow-up their outcome was better, although not significantly so. 
Multivariate analyses of the 5-year outcome with logistic regression models are presented in Table 
3.2A. The model with intake variables only retained sex, age at intake, initial EEG, etiology, history 
of febrile seizures and postictal signs. Etiology and history of febrile seizures interacted.  
 
Table 3.2A: Multivariate analyses 
 
 Intake variables Intake and 6-month 
variables 
Number of children 453 453 
Number of covariate patterns 43 119 
Pearson χ2 (74) 35.30 93.63 
Probability > χ2 0.45 0.84 
Area under ROC curve 0.70 0.77 
   
VARIABLES OR (95% CI) OR (95% CI) 
Sex (male/female) 1.49 (0.93, 2.37) 1.64 (1.00, 2.70)* 
Age at intake (<6/> 6 years) 0.62 (0.39, 0.99)* 0.87 (0.52, 1.43) 
EEG at intake (normal/abnormal) 1.34 (0.77, 2.34)  
Etiology (idiopathic/not idiopathic)   
        If no febrile seizures occurred 3.72 (2.20, 6.30)*** 3.58 (2.05, 6.27)*** 
       If febrile seizures occurred 0.63 (0.17, 2.30) 0.56 (0.14, 2.18) 
History of febrile seizures (no/yes)   
       If etiology is idiopathic                      4.37 (1.70, 11.26)** 5.28 (1.92, 14.51)*** 
       If etiology is non-idiopathic                      0.74 (0.27, 2.08) 0.82 (0.28, 2.4) 
Postictal signs (no/yes) 1.83 (0.93, 3.60) 2.23 (1.08, 4.63)* 
No. of seizures in 1st 6 months (< 25/>25)  0.77 (0.42, 1.41) 
3-month remission (no/yes)  0.58 (0.29, 1.13) 
Terminal remission at 6 months   
        6 months (no/yes)  1.00 
        2 to 6 months (no/yes)  1.57 (0.78, 3.17) 
        0 to 2 months (no/yes)  4.47 (2.00, 9.99)*** 
 
The table shows odds ratios (OR) and 95% confidence intervals (CI) for the models with intake 
variables only and with intake and 6-month variables for a terminal remission (TR5) of <1 year at 5 
years of follow-up. Logistic regression model with interaction according to Harrell et al., 1996.  
*P < 0.05; **P < 0.01; ***P < 0.001. 
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Children with cryptogenic or remote symptomatic etiology without a history of febrile convulsions 
had a worse prognosis than those with idiopathic etiology and no febrile convulsions. On the other 
hand, a history of febrile convulsions was a significant predictor of a worse outcome in all children 
with idiopathic epilepsy, but not in the children with non-idiopathic epilepsy. The model with intake 
and 6-month variables combined retained the above variables except for the initial EEG, and, in 
addition, the number of seizures and the longest remission during the first 6 months of follow-up, 
and the duration of terminal remission at 6 months. The following variables attained significance. 
The outcome was worse for girls than for boys, as well as in children with postictal signs, a TR at 6 
months of <2 months, non-idiopathic etiology and a history of febrile seizures. Again we found a 
significant interaction between etiology and febrile convulsions. 
Based on the models presented here, it is possible to determine the individual prognosis of children 
with newly diagnosed epilepsy by calculating the sum score (Table 3.2B). In these models, the 
value of the sum score for an individual reflects his or her chance of having a TR5 <1 year. In the 
model with intake variables only, the sum score cut-off equals 110, which is derived from P = 0.25. 
This P value corresponds to the best combination of sensitivity (0.65) and specificity (0.64), 
resulting in a predictive value for TR5 <1 year of 0.36 and predictive value for TR5 >1 year of 0.85. 
The interpretation of these figures is that for sum scores more than 110, a TR5 >1 year is predicted 
with few false predictions (15%). However, the prediction of TR5 <1 year (sum score lower than 
110) yields a large number of false predictions (64%). The number of misclassifications amounts to 
38 (false prediction of TR5 >1 year) + 124 (false prediction of TR5 <1 year) = 162 (36%). 
For the model with intake and 6-month variables combined, the sum score cut-off equals 132 
derived from a P = 0.21. The resulting values for sensitivity, specificity, positive and negative 
predictive value are 0.69, 0.71, 0.43 and 0.88. One can see that this model is more reliable than the 
one with intake variables only, but suffers from the same deficit: too many false predictions of TR5 
<1 year. The number of misclassifications amounts to 33 + 101 = 134 (30%). A simplified way of 
calculating the individual prognosis with the help of these data is given in Table 3.2B. 
For children with a defined epilepsy syndrome, it may not be necessary to use a complicated model 
to determine the prognosis, because the syndrome itself largely determines the prognosis. 
Therefore, we analyzed the group that remained after removal of all children with a well-defined 
epilepsy syndrome and with idiopathic generalized epilepsy not otherwise defined. The 182 residual 
children had cryptogenic (86) or symptomatic (67) partial epilepsy, and symptomatic or cryptogenic 
generalized epilepsy (29). Multivariate analysis of the 153 children with symptomatic or 
cryptogenic partial epilepsy retained sex, age, family history, postictal signs, 3-month remission 
during and terminal remission at 6 months in the model. Only the determinant ‘postictal signs’ was 
significant. After bootstrapping, the following results were found: the best cut-off value for P with 
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the highest sensitivity (0.65) and specificity (0.67) is at 0.39. The predictive value for TR5 <1 year 
for any value above this cut-off is 0.53 and the predictive value for TR5 >1 year for any value 
below the cut-off is 0.78. This amounts to 19 + 32 = 51 misclassifications (33%). 
 
Table 3.2B: Simple formula for the calculation of the prognosis with the above models 
 
 Model with intake 
variables only 
Model with intake and 
6-month variables 
If female, add -37 -45 
If age at intake > 6 years, add 45 13     
If epileptiform features on first EEG, add -28  
If non-idiopathic etiology, add -123 -115 
If history of febrile seizures, add -139 -150 
If postictal signs present, add -57 -72 
If >25 seizures in first 6 months of follow-up, add  24 
If ≥3 months remission in first 6 months, add  49 
If TR at 6 months 2-6 months, add  -41 
If TR at 6 months 0-2 months, add  -135 
If combination of non-idiopathic etiology and 
history of febrile seizures, add 
166 167 
Constant x 100 228 256 
Calculate sum score of individual child   
Cut-off value sum score 110 132 
Good outcome predicted Sum score > 110 Sum score > 132 
Poor outcome predicted Sum score < 110 Sum score < 132 
 
The numbers in the table are the RCs of each contributing variable multiplied by (-100) and the 
shrinkage factor. For the model based on intake variables only, the shrinkage factor derived from 
bootstrapping was 0.94 and for the model with intake and 6-month variables combined it was 0.90. For 
each variable, enter the number given in the table if the child has the defined category or property, but 
0 if the child does not. For example, for a girl, enter 37 in the model with intake variables only and 45 
in the model with intake and 6-month variables, but for a boy enter 0. The value for the interaction 
term can only be entered if both terms (non-idiopathic etiology and history of febrile seizures) are 
present. Adding the numbers for any particular child results in its sum score. This sum score has to be 
compared with the sum score cut-off value which was derived from the probability cut-off with the 
highest values for sensitivity and specificity. For the model with intake variables only, the cut-off was 
110 and for the model with intake and 6-months variables it was 132. Values below the cut-off indicate 
a higher probability of TR5 <1 year and values above the cut-off indicate a smaller probability.  
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Comparison of the results at 2 and at 5 years 
The correlation of the outcomes 2 and 5 years after intake, measured as continuous variables, was 
highly significant. For the 442 children whose outcome could be measured this way both at 2 and at 
5 years, Kendall’s tau-b correlation coefficient was 0.591 (P < 0.0001). 
The correlation between the categorical remissions at 5 and 2 years is presented in Figure 3.4. In 
two children, the outcome at 2 and at 5 years could not be compared. 
 
Figure 3.4: Correlation between the categorical outcomes at 2 and 5 years for 453 children in 
the 5-year analysis. The outcome measures are terminal remission <1 year or >1 year at 2 and 
5 years of follow-up 
 
 
 
 
TR5 was >1 year in 231 of the 259 children with a TR2 of >1 year (89%, or 51% of the entire 
cohort). In univariate analyses, this was associated with seizure type (absences and tonic–clonic 
seizures), epilepsy type (idiopathic generalized epilepsy), etiology (idiopathic), EEG (normal), 
remission of 3 months in the first 6 months of follow-up and absence of postictal signs, pre-existing 
neurological signs and imaging abnormalities. A deteriorating course was seen in 28 of the 259 
children (11%, or 6% of the entire cohort). All of these had a TR2 of >1 but seizures during the fifth 
year. Significantly associated with a deteriorating course were age at onset >4 and the presence of 
postictal signs.  
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On the other hand, an improving course was seen in 113 out of 193 children with TR2 less than one 
year (59%, or 25% of the entire cohort) but TR5 >1 year. Six of these had been intractable at 2 
years. An improving course was associated with seizure type (simple partial seizures), negative 
family history and abnormalities in imaging studies. A constantly poor course was observed in 78 
children (17%) who attained a 1-year terminal remission neither at two nor at 5 years. Age at onset 
(<6 years), a large number of seizures before and in the 6 months after intake, seizure type 
(complex partial seizures, infantile spasms and myoclonic and atonic seizures), epilepsy type 
(symptomatic partial and cryptogenic partial and generalized), etiology (non-idiopathic), a history 
of febrile seizures and absence of remission during the first 6 months of follow-up were all 
associated with a constantly poor course. 
Fifteen out of the 27 children who were intractable at 5 years had also been intractable at 2 years. 
Some other intractable children had had at least one long-term remission during the 5-year follow-
up, but relapsed (Table 3.3). Two of these had had a remission of >2 years. More than half of the 
108 children having seizures during the fifth year had had an intercurrent remission of at least 1 
year. 
 
Table 3.3: Longest remission ever during 5 years of follow-up of 27 children matching the 
definition of intractable at 5 years, of 108 children with TR5 <1 year and of the remaining 
children with a TR5 of >1 year 
 
 Number of children (%) 
Longest remission 
during 5 years 
27 intractable children 108 children with TR5  
< 1 year 
345 children with TR5  
> 1 year 
0 – 3 months 11 (41) 13 (12) 0 
3 – 6 months 6 (22) 9 (8) 0 
6 – 12 months 3 (11) 19 (18) 0 
12 – 24 months 5 (19) 30 (28) 29 (8) 
> 24 months 2 (8) 37 (34) 316 (92) 
 
 
Results at the level of epileptic syndromes 
For virtually every syndrome, the largest group did well from the onset, and the second largest 
group showed an outcome improvement at 5 compared with 2 years (Figure 3.5). This was most 
obvious for benign partial epilepsy with rolandic spikes and for idiopathic generalized epilepsies. 
Much smaller groups of children doing poorly from the onset or showing a worse outcome at five 
than at 2 years were found mainly in the categories of symptomatic or cryptogenic epilepsies. 
Since the epileptic syndromes were classified in retrospect 2 years after the intake, syndromes were 
not included as a variable in the multivariate analyses. In the model with intake variables only, age 
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(<6 versus >6 years or older) was significant. Epileptic syndromes occurring at certain ages may 
have caused this. Therefore, we looked at the relation between age and outcome. In univariate 
analysis, age >6 years was associated with a significantly better outcome [odds ratio (OR) 0.46 with 
95% confidence interval (CI) 0.23–0.92]. 
 
Figure 3.5: Outcome at 2 and 5 years of 453 children followed for 5 years, according to 
epileptic syndrome (Commission on Classification and Terminology of the International 
League Against Epilepsy, 1989) as defined 2 years after intake.  
 
 
Numbers in parentheses are numbers of patients.  
BECTS: benign partial epilepsy of childhood with centrotemporal (rolandic) spikes,  
IGE: idiopathic generalized epilepsy. 
 
 
Stratifying for epilepsy syndrome did not yield a significant association between age and outcome 
[Mantel–Haenszel common odds ratio estimate: 0.71 (asymptotically 95% CI, 0.44, 1.14)], with one 
exception: age at intake <6 years had a worse prognosis if the child had symptomatic partial 
Page | 45  
 
epilepsy. Stratifying for age according to the five groups shown in Table 3.1 demonstrated also that 
symptomatic partial had a worse outcome below the age of 6 years (significantly so between 3 and 
6 years), whereas cryptogenic partial had a significantly worse outcome between 3 and 9 years.  
Idiopathic generalized syndromes had a better outcome in the younger age groups (significant at the 
ages of 3–9 years). Without exception, all idiopathic partial syndromes (mostly occurring between 6 
and 12 years) had a good outcome. Our finding that age at intake was significant in the model with 
intake variables only may have been caused by the occurrence of epileptic syndromes at the various 
ages. 
 
DISCUSSION 
 
The data presented here provide some insight in the evolution of childhood epilepsy over the years 
and in the variables that may influence the outcome. We hypothesized that we would be able to 
predict the outcome of childhood epilepsy based on (combinations of) determinants that can be 
identified at the moment of the diagnosis of epilepsy or shortly thereafter. Such a strategy might 
lead to individualized treatment regimens depending on the prognosis of the child. Evaluating this 
possibility, we were able to elaborate on the concept of ‘smooth sailing epilepsy’ (Camfield et al., 
1990) on the one hand and of intractability (Huttenlocher and Hapke, 1990; Berg et al., 2001) on the 
other. 
 
Outcome and response to treatment 
There seems to be a general consensus that both adults and children with newly diagnosed epilepsy 
have a 65–75% chance of entering long-term remission (Annegers et al., 1979; Beghi and Tognoni, 
1988; Camfield et al., 1993; Cockerell et al., 1997, Sillanpää et al., 1998). About 10–15% are due to 
become really intractable and 10–25% end up somewhere in between. This is rather surprising in 
view of the large discrepancies in patient selection, duration of follow-up and outcome definitions 
in the cohorts described so far. In our cohort, we find a large proportion with an improving course 
over time whereas the proportion with a deteriorating course is relatively small. Eventually, the 
outcome figures resemble the general beliefs. Our data clearly show that this is a dynamic process, 
and that outcome is more dependent on the duration of follow-up than may previously have been 
thought. 
The response to treatment with AEDs follows a pattern that bears superficial resemblance to the one 
that has recently been described in the retrospective study by Kwan and Brodie (2000) in a hospital-
based patient group aged 9 to 93 years, but our final results are better. They found a success rate 
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(seizure free for at least 1 year at the time of last follow-up) for the first AED in 47% of all patients 
treated, for the second in 13%, and in 4% for any further AED regime. They do not state the number 
of patients who were not treated. In our childhood cohort, the 388 treated children have similar 
results: 46% had a TR5 >1 year on the first AED, 19% on the second and 9% on any further AED 
regime. However, the success rate of any further AED or AED combination after the first AED had 
failed was almost twice as high (58%; Kwan and Brodie, 32%). The better results found by us and 
by Camfield et al. (1993) were probably largely caused by the different composition of the groups 
investigated: children versus all ages, and (largely) population-based versus hospital-based. 
Therefore, we want to stress that, at least in children, failure of one (or two) AED(s) certainly is a 
risk factor for a poor outcome, but that a considerable proportion of these patients will do well in 
the end. 
 
Course during the follow-up 
In more than two-thirds of patients, the 5-year outcome mirrored the 2-year outcome (in 51% both 
>1 year, in 17% both <1 year). For the best seizure–outcome group, the relevant variables pointed 
heavily to all qualities of ‘idiopathic’ as the main predictor. For the worst outcome group,  
indications for a symptomatic or cryptogenic etiology and for malignant types of seizures or 
epilepsy, an early age at onset and a history of febrile seizures (despite the absence of children with 
severe myoclonic epilepsy of childhood in our cohort) were the leading variables. 
An improving course was seen in one quarter of the cohort. The association of the improvement 
with simple partial seizures may be partly explained by the presence of a considerable number of 
children with benign partial epilepsy in this group. In this clinical epidemiological study, their long-
term outcome was invariably good (Figure 3.5), in contrast to the outcome at 2 years. This finding 
is in agreement with a recent meta-analysis of studies on benign partial epilepsy of childhood with 
rolandic spikes (Bouma et al., 1997). But the number of children with a remote symptomatic 
etiology, who attained a TR5 of >1 year, also increased by almost 25% in comparison with TR2 
(Table 3.1). Deterioration after a favorable early course was much less frequent (6% of our entire 
cohort) than improvement after an initially poor course. This was associated with the variable age at 
onset above 9 years. 
Our data suggest that the two main outcome groups at 5 years (the first ‘good to excellent’, the 
second ‘poor’) predominate numerically and that the in-between group is relatively small (Figure 
3.1). After a longer follow-up, the outcomes become better more often than worse for children who 
do not have a stable course of their epilepsy. The improvement found in about one-quarter of the 
children adds to the good result of the children with smooth-sailing epilepsy. On the other hand, the 
number of children found to be intractable had not decreased when we compared the outcome at 2 
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and 5 years. Children who deteriorated took the place of children who had improved. Further 
follow-up is mandatory to find out whether the intractability leading to an indication for epilepsy 
surgery at adult age may arise after a (much) longer delay (Berg et al., 2003). 
 
 
Intractability 
Our finding that the number of children with a worsening course was relatively small confirms our 
idea that childhood epilepsy is generally not a progressive disease (van Donselaar et al., 1997). This 
is in contrast to the opinion of those authors adhering to Gowers’ dictum that ‘seizures beget 
seizures’ (Gowers, 1881; Reynolds et al., 1983). However, fluctuations during the course do occur 
and even fulfilling criteria for intractability may be a temporary phenomenon. Of the 419 patients 
with a seizure-free period of at least 12 months at any time during the follow-up, 74 (18%) did not 
reach a TR5 of >1 year and seven (2%) became intractable (Table 3.3). On the other hand, 10 of the 
25 children considered intractable at 2 years were not intractable at 5 years and six even had a TR5 
of >1 year. In the Connecticut study (Berg et al., 2001), there was no fixed duration of follow-up 
but the range and median duration of follow-up were given. Intractability was considered to be early 
if it began within the first 2 years of follow-up and was observed during at least 18 months. Ten per 
cent of the children fulfilled their criteria for early intractability, comparable to our findings (6%). 
Of their 60 children with early intractability, seven (12%) went on to attain a remission of at least 1 
year. In our cohort, this was 24% (six out of 25 children). Other authors found that in a group of 
children that had been refractory to AED therapy for at least 2 years, about 4% entered remission 
during each year of further follow-up (Huttenlocher and Hapke, 1990). A recent editorial comment 
(Holmes and Engel, 2001), therefore, rightly cautions against an early rush to aggressive 
intervention, but on the other hand acknowledges the possibly adverse effects of a period with 
continuing seizures, fitting the definition of at least temporary intractability, on the patient and his 
or her family. Improvement in the course of lesional epilepsy in childhood may come late, and our 
findings clearly underscore the need for a careful decision about which children should be referred 
for epilepsy surgery and when. It is difficult to give an accurate and broad definition of medical 
intractability. Not being in remission is insufficient, since treatment, duration of remission, number 
and/or frequency of seizures and the time interval during which seizures were counted should be 
specified. To predict intractability correctly, there should not be too many false-negatives and false-
positives. It would be worthwhile to develop a consensus on the definition or definitions of 
intractability, enabling investigators to compare the results of various studies. The definitions 
applied in this study were used in various publications by Berg and colleagues and also in our 
former study on the 2-year outcome of childhood epilepsy. 
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Smooth course 
A considerable proportion of our cohort fulfilled one or more criteria for an uncomplicated course. 
Sixty-five (14%) children were completely seizure free since the intake (28 without treatment, 35 
successfully withdrawn from AEDs), and 122 (27%) came into terminal remission during the first 
year of follow-up (17 without treatment, 95 successfully withdrawn). For such a favorable course, 
Camfield and colleagues coined the term ‘smooth-sailing epilepsy’ (Camfield et al., 1990). By this, 
they meant the children who became seizure free immediately after the start of AED treatment and 
remained seizure free during the follow-up, even after the withdrawal of medication. In their cohort 
(Camfield et al., 1993), this group comprised 20% of the entire sample. To this could be added a 
group that had never been treated at all (3%). It can be concluded from their and our data that 
smooth-sailing epilepsy does exist and accounts for at least a quarter—more probably a third or 
more—of all children with newly diagnosed epilepsy. 
 
Determinants, outcome prediction 
Both in the univariate and in the multivariate analysis, the variables reaching significance in the 
prediction of the outcome were largely identical at 5 years compared with 2 years of follow-up. The 
modelling strategy used in the present analysis, including interaction terms, seems to predict the 
outcome better than the variables per se. Notably, we found a dichotomy concerning etiology. In the 
group with idiopathic etiology, febrile seizures were a significant predictor of a worse outcome. In 
the group with non-idiopathic etiology, this predictor was no longer significant. As far as we know, 
this has not been reported before. 
Variables predictive of the outcome of childhood epilepsy in multivariate analyses were found to be 
etiology, seizure type, early response to treatment (Sillanpää et al., 1998), number of pretreatment 
seizures, age at onset and a history of neonatal convulsions (Camfield et al., 1993). In these and our 
studies, children with clear mental retardation were considered to have remote symptomatic 
epilepsy. Except for age at onset and history of neonatal convulsions (which was not recorded by 
us), our findings were similar. Camfield and colleagues found age at onset below 12 years to be 
predictive of remission. Our group of patients older than 12 years was perhaps too small to confirm 
this finding. In our cohort, secondary deterioration was associated with age at intake above 9 years. 
Otherwise, the influence of age seemed to be correlated with epilepsy syndromes and the age at 
which they usually occur. 
A model with determinants identified at intake was able to predict the outcome at 5 years correctly 
in 64% of our cohort. With the model based on the intake and 6-month variables together, the 
outcome was correctly classified in 70% of the cohort. In our earlier study, the outcome at 2 years 
of follow-up was predicted correctly in 70 and 76% (Arts et al., 1999). These data suggest that 
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predictive models have a place in the determination of the prognosis of childhood epilepsy, 
especially in the prediction of a long terminal remission. When the models predict a long terminal 
remission, the chance that the prediction will be incorrect is much smaller than when they predict a 
short terminal remission. The resulting expectations may be used to inform the parents, and as a 
basis for the choice of treatment strategy. Caution with the interpretation of such predictions is 
warranted, however, because the number of those misclassified (especially children predicted to 
have a poor outcome) is considerable due to the lack of sensitivity of the models. Nevertheless, it is 
justified to ask whether AED treatment really would be necessary if the prognosis is good, and 
whether early aggressive intervention could prevent the development of expected intractability. 
Our findings indicate that there are no ethical or practical objections against designing studies that 
aim to test hypotheses based upon these questions. 
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ABSTRACT 
 
The purpose was to study the course and outcome of childhood-onset epilepsy during 15-year 
follow-up (FU). We extended FU in 413 of 494 children with new-onset epilepsy recruited in a 
previously described prospective hospital-based study by questionnaire. 
Mean FU was 14.8 years (range 11.6–17.5 years). Five-year terminal remission (TR) was reached 
by 71% of the cohort. Course during FU was favorable in 50%, improving in 29%, and poor or 
deteriorating in 16%. Mean duration of seizure activity was 6.0 years (range 0–21.5 years), strongly 
depending on etiology and epilepsy type. Duration was <1 year in 25% of the cohort and exceeded 
12 years in another 25%. Antiepileptic drugs (AEDs) were used by 86% during a mean of 7.4 years: 
one-third had their last seizure within 1 year of treatment, and one third continued treatment at the 
end, although some had a 5-year TR. At last contact, 9% of the cohort was intractable. 
In multivariate analysis, predictors were non-idiopathic etiology, febrile seizures, no 3-month 
remission, and early intractability. Eighteen patients died; 17 had remote symptomatic etiology. 
Standardized mortality ratio for remote symptomatic etiology was 31.6 [95% confidence interval 
(CI) 18.4–50.6], versus 0.8 [95% CI 0.02–4.2] for idiopathic/cryptogenic etiology. 
In most children with newly diagnosed epilepsy, the long-term prognosis of epilepsy is favorable, 
and in particular, patients with idiopathic etiology will eventually reach remission. In contrast, 
epilepsy remains active in ~30% and becomes intractable in ~10%. AEDs probably do not influence 
epilepsy course; they merely suppress seizures. Mortality is significantly higher only in those with 
remote symptomatic etiology. 
 
INTRODUCTION 
 
Knowledge of the long-term outcome of epilepsy is of the utmost importance in the treatment of 
children with epilepsy. Many investigators have studied cohorts with the purpose of describing 
epidemiology, prognosis, and mortality, as well as social and educational outcomes (Camfield et al., 
1993; Berg et al., 1999b; Wakamoto et al., 2000; Sillanpää & Schmidt, 2009). Next to methodology 
and cohort size, length of follow-up (FU) determines the significance of the results of these studies, 
especially when it comes to aspects such as course of epilepsy, intractability, terminal remission, 
and mortality. A lifelong FU of cohorts would be ideal to cover all aspects; however, although this 
has not yet been realized, studies with prolonged FU are valuable.  
Whereas outcome in terms of remission or death can be determined easily, the course of epilepsy 
during FU is more difficult to describe. This can be done in terms of success or failure of 
antiepileptic drugs (AEDs), or in terms of remission and relapse (Camfield et al., 1993; Sillanpaa & 
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Schmidt, 2006). The course of epilepsy is in our view important to investigate, because intra- and 
inter-individual variation may be considerable (Berg et al., 2006; Sillanpää & Schmidt, 2006). 
Periods of remission and relapse may interchange. Such a dynamic course might influence our 
interpretation of the results of prognostic studies, advice to patients, treatment strategies, and timing 
of referral for surgery. Moreover, it is still largely unknown whether the long-term outcome of 
epilepsy is determined by its natural course or whether it can be modified by treatment. Long-term 
FU studies may be helpful to solve this dispute. 
Between 1988 and 1992 we consecutively recruited children who attended hospital with new-onset 
epilepsy. Results at 2 and 5 years after diagnosis have already been published (Arts et al., 1999, 
2004). We extended the FU of 413 children to a mean of 15 years. To date, there have been no 
reports of studies with cohorts of this size combined with this length of FU. The main purpose of 
this study was to investigate course and outcome of childhood epilepsy and its determinants, 
treatment, and mortality. 
 
METHODS 
 
Setting 
Between 1988 and 1992, we recruited a hospital-based cohort (n = 494) of children aged 1 month to 
16 years with newly diagnosed epilepsy. The original 2-year FU was prolonged to 5 years. About 
10 years later, we contacted the cohort again. Four hospitals in The Netherlands participated in this 
study. Written informed consent was given by all parents and children of 12 years or older, not 
intellectually handicapped. The hospitals ethical committees approved the study. 
 
Cohort 
All 494 children experienced at least two unprovoked— not acute symptomatic—epileptic seizures 
or one unprovoked status epilepticus (SE) before enrollment. Subjects with SE have been described 
in detail (Stroink et al., 2007). The 453 subjects with a 5-year FU were the starting point of this 
study (Figure 4.1). Detailed descriptions of the original study and the results at 2 and 5 years of FU 
have been published (Arts et al., 1999, 2004; Callenbach et al., 2001). The recruitment rate of the 
original study approximated 75% of the expected annual incidence in the referral area (Arts et al., 
1999). 
 
Classifications 
A panel of three pediatric neurologists classified the seizures and epilepsies shortly after enrollment 
(Gastaut, 1969; ILAE, 1981). At 2 years of FU, the original classifications were replaced by the 
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later classifications of the International League against Epilepsy (ILAE, 1989). Etiology was 
idiopathic, cryptogenic, or remote symptomatic, including mental retardation (ILAE, 1993). 
Children were mentally retarded if specialized care or schooling for the intellectually disabled was 
needed (presumed IQ <70) (Hauser et al., 1982). 
 
Figure 4.1: Diagram of the cohort. FU, follow-up 
 
 
 
Follow-up and questionnaire 
During the first 5 years of FU, children attended hospital at regular intervals. After 5 years, the 
regular check-ups stopped according to the study protocol. Between 2004 and 2006, all subjects or 
their parents received a questionnaire with items concerning their epilepsy. A total of 453 
questionnaires were sent of which we received 413 in return. Five subjects had emigrated, eight had 
died, two subjects refused to cooperate and returned their forms uncompleted, and 25 did not 
respond despite reminders. The response rate based on the original 494 subjects was 84%. 
 
Definitions 
Terminal remission (TRE) was defined as the interval between the last seizure and the end of FU. 
Intractability: no remission exceeding 3 months during a 1-year period of observation despite 
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adequate treatment during that year and the years before (Arts et al., 2004). In this study, adequate 
treatment was considered to be the optimal use of at least two AEDs, either alone or in combination. 
Active epilepsy: at least one seizure in the last 5 years of FU, regardless of actual or earlier 
treatment (ILAE, 1993). Fast response to AED: starting a 6-month remission within 2 months after 
starting treatment. 
We assessed the course of epilepsy by comparing the second year, the fifth year, and the last year of 
FU on the occurrence of seizures or not. Course was favorable if all 3 years were without seizures; 
improving with seizures in the second year, but remission in the last year regardless of the outcome 
of the fifth year; poor with seizures in all 3 years; deteriorating with remission in the second year, 
but with seizures in the last year regardless of the outcome in the fifth year; and varying with 
outcome in the fifth year opposite to outcome in both other years. 
We considered the interval between the very first seizure in life and the last seizure before last 
contact as duration of seizure activity. Possible sudden unexpected death in epilepsy (SUDEP) 
includes cases in which SUDEP cannot be ruled out but there is insufficient evidence regarding the 
circumstances of death and no postmortem report is available (Annegers & Coan, 1999). 
 
Statistical analysis 
Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago, IL, U.S.A.). We assessed the 
standardized mortality ratio (SMR) to evaluate the risk of dying in our cohort compared with the 
general Dutch population in 2004. We used binary logistic regression to study the strongest 
predictors of intractability (stepwise backward conditional method). The area under the receiver 
operating characteristic (ROC) curve was used as a measure of accuracy. An area of 1 represents a 
perfect test and an area of 0.5 represents a worthless test. We used one-way analysis of variance 
(ANOVA) to compare means, and Pearson chi-square or likelihood-ratio square to compare 
proportions. 
 
RESULTS 
 
A total of 413 subjects were analyzed, of whom 47% were male. The mean age at onset of epilepsy 
was 5.5 years (median 5.1; range 1 month to 15.5 years), and the mean age at last contact was 20.8 
years (median 20.4; range 12.2–32.5 years). Etiology was idiopathic in 50.8%, remote symptomatic 
in 27.8%, and cryptogenic in 21.3%. The mean FU was 14.8 years (median 14.8; range 11.6– 
17.5 years). 
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Final outcome 
Two hundred ninety-three subjects had a TRE of at least 5 years at the end of the study (70.9%: 
61.9% off AEDs, 9.0% on AEDs). Figure 4.2 shows the proportion of subjects reaching their 5-
year TRE during the years of FU. It demonstrates for example that at 5 years after enrollment 60% 
of the cohort reached their TRE. An extra Figure S1 showing the proportion of subjects reaching a 
2-year TRE may be found in Appendix 3.  
In addition to the 293 subjects in remission, epilepsy was still active in the remaining 120 subjects 
(29.1%: 5.3% off AEDs, 23.7% on AEDs). Thirty-five subjects were intractable in the final year of 
FU, with no remissions exceeding 3 months despite adequate treatment (8.5%). Table 4.1 shows the 
proportion of subjects in remission or with intractability for each epilepsy type and syndrome. 
 
Figure 4.2: Cumulative proportion reaching a 5-year terminal remission (TRE) during follow-
up. AED, antiepileptic drug. 
 
 
Course during FU 
A favorable course was found in 48.4% of all subjects, with no seizures in the second, fifth, and 
final year of FU. The next largest was the group with an improving course (29.1%), with seizures in 
the second year, but with remission in the fifth year or later. Furthermore, 9.9% had a poor course 
with seizures in each of the 3 years, 6.1% had a deteriorating course, whereas a varying course was 
found in 6.5%. The age at onset was significantly different between the groups (Table 4.2).  
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In those with a favorable course idiopathic etiology was predominant, and the mean longest 
remission during the first 5 years of FU (LR5) was significantly higher than in all other groups. 
In contrast, the group with a poor course had the lowest LR5, only 36.6% had a 3-month remission 
in the first 6 months of FU, and only 14.6% had a fast AED response. There was no difference in 
time to treatment between the groups. 
In the last year of FU, 63.4% of the poor group was intractable, whereas this was 28.0% in the 
deteriorating and 14.8% in the varying group. On the other hand, 93.0% of the favorable group had 
a TRE >5 years, 80.8% of the improving, and 37.0% of the varying group. Table 4.1 shows the 
course for each epilepsy type and syndrome separately, which differed significantly between the 
groups (p < 0.0001). 
 
Early good course 
An early good course was found in 35% of our cohort: 144 subjects were completely free of 
seizures during the first 5 years of FU (n = 58) or had seizures during the first 6 months only and 
subsequently were in remission until 5 years after enrollment (n = 86). AEDs were prescribed in 
112 subjects (77.8%). After these 5 years, 25 subjects relapsed (17.4%). For only 10 subjects, we 
found an explanation: five had photosensitivity, one had seizures due to an arteriovenous 
malformation diagnosed at enrollment, and four had epilepsy with a high relapse rate (West 
syndrome, Lennox-Gastaut syndrome, juvenile myoclonic epilepsy, and generalized tonic–clonic 
seizures on awakening). Only three of the 25 subjects used AED at the time of relapse 
[photosensitivity (2), Rett syndrome]. One other subject with photosensitivity relapsed after AED 
withdrawal. All others had been without treatment for many years following their long remission, 
excluding withdrawal as a cause of relapse. 
Fourteen of the 25 with a relapse ended with active epilepsy—most of the 10 subjects mentioned 
above for whom we found an explanation. Two of those with active epilepsy were intractable in the 
last year of FU (Lennox-Gastaut, symptomatic multifocal epilepsy). 
Idiopathic etiology was more frequent in the group with an early good course than in the remainder 
of the cohort: 64.6% versus 43.5% [95% confidence interval (CI) of the difference: 11.8–31.3%]. 
Relapse was found in 38% of subjects with remote symptomatic etiology versus 13% of those with 
idiopathic and 8% of those with cryptogenic etiology. 
 
Duration of seizure activity 
The mean interval between the very first seizure in life and the last reported seizure during this 
study was 6.0 years (median 3.7; range 0.0–21.5 years). Table 4.1 shows this duration of seizure 
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activity for each epilepsy type or syndrome. The mean intervals differed significantly (p < 0.0001). 
In 25% of the cohort, the interval was <1 year, and in another 25% of the cohort it was >12 years. 
Etiology strongly influenced the duration of seizure activity. Idiopathic etiology had a mean 
duration of 4.5 years (95% CI 3.8–5.3; median 2.3 years), whereas in remote symptomatic etiology 
it was 8.1 years (95% CI 7.0–9.2; median 7.6 years). Cryptogenic etiology had a mean duration of 
6.6 years (95% CI 5.3–7.9; median 4.3 years). At 5 years after onset, 68.3% of the subjects with 
idiopathic etiology had their last seizure: 53.4% of those with cryptogenic and 39.5% of those with 
remote symptomatic etiology (p < 0.0001). At 10 years these numbers were 79.0% for idiopathic, 
65.9% for cryptogenic and 55.3% for remote symptomatic etiology (p < 0.0001). 
 
Treatment 
During the entire FU, 356 of the 413 subjects started treatment (86.2%). For each etiological 
category, the mean number of years during which AEDs were used is shown in Table 4.3, 
uncorrected for periods without AEDs in-between. One-third of the subjects had their very last 
seizure within the first year of treatment. 
Before the end of FU, 221 of the 356 subjects discontinued treatment (62.1%). Their mean number 
of treatment years was 3.2 years (median 2.0; range 0.1–14.8 years). Beside this group, 135 subjects 
(37.9%) continued treatment until the end of FU, 50 of them using polytherapy. Sixty-nine of these 
135 (51.1%) had seizures in the last year of FU, and 37 (27.4%) were in remission for at least 5 
years. Reasons for continuing AEDs were among others: photosensitivity (9), juvenile myoclonic 
epilepsy (2), fear of new seizures (4), failed trials of stopping treatment (4), and ‘‘infantile 
convulsions and choreoathetosis’’ (1). Table 4.4 shows the AEDs used at the end of FU. At last 
contact, the 98 subjects with active epilepsy more often used new drugs available since 1993 
(gabapentin, lamotrigine, topiramate, oxcarbazepine, and levetiracetam) than the 37 subjects in 
remission: 51.0% versus 18.9% (95% CI of difference 16.1–48.1%). 
During the entire FU, 57 subjects never used AEDs (13.8% of 413). Their final outcome, with 
>90% in remission, was comparable with those stopping AED >5 years before the end of FU. These 
two groups did not differ in etiology and epilepsy type. However, subjects never using AEDs were 
younger at epilepsy onset (4.1 vs. 5.4 years; 95% CI of difference 0.2–2.4) and had fewer seizures 
before enrollment (<25 seizures before enrollment: 78.9% vs. 58.7%; 95% CI of difference 7.7–
32.7). 
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Four subjects in our cohort had surgery. In one subject a hypothalamic hamartoma was diagnosed 
during FU. Surgery did not prevent this patient from becoming intractable in the last year of FU. In 
two patients a low-grade ganglioglioma was found during FU.  
After surgery, one patient ended with seizures in the last year of FU, whereas the other never 
relapsed after surgery. One patient had five primarily generalized seizures before enrollment and 
subsequently was in remission for almost 5years. Then he had 10 acute symptomatic seizures within 
1 month as a result of intracranial pressure due to a cerebellar astrocytoma. Operation was followed 
by remission. 
 
Risk factors for active epilepsy and intractability 
The following variables were significantly associated with active epilepsy and intractability in the 
last year of FU: epilepsy type, etiology at enrollment, number of seizures and 3-month remission in 
first 6 months of FU, fast response to AED, TR at 2 and 5 years, intractability in the first 5 years of 
FU, longest remission and number of AEDs in the first 5 years of FU (Appendix 3: Table S1). 
In multivariate stepwise backward analysis predicting intractability, ‘non-idiopathic etiology,’ ‘a 
history of febrile seizures,’ ‘no 3-month remission during the first 6 months of FU,’ and 
‘intractability in the first 5 years of FU’ remained in the model (Table 4.5). The accuracy of the 
model was good (area under ROC 0.88). 
 
Mortality 
During the first 5 years of FU nine children died. Their causes of death have been described in 
detail previously (Callenbach et al., 2001). After these years another nine subjects died (Appendix 
3: Table S2). Based on 18 deaths and 6,775.4 person years of FU, the crude mortality rate was 2.7 
per 1,000 person-years. Compared with the general population, the SMR was almost 10 times 
higher in the current cohort (SMR 9.7; 95% CI 5.7–15.3). Seventeen of the 18 who died had a 
remote symptomatic etiology and one had a localization-related cryptogenic etiology. The SMR of 
remote symptomatic etiology was 31.6 (95% CI 18.4–50.6) and was significantly higher than the  
SMR of idiopathic/cryptogenic etiology: 0.8 (95% CI 0.02 to 4.2). 
Fourteen patients died as a result of their underlying condition, and two other patients died probably 
as a result of an epileptic seizure, but according to the criteria were not regarded as SUDEP 
(Annegers & Coan, 1999). In two other patients, the cause of death could not be established.  
Because SUDEP criteria were not sufficiently met and no postmortem report was available, we 
considered these two as ‘‘possible SUDEP’’ (Annegers & Coan, 1999). Based on these two, our 
SUDEP rate might have been 3/10,000 person-years of FU maximally. 
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DISCUSSION 
 
Final outcome 
Compared with the available literature, our study concerns a relatively large cohort of children with 
new-onset epilepsy with long-term follow-up. First of all, it demonstrates that the majority of the 
children had a good outcome at last contact, with 71% being in remission for at least 5 years. This 
finding is comparable with that of a Finnish population-based study of 144 children (Sillanpaa & 
Schmidt, 2006). They found a 5-year TR in 67% after a mean FU of 37 years. Our findings are also 
in agreement with a retrospective hospital-based Japanese study of 148 children with epilepsy 
(Wakamoto et al., 2000). After a mean FU of 18.9 years, 63% of their cohort achieved a 5-year TR. 
Considering the results of these three long-term FU studies, we conclude that the long-term 
outcome in childhood-onset epilepsy is favorable in about two-thirds of children. 
On the other side, 8.5% of our cohort was intractable in the final year. Long-term intractability was 
reported in only one other study, in which at last contact 11.7% of 613 subjects were intractable 
after a median FU of ~10 years (Berg et al., 2006). In addition, two other studies reported on 
intractability, but their mean FU was only 55 months. Oskoui found 6.9% of 196 children with 
intractability using a stricter definition, which probably led to a lower rate, whereas Kwong found a 
higher rate (14.2% of 309 children), which probably resulted from more subjects with remote 
symptomatic etiology (40.8% vs. 27.8% in our cohort) (Kwong et al., 2003; Oskoui et al., 2005). 
 
Course 
We analyzed the course of epilepsy by comparing three separate years during FU on the occurrence 
of seizures or not. The course was favorable in half of the cohort, and outcome improved in 29%. In 
more than one-fourth of subjects, improvement started only after 5 years of FU; 62% of these 
reached a 5-year TR versus 88% in subjects with earlier improvement. This suggests that late 
improvement leads to a worse outcome than early improvement or that more time is needed to reach 
remission. 
The fact that remote symptomatic etiology was more frequent in the deteriorating than in the 
favorable group was probably the cause of their worse course and perhaps illustrates the natural 
course of epilepsy. In at least half of the group, deterioration began after 5 years of FU, but was not 
caused by age or etiological differences within this group. A poor course started already in the first 
half year of FU, with only a few subjects having a 3-month remission or a fast response to 
treatment. 
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We conclude that the course of epilepsy can be inconsistent. Especially improvement but also 
deterioration may occur after considerable time has passed. A good example is subjects with an 
early good course with no seizures during the first 5 years of FU or only during the first 6 months. 
After long remission, 17% relapsed and half of them ended with active epilepsy and some even 
became intractable. Short-term results and predictions of outcome should, therefore, be interpreted 
with caution. The question remains whether in the future such an inconsistent course can be 
influenced by treatment strategies to prevent deterioration or to accelerate improvement. 
This brings us to the question of whether AEDs influence the course of epilepsy or merely suppress 
seizures. In the present study, the favorable and improving course could have been the result of 
treatment, although some never used AEDs and improvement sometimes was delayed for many 
years. In the poor group, treatment certainly was not effective and in the deteriorating group 
development of drug resistance or tolerance might have occurred. Like others, we found non-
idiopathic etiology and young age at onset significantly associated with a poor course of epilepsy 
(Huttenlocher & Hapke, 1990; Kwong et al., 2003). Considering this, we think that treatment does 
not seem to have a major impact on the outcome of epilepsy. In our opinion, the natural course of 
epilepsy better explains our results, with some types of epilepsy being short-lived and others having 
a designated poor outcome. This is in line with the hypothesis of Shinnar and Berg, who state that 
the long-term prognosis of seizure disorders appears to be primarily a function of the epileptic 
syndrome and the underlying etiology (Shinnar & Berg, 1994). Furthermore, there is evidence from 
retrospective studies that untreated epilepsy can result in spontaneous remission (Placencia et al., 
1994; Nicoletti et al., 2009). 
 
Treatment 
At the end of FU one-third of our cohort continued AEDs, not only those with active epilepsy, but 
also a considerable number of patients in remission (27%). At least for part of those in remission 
treatment was probably no longer necessary. Physicians should be aware of this; incorrectly 
maintaining treatment may result from a patient’s steady state without seizures or noticeable side 
effects or it can result from infrequent visits. A trial of AED withdrawal is always justified after 
some seizure-free years. 
The proportion of subjects continuing treatment at last contact was slightly lower in our study than 
in two other studies, with proportions of 45% and 42% maximally (Camfield et al., 1993; Sillanpaa 
& Schmidt, 2006). Differences in etiology and length of FU could explain this, together with a more 
reserved attitude toward AEDs through the recent years. The latter is illustrated by the fact that 
>13% of our cohort never used AEDs during the entire FU, which is a unique feature. Only Berg 
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(initially 10% without AEDs) and Camfield (3% without AEDs) reported on this (Camfield et al., 
1993; Berg et al., 1999a, 2006). 
One-third of our subjects had their last seizure within the first year of treatment and remained 
seizure free until the end of FU (early remission group). In the Finnish study, a comparable 
proportion of subjects started a 5-year remission within 1 year of treatment. However, half of them 
later relapsed (Sillanpaa & Schmidt, 2006). Another study reported that 45% of children with 
localization-related cryptogenic epilepsy instantly became seizure free after starting treatment 
(Camfield & Camfield, 2002). About 13% of our early remission group had this epilepsy type. We 
conclude that early remission after initiation of treatment may occur, especially in favorable 
epilepsy types. Yet 16% of our early remission group had a remote symptomatic etiology, meaning 
that part of the explanation is still lacking. 
 
Mortality 
The SMR in the present hospital-based study (9.7) was slightly higher compared with the 7.0 we 
found after 5 years of FU (Callenbach et al., 2001). The SMR for those with symptomatic etiology 
was 31.6. In a community-based cohort in the United States the SMR was 7.5 for the whole cohort 
and 33.5 for children with symptomatic etiology (Berg et al., 2004). Although we cannot compare 
the SMRs of these two studies, because of differences in composition of the cohorts, obviously 
more subjects with symptomatic etiology die (Logroscino & Hesdorffer, 2005). The finding 
that more subjects with symptomatic etiology die was also shown in other studies and is probably a 
result of the underlying severe disorder (Annegers et al., 1979; Brorson & Wranne, 1987; Sillanpaa 
et al., 1998; Lhatoo et al., 2001; Camfield et al., 2002). 
We had two deaths in our study without a known cause. Although we are not sure if these could 
have been SUDEP, the maximum SUDEP rate would be 3/10,000 person-years of FU. Others 
reported rates between 1–2/10,000 and 4/10,000 (Donner et al., 2001; Camfield & Camfield, 2005; 
Weber et al., 2005). 
 
Advantages and limitations 
In this prospective cohort study, children with epilepsy were included and followed up since 
diagnosis. The size of the cohort and the length of FU are advantages of this study, in addition to 
the thorough panel-classification and the regular check-ups with detailed questionnaires. Not many 
cohorts are comparable on these points: most have fewer children (Brorson & Wranne, 1987; 
Kwong et al., 2003; Oskoui et al., 2005) sometimes with longer FU (Wakamoto et al., 2000; 
Sillanpaa & Schmidt, 2006), and those with more children have shorter FU thus far (Camfield et al., 
1993; Berg et al., 2006). Furthermore, only a few studies like ours included exclusively children 
 Page | 69  
 
with new-onset epilepsy and followed them prospectively (Berg et al., 1999b; Shinnar et al., 1999). 
A limitation of our study is the fact that we had regular visits only during the first 5 years. To 
extend FU, we sent a concise questionnaire taking little time to optimize cooperation. Wherever 
possible, the gathered data were supplemented with data from the medical files. However, details on 
dates of seizures and AED changes may have become less accurate in the course of time. 
 
CONCLUSIONS 
 
The long-term prognosis of epilepsy is favorable in the majority of children, especially for those 
with idiopathic etiology. In contrast, epilepsy remains active in ~30% and is intractable in ~10%, 
and is then highly associated with non-idiopathic etiology or an early unfavorable course. During 
FU, the course of epilepsy can be inconsistent: periods of remission can interchange with periods of 
seizures. It remains to be seen whether such a course is influenced by the treatment given, since 
childhood-onset epilepsy is often a benign self-limiting disorder and treatment proved to be 
ineffective in those with active epilepsy or intractability. Mortality is significantly higher only in 
those with remote symptomatic etiology, and SUDEP in children is rare. 
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Additional Supporting Information may be found in the online version of this article or in 
Appendix 3:  
Table S1. Significant variables for active epilepsy (TRE < 5 year) and final intractability, and odds 
ratios for intractability (OR) for each value as compared with the reference value of that variable. 
Table S2. Characteristics of nine subjects who died after more than 5 years of follow-up (FU). The 
causes of death of those who died in the first 5 years have been described in detail previously 
(Callenbach et al., 2001). 
Figure S1. Cumulative proportion reaching a 2-year terminal remission (TRE) during follow-up. 
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ABSTRACT 
 
Epilepsy may have far-reaching consequences for patients, other than having seizures and 
medication. At 15 years after diagnosis, this study investigates health perception, restrictions due to 
epilepsy, living arrangements (including marital status, and offspring), and the educational and 
occupational attainment of subjects with childhood-onset epilepsy.  
A total of 453 subjects with epilepsy had a five-year follow-up since diagnosis with regular visits 
and data collection. Ten years later, a questionnaire addressing epilepsy was completed by 413 
subjects, resulting in a mean follow-up of 15 years. Subjects were compared with age peers of the 
Dutch population for each etiological group separately, and also for subjects with/without a five-
year terminal remission regardless of treatment. Age-adjusted standardized incidence rates were 
calculated for each variable. 
Subjects with normal intelligence had a health perception comparable with that of the general 
population, but significantly more subjects without remission had a worse health perception, 
especially those still using medication. Restrictions and symptoms due to epilepsy were reported by 
14% of the subjects, mainly by those without remission or with ongoing medication. The living 
arrangement of subjects with idiopathic or cryptogenic etiology was similar to that of Dutch age 
peers. Subjects with remote symptomatic etiology less often lived independently or with a partner, 
and more frequently resided in an institution or living group for the disabled. Those with and 
without remission were more often part of another household, mainly due (in both groups) to having 
a remote symptomatic etiology. Rates of having a partner and offspring were significantly reduced 
only for subjects with remote symptomatic etiology.  
Fewer students with idiopathic/remote symptomatic etiology and students in remission followed 
higher vocational or scientific education. In these latter groups, the highest attained education of 
employees was lower than expected. The employment status of subjects with idiopathic or 
cryptogenic etiology was comparable with that of their Dutch age peers, but fewer subjects with 
remote symptomatic etiology were employed and more of them were part of the dependent 
population. However, for those in the labor force (employed/unemployed) all employment rates 
were ≥ 90%, even for those with remote symptomatic etiology. Nevertheless, fewer employees than 
expected had a higher vocational or scientific level of occupation, even those with idiopathic 
etiology and those in remission. 
Health perception, living arrangement and socioeconomic status were influenced by epilepsy, 
comorbidities or treatment, particularly for subjects with remote symptomatic etiology or no 
remission. The group in remission fared less well than expected, mainly due to the numbers of 
subjects with remote symptomatic etiology in this group. In line with others, we conclude that 
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childhood-onset epilepsy is associated with lower educational attainment, even for subjects with 
idiopathic etiology and subjects in remission; probably related to this, their occupational level was 
also lower than expected. 
 
INTRODUCTION 
 
After a diagnosis of epilepsy, the main focus is on clinical aspects, such as etiology, seizure 
frequency, treatment, and the subsequent prognosis. When seizures start during childhood, 
additional aspects become important, as epilepsy and its etiology may have consequences for 
cognitive, psychosocial/emotional development, education, and later employment. Moreover, 
epilepsy may negatively influence social functioning, self-esteem, and quality of life. 
Studies investigating these aspects in cohorts with childhood-onset epilepsy report that the long-
term prognosis is unfavorable in terms of level of cognition and education and rate of employment 
and marriage (Kokkonen et al., 1997; Sillanpaa et al., 1998; Wakamoto et al., 2000; Zelnik et al., 
2001; Sillanpaa et al., 2004; Camfield & Camfield, 2008; Yu et al., 2009; Sogawa et al., 2010), and 
that the risk of social and educational problems is increased even for those with ‘‘epilepsy only,’’ or 
with idiopathic epilepsy in remission without medication (Jalava et al., 1997; Sillanpaa et al., 
1998; Camfield & Camfield, 2010). In contrast, others found that normally intelligent children with 
epilepsy have a favorable educational and social prognosis (Wakamoto et al., 2000; Sillanpää & 
Schmidt, 2010), and that adults with well-controlled epilepsy (many with onset during childhood) 
and without other impairments or disabilities generally experience no problems with employment 
(Jacoby, 1995). 
However, these findings remain controversial and childhood-onset epilepsy in neurologically intact 
children is not as innocent as it may seem. In these children, initiation of special education services 
often precedes the onset of seizures (Schouten et al., 2001; Berg et al., 2005), and progress at school 
may be worse before seizure onset, with more children having ‘‘epilepsy only’’ repeating a school 
year (Schouten et al., 2001). Psychiatric disorders are significantly more frequent in children with 
uncomplicated epilepsy than in controls (Davies et al., 2003). Moreover, MRI studies in children 
with epilepsy point to discrete anatomic abnormalities in those with attention deficit hyperactivity 
disorder (Hermann et al., 2007). 
Based on these findings, more data from cohorts with long-term follow-up are required. Between 
1988 and 1992, consecutively recruited children attending hospital with new-onset epilepsy were 
followed prospectively; course and outcome at 2, 5, and 15 years after diagnosis are already 
published (Arts et al., 1999, 2004; Geerts et al., 2010). Here we report the health perception and 
socioeconomic status for each etiologic group, and for subjects with or without 5-year terminal  
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remission, regardless of treatment. 
 
METHODS 
 
Ethical approval for this study was obtained from the review boards of the hospitals. 
 
Cohort 
Detailed descriptions and setting of the original prospective hospital-based study of 494 children 
with new-onset epilepsy have been published (Arts et al., 1999). Children were enrolled between 
1988 and 1992. A panel of three pediatric neurologists classified seizures and epilepsies shortly 
after enrollment based on history, neurologic examination, electroencephalography (EEG), 
computed tomography (CT) scans, or (sometimes) magnetic resonance imaging (MRI) (Gastaut, 
1969; ILAE, 1981). At 2-year follow-up, the original classifications based on older guidelines were 
replaced by the later classifications of the International League against Epilepsy (ILAE, 1989). 
Etiology was idiopathic, cryptogenic, or remote symptomatic including mental retardation (ILAE, 
1993). At the end of the present study, the etiologic classifications were reconsidered as some 
subjects proved to have neurologic brain-related morbidities. 
All subjects had had at least two unprovoked epileptic seizures or one status epilepticus before 
enrollment. Subjects with brain tumors and other progressive affections diagnosed at entry were 
excluded. Although hospital based, our recruitment rate was ~75% of the expected annual incidence 
in the referral area (Arts et al., 1999). 
 
Follow-up and questionnaire 
During the first 5-year follow-up, children attended hospital at regular intervals; after this period 
follow-up stopped. Between 2004 and 2006, all subjects with a 5-year follow-up (n = 453) received 
a simple questionnaire (that did not burden the subjects too much) with items addressing epilepsy 
(Supporting Information A, Appendix 1). The questionnaire was returned by 413 subjects (response 
rate: 84% of the original 494 subjects). After informed consent, we also consulted the medical files 
of patients who still had seizures in the last year of follow-up. 
 
Statistical analyses 
Results of the responders were compared with data of age peers from the general population in The 
Netherlands. Indirect standardization was used, meaning that we multiplied the age-specific rates of 
the Dutch population by the total number of subjects in each age group of our cohort, to calculate 
the number of cases that would have been expected. The sum of all observed cases in our cohort 
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was divided by the sum of all expected cases to yield the age-adjusted standardized incidence rate. 
Values >1 suggest a higher rate in the cohort than in the reference population, and <1 a lower rate. 
The computer-program Confidence Interval Analysis was used to calculate the standardized 
incidence rates, confidence intervals, and significance (Gardner & Altman, 1989; Gardner et al., 
1989). The observed and expected cases, and the standardized incidence rate for each variable, can 
be found in Supporting Information B (Appendix 4). For some variables, specific groups of the 
cohort and of the Dutch population were used (e.g., subjects not in institutions, students, 
employees). Data on the Dutch population were provided by Statistics Netherlands (CBS): This is a 
national organization (covering many social aspects) that collects/analyzes data and publishes 
statistics on the general population on behalf of practice, policy, and science (CBS, 2005). 
The health perception of the cohort was compared with that of Dutch age peers in the CBS Health 
Inquiry. This is an annual inquiry among a randomly drawn sample of approximately 10,000 
subjects in private households (excluding subjects in institutions). This means that the age-specific 
rates for health perception are estimates; all other rates are based on absolute numbers of cases in 
the general population.  
Health perception was categorized as ‘‘very good,’’ ‘‘good,’’ or ‘‘less than good.’’ These categories 
were not defined but were ‘‘interpreted’’ by each of the subjects who were giving their opinion. We 
present health perception and restrictions only for subjects with normal intelligence. The rationale 
for this is that, in the case of mental retardation, the caregivers/parents often gave answers and this 
was considered to be less accurate. Moreover, in the case of severe retardation it is difficult to 
assess restrictions due to epilepsy alone, as other morbidities are often present. 
Responders were categorized according to etiology and to outcome, with both parameters as defined 
at the end of follow-up (Table 5.1). Because the groups with a 5-year terminal remission on 
antiepileptic drugs (AEDs) (n = 37) and with active epilepsy off AEDs (n = 22) were small, we 
present the results for the group with or without a 5-year terminal remission irrespective of 
treatment. 
As most data of the CBS were available for 10-year age groups only, we excluded 28 subjects aged 
12, 13, and 14 years, as their comparison with the 5- to 14-year-old age group would lead to bias. 
Only for ‘‘living arrangements’’ were 5-year age groups available. Occupational level was 
classified according to the International Standard Classification of Occupations (ISCO-88) (ISCO, 
2010). 
 
 
 
 
 Page | 78  
 
Table 5.1: Data on subjects in the present study, by age group 
  
A: Etiology at end of follow-up 12-14 years  15-24 years  25-34 years  Total 
Idiopathic 9 (4.7%) 136 (70.8%) 47 (24.5%) 192 [46.5%] 
Cryptogenic  2 (2.9%) 54 (77.1%) 14 (20.0%) 70 [16.9%] 
Symptomatic 17 (11.3%) 112 (74.2%) 22 (14.6%) 151 [36.6%] 
Total 28 (6.8%) 302 (73.1%) 83 (20.1%) 413 [100%] 
     
B: Outcome 12-14 years  15-24 years  25-34 years  Total 
Remission (TR > 5 years ) 19 (6.5%) 214 (73.0%) 60 (20.5%) 293 [70.9%] 
No remission (TR < 5 years ) 9 (7.5%) 88 (73.3%) 23 (19.2%) 120 [29.1%] 
Total 28 (6.8%) 302 (73.1%) 83 (20.1%) 413 [100%] 
TR: terminal remission. 
 
Definitions 
Terminal remission: the interval between the last seizure and the end of follow-up. From here 
onward the group with a 5-year terminal remission (regardless of treatment) is called the group in 
remission and the words ‘‘remote symptomatic’’ are abbreviated to symptomatic. Active epilepsy: 
at least one seizure in the last 5-year follow-up regardless of treatment (ILAE, 1993). 
Children had no formal IQ testing at enrollment. Those attending special schools for the 
intellectually disabled were classified as mentally retarded (IQ < 70) and as having symptomatic 
etiology (Hauser et al., 1982). In The Netherlands, children with an IQ of 50–70 occasionally 
follow mainstream education, but most go to specialized schools. Employed: having a job for at 
least 12 h/week. Unemployed: having no job or working <12 h/week, but willing to work for at 
least 12 h/week, being available and actively looking for work (CBS, 2005). Dependent: not 
wanting or not able to work for at least 12 h/week or to work at all, not being available for work, or 
not actively looking for work. This definition includes students, housewives, and persons who are 
ill or disabled. Employment (unemployment) rate: number of employed (unemployed) individuals 
divided by all the employed plus unemployed individuals (i.e., the labor force). 
 
RESULTS 
 
General 
The 413 subjects (47.2% male) had a mean age of 5.5 years (median 5.1; range 1 month–15.5 years) 
at onset of epilepsy and of 20.8 years (median 20.4; range 12.2–32.5) at last contact. Etiology at 
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enrollment was idiopathic in 50.8% of the cohort, cryptogenic in 21.3%, and symptomatic in 27.8%. 
At last contact the mean follow-up was 14.8 years (median 14.8, range 11.6–17.5) and 70.9% 
subjects had a 5-year terminal remission (61.9% off AEDs, 9.0% on AEDs). The remainder had 
active epilepsy (5.3% off AEDs, 23.7% on AEDs). In the last year of follow-up, 8.5% of the cohort 
was intractable with no remissions exceeding 3 months, despite the use of at least two AEDs 
(Geerts et al., 2010). 
In addition to their epilepsy, 205 subjects (49.6%) reported one or more neurologic brain-related 
morbidities (mostly the cause of their epilepsy) or other impairments and disabilities. The brain-
related morbidities included Sturge-Weber syndrome (n = 1), cerebral malformations (n = 14), 
inborn metabolic errors (n = 3), mental retardation (n = 112; IQ 50–70: n = 24, IQ < 50: n = 88), 
autism spectrum disorders (n = 16), and brain tumors diagnosed during follow-up (n = 3). Based on 
these results the etiology of 36 subjects changed to symptomatic at last contact (Table 5.1). The 
other impairments and disabilities included heart and coronary diseases (n = 5), chronic obstructive 
pulmonary diseases (n = 14), diseases of abdominal organs (n = 8), hormonal disorders (n = 5), 
disorders of the musculoskeletal system (n = 17), allergy and skin disorders (n = 15), deafness (n = 
6), recurrent infections (n = 6), and autoimmune disorder (n = 1). Twelve subjects reported 
headaches and migraine, and 59 subjects reported attention deficit hyperactivity disorder, 
depression, fears or problems with concentration, learning, or behavior. 
 
Health perception 
The health perception of the cohort (excluding 112 mentally retarded subjects and 18 subjects 
giving no answer) is presented in Figure 5.1. The age-adjusted standardized incidence rates showed 
that more subjects without remission had a worse health perception than respondents of the CBS 
Health Inquiry (excluding institutionalized subjects). Furthermore, fewer subjects with   
cryptogenic/ symptomatic etiology reported a very good health perception. 
In the group without remission, more subjects still using AEDs reported a worse health perception 
than those off AEDs [26.7% vs. 6.7%, 95% confidence interval (CI) of difference: 1.9–38.1, p < 
0.05). 
 
Restrictions 
Subjects were asked to what extent epilepsy restricted their daily activities at home, at school, or 
work and during sports or other leisure activities, and to what extent epilepsy restricted commuting 
or traveling. Some subjects reported not being allowed to do certain things, whereas others 
mentioned symptoms due to epilepsy that restricted them from performing certain activities. 
Excluding mentally retarded subjects, 42 of the 301 subjects (14.0%) reported one or more 
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restrictions or symptoms. Fewer subjects in remission (5.5%) reported restrictions than subjects 
without remission (45.3%) (Pearson χ2 66.57, d.f. 1, p < 0.0001). No difference was found between 
the etiologic groups. Of the 68 subjects still using AEDs, 39.7% reported restrictions versus 6.4% of 
the 233 subjects off AEDs (Pearson χ248.52, d.f. 1, p < 0.0001). 
 
Figure 5.1: Subjective health perception of 283 subjects (excluding those with an IQ < 70 and 
18 subjects who gave no answer) compared with the respondents (excluding institutionalized 
subjects) of the Dutch Health Inquiry in the year 2005 
 
Age-adjusted standardized incidence rates with 95% confidence interval (# p<0.1, * p<0.05). 
 
Very good Good Less than good 
Idiopathic (n=184) 1.09 (0.83-1.41) 0.95 (0.78-1.15) 1.03 (0.63-1.59) 
Cryptogenic / Symptomatic (n=99) 0.66 (0.40-1.02)# 1.14 (0.89-1.45) 1.16 (0.60-2.02) 
    
Remission (n=223) 0.98 (0.76-1.25) 1.04 (0.88-1.23) 0.81 (0.49-1.27) 
No remission (n=60) 0.80 (0.44-1.34) 0.92 (0.63-1.29) 2.03 (1.08-3.46)* 
 
 
Because of small numbers, the cryptogenic (crypto) and symptomatic group (sympto) were combined. 
Remission: 5-year terminal remission either on or off AEDs. Numbers of subjects in the three age groups: 
idiopathic (50, 89, 45), cryptogenic, and remote symptomatic (27, 52, 20), remission (63, 111, 49), no 
remission (14, 30, 16). (#p < 0.1; indicating the difference between that group and the population). 
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The most often reported restrictions were related to performing activities or learning things because 
of concentration and memory problems, and restrictions in practicing or choosing sports, followed 
by having to avoid seizure triggers such as TV or alcohol. Subjects without remission mentioned 
restrictions regarding transportation or getting a driving license more often than those in remission 
(8 of 29 vs. 1 of 13 subjects, p < 0.10). 
 
Living arrangements 
Compared with the population, more subjects of the cohort were part of a household other than that 
of their family or of themselves, which resulted in significantly higher age-adjusted standardized 
incidence rates for both outcome groups (Figure 5.2). This was mainly due to subjects with 
symptomatic etiology of whom many lived in an institution or a living group for the disabled. 
About 25% of the group in remission and 50% of the group without remission had symptomatic 
etiology. Overall, fewer subjects with symptomatic etiology lived independently (single) or with a 
partner (couple). In contrast, the living arrangements of subjects with idiopathic or cryptogenic 
etiology and their Dutch age peers were comparable, for whom ‘‘another household’’ meant a 
shared house or a student home. They also resembled the Dutch population in having offspring, 
whereas none of the subjects with symptomatic etiology had children. 
 
Education 
In the age group 15–24 years, at last contact 151 subjects went to school, of which 92.7% were full 
time. Another 11 subjects aged ≥25, still went to school, most of them in addition to their job. 
Subjects with idiopathic or cryptogenic etiology resembled their Dutch age peers, although in the 
group with idiopathic etiology higher vocational or scientific education was slightly 
underrepresented (Figure 5.3). The latter was also true for subjects in remission and subjects with 
symptomatic etiology. In the latter group the rate of special education was high. Even for the group 
in remission the rate of special education was higher than expected. Of the 18 subjects following 
special education, 12 visited a specialized school for those with an IQ < 55 or an IQ of 55–70 but 
with additional problems, such as autism spectrum or attention deficit hyperactivity disorder. 
Figure 5.4 shows the highest educational attainment of our employees (n = 137) and job seekers (n 
= 11), and of the Dutch labor force. In the highest age group, fewer subjects with idiopathic or 
remote symptomatic etiology and subjects in remission completed higher education, whereas lower 
education was overrepresented. The age-adjusted standardized incidence rates for higher education 
were lower than expected for these groups. 
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Figure 5.2: Living arrangements of 377 subjects compared with Dutch age peers (including 
institutionalized subjects) 
 
Age-adjusted standardized incidence rates with 95% confidence interval (** p<0.01). 
  living with 
parents 
single couple other household offspring 
Idiopathic 
(n=178) 
0.91 
(0.73-1.12) 
1.04 
(0.71-1.47) 
1.07 
(0.78-1.44) 
1.72 
(0.86-3.08) 
1.20 
(0.71-1.90) 
Cryptogenic 
(n=67) 
0.98 
(0.69-1.34) 
0.87 
(0.42-1.60) 
1.21 
(0.70-1.93) 
0.81 
(0.10-2.92) 
1.23 
(0.45-2.68) 
Symptomatic 
(n=132) 
0.96 
(0.76-1.19) 
0.35 
(0.14-0.73)** 
0.39 
(0.18-0.75)** 
7.56 
(5.27-10.50)** 
0.00 
      
Remission 
(n=267) 
0.85 
(0.64-1.10) 
0.80 
(0.44-1.35) 
0.84 
(0.50-1.33) 
5.42 
(3.36-8.29)** 
0.89 
(0.53-1.41) 
No remission 
(n=110) 
0.98 
(0.83-1.15) 
0.78 
(0.55-1.09) 
0.92 
(0.69-1.21) 
2.80 
(1.85-4.08)** 
0.81 
(0.30-1.76) 
 
Because of many data, we did not present the percentages for etiology and outcome separately in this figure. 
Data were unknown for eight subjects. Remission: 5-year terminal remission either on or off AEDs. (#p < 
0.1, *p < 0.05, **p < 0.01, indicating the difference between that group and the population). 
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Figure 5.3: Present education followed by the 151 students aged 15–24 years at the end of 
follow-up compared with the Dutch age peers following education (including special 
education, excluding institutionalized subjects) in the year 2005/2006  
 
 
Remission: 5-year terminal remission either on or off AEDs. Lower vocational (voc)/lower general 
secondary (gen sec)/pre-university (pre-uni) education, intermediate vocational (intermed voc) education, 
higher education: higher vocational or university education. (#p < 0.1, *p < 0.05, **p < 0.01, indicating the 
difference between that group and the population). 
 
 
Employment status and occupation 
The employment status for subjects with idiopathic or cryptogenic etiology resembled that of Dutch 
age peers, whereas fewer subjects with symptomatic etiology (excluding institutionalized subjects) 
were employed and more were dependent (Figure 5.5). Most of the latter were physically and/or 
mentally disabled and received a welfare pension. However, when considering only those subjects 
who are part of the labor force (employed or unemployed), similar employment rates were found 
(idiopathic 91.5%, symptomatic 91.3%, cryptogenic 97.1%, in remission 93.2%, active epilepsy 
91.2%, Dutch age peers 92.0%). 
A total of 139 subjects (33.7%) had a job (Figure 5.6). Fewer employees with idiopathic etiology 
had an occupation based on higher education. This was also true for employees in remission. None 
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of the employees with symptomatic etiology had a higher vocational or scientific job, and 
significantly more of them had an elementary job. 
 
Figure 5.4: The highest attained education of 137 employees and 11 jobseekers in our cohort 
compared with age peers of the labor force of the Dutch population  
 
 
 
Age-adjusted standardized incidence rates with 95% confidence interval (# p<0.1, ** p<0.01). 
  lower education intermediate education higher education 
Idiopathic (n=94) 1.32 (0.93-1.81) 1.09 (0.80-1.44) 0.44 (0.20-0.84)** 
Cryptogenic (n=34) 0.48 (0.16-1.13) 1.38 (0.86-2.08) 0.97 (0.39-2.01) 
Symptomatic (n=20) 1.64 (0.85-2.86) 0.62 (0.25-1.28) 0.20 (0.01-1.11)# 
    
Remission (114) 1.25 (0.91-1.68) 1.09 (0.83-1.40) 0.42 (0.21-0.76)** 
No remission (n=34) 0.96 (0.48-1.73) 1.03 (0.60-1.65) 0.91 (0.33-1.98) 
 
 
Remission: 5-year terminal remission either on or off AEDs. Number of subjects in the two age groups: 
idiopathic etiology (n = 56, 38), cryptogenic (n = 21, 13), symptomatic (n = 14, 6); remission (n = 67, 47); no 
remission (n = 24, 10). Lower education: primary, lower vocational or lower general secondary education. 
Intermediate education: higher general secondary or pre-university education or intermediate vocational 
education. Higher education: higher vocational or university education. (*p < 0.05, **p < 0.01, indicating the 
difference between that group and the population). 
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Figure 5.5: Employment status of 352 subjects compared with the age peers of the Dutch 
population (excluding institutionalized subjects in the cohort and in the Dutch population)  
 
 
Age-adjusted standardized incidence rates with 95% confidence interval  
(# p<0.1, * p<0.05, ** p<0.01). 
  Employed  Unemployed Dependent 
Idiopathic (n=183) 0.95 (0.76-1.18) 0.80 (0.35-1.58) 1.08 (0.87-1.33) 
Cryptogenic (n=68) 1.03 (0.71-1.44) 0.27 (0.01-1.50) 1.06 (0.73-1.48) 
Symptomatic (n=101) 0.46 (0.29-0.70)** 0.36 (0.04-1.30) 1.57 (1.24-1.96)** 
    
Remission (n=261) 0.88 (0.72-1.06) 0.56 (0.24-1.11) 1.18 (0.99-1.39)# 
No remission (n=91) 0.71 (0.48-1.01)# 0.60 (0.12-1.76) 1.34 (1.02-1.74)* 
 
Remission: 5-year terminal remission either on or off AEDs. Number of subjects in the two age groups: 
idiopathic etiology (n = 136, 47), cryptogenic (n = 54, 14), symptomatic (n = 85, 16); remission (n = 204, 
57); no remission (n = 71, 20). (#p < 0.1, *p < 0.05, **p < 0.01, indicating the difference between that group 
and the population). 
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Figure 5.6: Occupational level of 138 employees in our cohort compared with that of age peers 
of Dutch employees  
 
Age-adjusted standardized incidence rates with 95% confidence interval (# p<0.1, ** p<0.01). 
  Elementary Lower  Intermediate Higher/scientific 
Idiopathic (n=86) 0.52 (0.17-1.22) 1.26 (0.88-1.74) 1.16 (0.81-1.60) 0.56 (0.26-1.07)# 
Cryptogenic (n=32) 0.00 0.62 (0.25-1.28) 1.52 (0.90-2.41) 1.19 (0.48-2.45) 
Symptomatic (n=20) 3.00 (1.21-6.19)* 0.86 (0.31-1.86) 0.92 (0.37-1.90) 0.00 
     
Remission (n=108) 0.85 (0.41-1.56) 1.09 (0.78-1.49) 1.16 (0.85-1.55) 0.62 (0.33-1.06)# 
No remission (n=30) 0.52 (0.06-1.89) 0.89 (0.43-1.64) 1.39 (0.78-2.29) 0.62 (0.13-1.81) 
 
The occupation of two other employees was unknown. Number of subjects in the two age groups: idiopathic 
etiology (n = 49, 37), cryptogenic (n = 19, 13), symptomatic (n = 12, 8); remission (n = 59, 49); no remission 
(n = 21, 9). Elementary: jobs with simple duties. Lower: jobs with duties at the level of preliminary 
vocational education. Intermediate: jobs with duties at the level of intermediate vocational education. 
Higher/scientific: jobs with duties at the level of higher vocational or scientific education. (#p < 0.1, **p < 
0.01, indicating the difference between that group and the population). 
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DISCUSSION 
 
This study examined the health and socioeconomic status of subjects with new-onset epilepsy, 
diagnosed in childhood and followed prospectively for a mean of 15 years. By comparing our 
subjects with age peers of the Dutch population, we aimed to reveal the long-term consequences of 
epilepsy other than seizures and medication. 
The results are presented for each etiologic subgroup separately, because cohorts generally include 
subjects with varying types of epilepsy and etiology, and with divergent prognoses. Comparing the 
entire cohort as one group with the general population would yield less meaningful results, and 
makes comparison with other cohorts difficult. 
In the group with idiopathic etiology, we were particularly interested in whether their life (without 
neurologic impairments or disabilities) would revert to normal once they reached long-term 
remission without medication. However, this group did less well than their Dutch age peers, even 
though 75% were in remission and off AEDs, and their health perception, living arrangements, and 
numbers of offspring were comparable. Although their employment rate was not lower than 
expected, they had lower educational and occupational levels. This could be due to the epilepsy and 
seizures (Baker et al., 2011), or to an assumed preexisting common cause for the epilepsy and other 
brain dysfunctions. Based on reports from our group and others (Schouten et al., 2001; Oostrom et 
al., 2003), we tend to opt for the latter possibility. Moreover, two recent studies showed that minor 
dysfunctions/disabilities were present not only in children with epilepsy but also in their healthy 
siblings (Clarke et al., 2007; Wandschneider et al., 2010). These findings support the hypothesis 
that dysfunctions or disabilities are part of the epileptic spectrum and are (at least in part) 
genetically determined (Berg, 2011; Jensen, 2011). We expected that the group with cryptogenic 
etiology would show at least similar results. However, subjects in this small group showed few 
differences with the Dutch population; they bore more resemblance to the idiopathic group than to 
the symptomatic group (which had the worst results). 
Besides etiology, we chose to present the results for two distinct outcome groups, as we 
hypothesized that the largest group would be the one including subjects whose epilepsy was 
(probably) a temporary, age-related experience. This group was expected to have a longstanding 
remission, mostly without AEDs, and most are expected to have normal intelligence and at first 
glance seem to live their life without restrictions. The other smaller group would fare much worse, 
with active epilepsy, still using AEDs, and many subjects almost certainly with obvious disabilities, 
and often depending on state welfare. Although not all of these aspects proved to be true, the 
distinction between a relatively good and a poor long-term outcome is clear.  
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Nevertheless, in the present study, the group in remission performs less well than expected. 
Although their health perception was good and they reported significantly fewer restrictions than 
subjects without remission, more were part of the dependent population and part of another 
household (mainly due to those subjects with symptomatic etiology). In addition, students and 
employees in remission less often followed or completed higher education, resulting in lower job 
levels; this is not surprising, since about 50% of this group had idiopathic etiology with similar 
results, and about 25% had symptomatic etiology with worse results. 
The group with active epilepsy confirmed our expectations. Their health perception was 
significantly worse, they reported more restrictions and were more often disabled and 
institutionalized; >50% had symptomatic etiology. For those able to study, the level of education 
was lower, although for employees no significant differences were found in highest attained 
education and level of occupation, probably due to the small numbers. 
 
Health perception 
In a population-based birth-cohort study, children with epilepsy with good cognitive development 
without comorbidities have similar adult health compared to the unaffected population (Chin et al., 
2011). A Finnish study comparing subjects with childhood-onset epilepsy with matched controls 
also found no significant difference in health perception; the study showed that 8.3% of 96 subjects 
with ‘‘epilepsy only’’ had a poor self-assessed health status (Jalava & Sillanpaa, 1997a). This result 
is similar to the 11% of our 184 subjects with idiopathic etiology reporting a worse health 
perception, the main reasons for this being active epilepsy and ongoing medication. This effect of 
medication was also found in another study, but only for subjects on polytherapy (Jalava et al., 
1997). 
 
Marriage or cohabitation, offspring 
Several cohort studies of childhood-onset epilepsy reported a lower rate of marriage or cohabitation 
for subjects with uncomplicated epilepsy or normal intelligence (Jalava & Sillanpaa, 1997b; 
Wakamoto et al., 2000; Sillanpää et al., 2004; Chin et al., 2011), and for non-institutionalized 
patients (Kokkonen et al., 1997). In our study, however, subjects with idiopathic or cryptogenic 
etiology did not differ regarding marriage/cohabitation from the Dutch population (apart from our 
symptomatic group). 
In three studies on childhood-onset epilepsy, subjects with uncomplicated epilepsy had fewer 
children than expected (Jalava & Sillanpaa, 1997b; Sillanpaa et al., 2004; Chin et al., 2011). In the 
present study, the group with symptomatic etiology had fewer children, whereas the idiopathic and 
cryptogenic groups were similar to the general population. Although our results look promising, one 
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reason for these divergent outcomes might be that most studies used matched controls, whereas we 
made a comparison with the Dutch population, which is probably less accurate. 
 
Education 
Similar to the present study, many studies on childhood-onset epilepsy reported a lower than 
average educational attainment for subjects with epilepsy (Kokkonen et al., 1997; Sillanpaa et al., 
1998, 2004; Wakamoto et al., 2000; Koponen et al., 2007); however, one study was partly based on 
prevalent cases and could have been biased toward more severe epilepsy (Jalava et al., 1997). Most 
of the latter studies also reported this trend for subjects with ‘‘epilepsy only,’’ normal intelligence, 
and for those in remission and off AEDs. As argued previously, these findings are not unexpected, 
since there is increasing evidence that mild impairment of cognitive functions likely precedes the 
onset of epilepsy, even in cases with ‘‘epilepsy only’’ (Schouten et al., 2001; Oostrom et al., 2003; 
Berg et al., 2005; Henkin et al., 2005; Vinayan et al., 2005; Beghi et al., 2006; Hermann et al., 
2007; Taylor et al., 2010). Our finding that subjects reported concentration and memory problems 
concurs with this. These results are one of the reasons why the phrase ‘‘epilepsy only’’ or ‘‘just 
epilepsy’’ should be avoided (Berg, 2011). 
 
Employment status 
Several studies reported on the employment rates of subjects with childhood-onset epilepsy. Two 
studies found that the employment rates were not significantly lower for subjects with epilepsy 
(Kokkonen et al., 1997; Wakamoto et al., 2000), whereas others reported a lower employment rate 
(Jalava et al., 1997; Sillanpaa et al., 1998; Koponen et al., 2007). This was even found for those 
who were seizure free and without medication for many years (Sillanpää et al., 1998). 
We found that the employment status of subjects with idiopathic or cryptogenic etiology did not 
differ from that of the general population, but significantly fewer subjects with symptomatic 
etiology were employed. However, when considering the labor force of our cohort the 
unemployment rates were low, even for those with symptomatic etiology. Some studies found a 
higher unemployment rate for subjects with epilepsy (Jalava et al., 1997; Kokkonen et al., 1997; 
Koponen et al., 2007). Sillanpaa et al. (2004) found that the risk of being unemployed in subjects in 
remission off medications was not significantly higher than that in controls; however, in those still 
taking medication, the risk was high and was the same whether or not the subjects were in 
remission. 
The contradictory results in employment and unemployment rates described above could be due to 
the small sample sizes, or to differences in definitions and control groups. Our ‘‘better’’ results 
might also be explained by the Dutch system in which slightly disabled persons are allowed to work 
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under special guidance in so-called ‘‘social workshops.’’ More studies are needed to elucidate this 
topic, preferably in large cohorts with matched controls that are prospectively followed. 
 
Occupation 
Few studies reported on the level of occupation, although this is an important issue. In the present 
cohort, relatively fewer subjects had a job with a higher/scientific level. Another important issue is 
underemployment. In one study, subjects with ‘‘epilepsy only’’ were significantly more often 
underemployed compared with controls (Jalava et al., 1997). In that study, ‘‘underemployment’’ 
meant that the level of education and training was significantly higher than the requirement for the 
present job. Of their patients, 23% were underemployed versus 9% of random controls, and 
14% of employee controls. In our cohort, 26% of employees had a job one or two levels beneath 
their educational level, which is comparable to that found by Jalava et al. We were unable to 
compare possible underemployment in our cohort with that of the Dutch population because these 
data were not available for the corresponding Dutch age groups. We recommend that 
underemployment should be investigated in future cohort studies. 
 
Considerations 
Some of the strengths and weaknesses of this study have been reported previously (Geerts et al., 
2010). Even though this study was hospital based, we think this prospectively followed cohort is a 
representative sample of patients diagnosed with childhood-onset epilepsy. Both the recruitment 
rate, which was approximately 75% of the expected annual incidence in the referral area, as well as 
the relatively low proportion with symptomatic etiology at enrollment (28%) support this. Two 
other prospective hospital based studies reported rates of 18% and 26% at enrollment (Berg et al., 
1999; Shinnar et al., 1999). We think our cohort is not biased toward more severe cases, as children 
with progressive disorders were excluded when diagnosed at the time of inclusion. If such a 
diagnosis was made during follow-up, that patient was retained in the study. Furthermore, in The 
Netherlands, severe epilepsy patients with other impairments or disabilities are frequently 
institutionalized before the onset of epilepsy and are treated in these specialized institutions and not 
elsewhere.  
As we had no matched controls, we compared our subjects with Dutch age peers. Statistics 
Netherlands provide their data in 5- or 10-year age groups. In our cohort, because the age group 25–
34 years was skewed to the left with more subjects of younger age, this may have influenced the 
comparisons; therefore, differences found in the highest age group may be less significant than 
reported. We think that only the comparison regarding occupational level may have been 
influenced, with fewer subjects having had a chance to achieve a higher level occupation. 
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CONCLUSIONS 
 
Based on these results we conclude that, even after long-term follow-up, childhood-onset epilepsy 
has a substantial impact on many aspects of life, especially for those with symptomatic etiology or 
with active epilepsy. For those with idiopathic etiology, the impact is less severe, but still 
significant with regard to educational and occupational achievement. 
 
 
ACKNOWLEDGMENTS 
 
The Dutch National Epilepsy Fund provided a grant for this study (no. 05-06). None of the authors 
has any conflict of interest to disclose. 
 
DISCLOSURE 
 
All authors confirm that they have read the Journal’s position on issues involved in ethical 
publication and affirm that this report is consistent with those guidelines. 
 
 
REFERENCES 
 
Arts WF, Geerts AT, Brouwer OF, Peters AC, Stroink H, Van Donselaar CA. (1999) The early 
prognosis of epilepsy in childhood: the prediction of a poor outcome. The Dutch study of 
epilepsy in childhood. Epilepsia 40:726–734. 
Arts WF, Brouwer OF, Peters AC, Stroink H, Peeters EA, Schmitz PI, Van Donselaar CA, Geerts 
AT. (2004) Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of 
epilepsy in childhood. Brain 127:1774–1784. 
Baker GA, Taylor J, Aldenkamp AP. (2011) Newly diagnosed epilepsy: cognitive outcome after 12 
months. Epilepsia 52:1084–1091. 
Beghi M, Beghi E, Cornaggia CM, Gobbi G. (2006) Idiopathic generalized epilepsies of 
adolescence. Epilepsia 47(Suppl. 2):107–110. 
Berg AT. (2011) Epilepsy, cognition, and behavior: the clinical picture. Epilepsia 52(Suppl. 1):7–
12. 
Berg AT, Shinnar S, Levy SR, Testa FM. (1999) Newly diagnosed epilepsy in children: 
presentation at diagnosis. Epilepsia 40:445–452. 
 Page | 92  
 
Berg AT, Smith SN, Frobish D, Levy SR, Testa FM, Beckerman B, Shinnar S. (2005) Special 
education needs of children with newly diagnosed epilepsy. Dev Med Child Neurol 47:749–
753. 
Camfield C, Camfield P. (2008) Twenty years after childhood-onset symptomatic generalized 
epilepsy the social outcome is usually dependency or death: a population-based study. Dev Med 
Child Neurol 50:859–863. 
Camfield P, Camfield C. (2010) Idiopathic generalized epilepsy with generalized tonic-clonic 
seizures (IGE-GTC): a population-based cohort with >20 year follow up for medical and social 
outcome. Epilepsy Behav 18:61–63. 
CBS (Dutch Central Bureau of Statistics). (2005) Dutch Central Bureau of Statistics. Available at: 
http://www.cbs.nl. 
Chin RF, Cumberland PM, Pujar SS, Peckham C, Ross EM, Scott RC. (2011) Outcomes of 
childhood epilepsy at age 33 years: a population-based birth-cohort study. Epilepsia 52:1513–
1521. 
Clarke T, Strug LJ, Murphy PL, Bali B, Carvalho J, Foster S, Tremont G, Gagnon BR, Dorta N, Pal 
DK. (2007) High risk of reading disability and speech sound disorder in rolandic epilepsy 
families: case–control study. Epilepsia 48:2258–2265. 
Davies S, Heyman I, Goodman R. (2003) A population survey of mental health problems in 
children with epilepsy. Dev Med Child Neurol 45:292–295. 
Gardner MJ, Altman DG. (1989) Statistics with confidence – confidence intervals and statistical 
guidelines, British Medical Journal, London. 
Gardner MJ, Gardner SB, Winter PD. (1989) Confidence interval analysis (CIA) microcomputer 
program manual. British Medical Journal, London. 
Gastaut H. (1969) Classification of the epilepsies. Proposal for an international classification. 
Epilepsia 10(Suppl.):14–21. 
Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, Laan L, Van Donselaar C. (2010) 
Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy 
in Childhood. Epilepsia 51:1189–1197. 
Hauser WA, Anderson VE, Loewenson RB, McRoberts SM. (1982) Seizure recurrence after a first 
unprovoked seizure. N Engl J Med 307:522–528. 
Henkin Y, Sadeh M, Kivity S, Shabtai E, Kishon-Rabin L, Gadoth N. (2005) Cognitive function in 
idiopathic generalized epilepsy of childhood. Dev Med Child Neurol 47:126–132. 
Hermann B, Jones J, Dabbs K, Allen CA, Sheth R, Fine J, McMillan A, Seidenberg M. (2007) The 
frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. Brain 
130:3135–3148. 
 Page | 93  
 
ILAE. (1981) Proposal for revised clinical and electroencephalographic classification of epileptic 
seizures. From the Commission on Classification and Terminology of the International League 
Against Epilepsy. Epilepsia 22:489–501. 
ILAE. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission 
on Classification and Terminology of the International League Against Epilepsy. Epilepsia 
30:389–399. 
ILAE. (1993) Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and 
Prognosis, International League Against Epilepsy. Epilepsia 34:592–596. 
ISCO (The International Standard Classification of Occupations). (2010) The International Standard 
Classification of Occupations. Available at: 
ttp://www.ilo.org/public/english/bureau/stat/isco/index.htm. 
Jacoby A. (1995) Impact of epilepsy on employment status: findings from a UK study of people 
with well-controlled epilepsy. Epilepsy Res 21:125–132. 
Jalava M, Sillanpaa M. (1997a) Physical activity, health-related fitness, and health experience in 
adults with childhood-onset epilepsy: a controlled study. Epilepsia 38:424–429. 
Jalava M, Sillanpaa M. (1997b) Reproductive activity and offspring health of young adults with 
childhood-onset epilepsy: a controlled study. Epilepsia 38:532–540. 
Jalava M, Sillanpaa M, Camfield C, Camfield P. (1997) Social adjustment and competence 35 years 
after onset of childhood epilepsy: a prospective controlled study. Epilepsia 38:708–715. 
Jensen FE. (2011) Epilepsy as a spectrum disorder: implications from novel clinical and basic 
neuroscience. Epilepsia 52(Suppl. 1):1–6.  
Kokkonen J, Kokkonen ER, Saukkonen AL, Pennanen P. (1997) Psychosocial outcome of young 
adults with epilepsy in childhood. J Neurol Neurosurg Psychiatry 62:265–268. 
Koponen A, Seppala U, Eriksson K, Nieminen P, Uutela A, Sillanpaa M, Hyvarinen L, Kalviainen 
R. (2007) Social functioning and psychological well-being of 347 young adults with epilepsy 
only – population-based, controlled study from Finland. Epilepsia 48:907–912. 
Oostrom KJ, Smeets-Schouten A, Kruitwagen CL, Peters AC, Jennekens-Schinkel A. (2003) Not 
only a matter of epilepsy: early problems of cognition and behavior in children with ‘‘epilepsy 
only’’ – a prospective, longitudinal, controlled study starting at diagnosis. Pediatrics 112:1338–
1344. 
Schouten A, Oostrom K, Jennekens-Schinkel A, Peters AC. (2001) School career of children is at 
risk before diagnosis of epilepsy only. Dev Med Child Neurol 43:575–576. 
Shinnar S, O’Dell C, Berg AT. (1999) Distribution of epilepsy syndromes in a cohort of children 
prospectively monitored from the time of their first unprovoked seizure. Epilepsia 40:1378–
1383. 
 Page | 94  
 
Sillanpaa M, Jalava M, Kaleva O, Shinnar S. (1998) Long-term prognosis of seizures with onset in 
childhood. N Engl J Med 338:1715–1722. 
Sillanpaa M, Haataja L, Shinnar S. (2004) Perceived impact of childhood-onset epilepsy on quality 
of life as an adult. Epilepsia 45:971–977. 
Sillanpaa M, Schmidt D. (2010) Long-term employment of adults with childhood-onset epilepsy: a 
prospective population-based study. Epilepsia 51:1053–1060. 
Sogawa Y, Masur D, O’Dell C, Moshe SL, Shinnar S. (2010) Cognitive outcomes in children who 
present with a first unprovoked seizure. Epilepsia 51:2432–2439. 
Taylor J, Kolamunnage-Dona R, Marson AG, Smith PE, Aldenkamp AP, Baker GA. (2010) 
Patients with epilepsy: cognitively compromised before the start of antiepileptic drug 
treatment? Epilepsia 51:48–56. 
Vinayan KP, Biji V, Thomas SV. (2005) Educational problems with underlying neuropsychological 
impairment are common in children with Benign Epilepsy of Childhood with Centrotemporal 
Spikes (BECTS). Seizure 14:207–212. 
Wakamoto H, Nagao H, Hayashi M, Morimoto T. (2000) Long-term medical, educational, and 
social prognoses of childhood-onset epilepsy: a population-based study in a rural district of 
Japan. Brain Dev 22:246–255. 
Wandschneider B, Kopp UA, Kliegel M, Stephani U, Kurlemann G, Janz D, Schmitz B. (2010) 
Prospective memory in patients with juvenile myoclonic epilepsy and their healthy siblings. 
Neurology 75:2161–2167. 
Yu PM, Ding D, Zhu GX, Hong Z. (2009) International Bureau for Epilepsy survey of children, 
teenagers, and young people with epilepsy: data in China. Epilepsy Behav 16:99–104. 
Zelnik N, Sa’adi L, Silman-Stolar Z, Goikhman I. (2001) Seizure control and educational outcome 
in childhood-onset epilepsy. J Child Neurol 16:820–824. 
 
SUPPORTING INFORMATION 
 
Additional Supporting Information may be found in the online version of this article or in 
Appendix 1 and 4: 
Supporting Information A: Questionnaire Epilepsy Research. 
Supporting Information B: Several tables show the observed and expected cases, and the 
standardized incidence rate for each variable.  
  
 Page | 95  
 
Chapter 6 Onset of intractability and its course over time: the Dutch Study 
of Epilepsy in Childhood 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ada T. Geerts, Oebele F. Brouwer, Hans Stroink, Cees A. van Donselaar, A.C. Boudewijn Peters, 
Els A.J. Peeters, and Willem F.M. Arts 
 
Epilepsia (2012), 53 (4), 741-751 
 Page | 96  
 
ABSTRACT 
 
Intractability in epilepsy is difficult to define, and little is known about its onset, course, and 
duration. We investigated these aspects (as well as the occurrence of intractability) during long-term 
follow-up in patients with epilepsy, focusing on possible explanations for the variation in time of 
onset and duration of intractability. 
After diagnosis, 453 patients with childhood-onset epilepsy had a 5-year follow-up with regular 
visits and data collection. Ten years later they received a questionnaire with items concerning 
epilepsy, which was completed by 413 patients resulting in a mean follow-up of 15 years. 
Intractability during the first 5 years was compared with that in the last year of follow-up. 
Intractability was defined as having no 3-month remission during a 1-year period despite adequate 
medical treatment. 
At least 12.1% of the cohort had a period of intractability during the 15-year follow-up, and 8.5% 
were intractable in the final year. Of the patients with idiopathic etiology 4.3% had a period of 
intractability versus 17.0% for those with cryptogenic, and 22.6% for those with remote 
symptomatic etiology (p < 0.001). Other risk factors at baseline were younger age at first seizure, 
generalized cryptogenic/symptomatic or localization-related symptomatic epilepsy, mental 
retardation, and febrile convulsions before enrollment. The cumulative risk of a period of 
intractability was 6.1% (95% confidence interval [CI] 3.7–8.5) at 2 years follow-up and 8.2% (95% 
CI 5.4–11.0) at 5 years. The mean time to onset of intractability during the first 5 years of follow-up 
was 1.6 (95% CI 1.3–2.0; median 1.0) years and the mean duration of intractability during these 5 
years was 3.3 (95% CI 2.8–3.8; median 3.6) years. Fifteen patients were intractable only during the 
first 5 years of follow-up (group A), and 19 subjects were intractable both during the first 5 years 
and the last year of follow-up (group B). Compared with group A, group B had shorter remission 
and a longer time to intractability during the first 5 years and more were intractable in the fifth year 
of follow-up. Sixteen other patients had a late onset of intractability after 5 years of follow-up, 
sometimes after long periods of remission (group C). No significant differences in baseline 
characteristics were found among groups A, B, and C, but slightly more children in groups B and C 
became mentally retarded during the follow-up. In all groups, antiepileptic drugs were of little use 
in preventing and ending intractability. 
There is a large unpredictable variation in time of onset, course, and duration of intractability, with 
a higher chance of final intractability after a poor course during the first 5 years of follow-up. The 
natural course of epilepsy probably best explains the variable course of intractability. The effect of 
medication seems to be minor. 
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INTRODUCTION 
 
Recent studies indicate that the course of childhood-onset epilepsy may vary during long-term 
follow-up. Periods of remission and periods with frequent seizures can interchange (Berg et al., 
2004, 2006; Sillanpää & Schmidt, 2006a; Berg et al., 2009; Geerts et al., 2010). The end of an 
episode with frequent seizures could result from the effectiveness of treatment, or from the self-
limiting character of some types of epilepsy. Conversely, persistent seizures (or so-called 
intractability) starting late in the course of epilepsy could result from poor adherence with the 
prescribed treatment, from development of drug resistance or tolerance, or from an ongoing process 
of epileptogenesis that is insensitive to treatment (Loscher & Schmidt, 2006; Abou-Khalil, 2007; 
Brown et al., 2009; Vervloet et al., 2011). 
Studying the course of intractability, especially its time of onset and the interchanging pattern with 
periods of remission, may enable one to find explanations for the development, discontinuation, or 
chronicity of intractability, and to distinguish the natural course of epilepsy from treatment effects.  
Between 1988 and 1992, we recruited 494 consecutive children who presented at the hospital with 
new-onset epilepsy. Results of the clinical course at 2 and 5 years after diagnosis have been 
published (Arts et al., 1999, 2004) as well as the results of 413 patients with a mean 15-year 
follow-up (Geerts et al., 2010); this latter publication presented risk factors for final intractability 
(non-idiopathic etiology, febrile seizures before enrollment, no 3-month remission in the first 6 
months of follow-up, and having a period of intractability during the first 5 years of follow-up). 
This report focuses on the course of intractability during follow-up and possible reasons for its 
variation. A comparison is made between intractability in the first 5 years and intractability in the 
final year. 
 
METHODS 
 
The methods of this study have been reported in detail elsewhere (Geerts et al., 2010). There 
follows a brief overview. 
 
Setting 
Between 1988 and 1992, four hospitals in The Netherlands recruited 494 children aged 1 month to 
16 years with newly diagnosed epilepsy. The ethical committees of the participating hospitals 
approved the study. Written informed consent was provided by all parents and children aged 
≥12 years. This Dutch Study of Epilepsy in Childhood had a recruitment rate approximating 75% of 
the expected annual incidence in the referral area. Excluded from the study were children with 
 Page | 98  
 
seizures as a result of brain tumors or other progressive diseases diagnosed at the time of 
recruitment. 
 
Follow-up 
Of the original cohort, 453 subjects had a 5-year follow-up with regular visits and data collection. 
Ten years later, they received a simple questionnaire (that did not burden the subjects too much) 
with items addressing epilepsy, such as date of the very last seizure, use of antiepileptic drugs 
(AEDs) at last contact and, if applicable, date of AED discontinuation. When subjects reported 
seizures in the last year of follow-up, we contacted their treating physician or checked their medical 
records to determine intractability in the final year. This means that only the information covering 
the first 5 years and the last year of follow-up was sufficiently detailed to investigate intractability. 
Non-responders were contacted again and the final response rate based on the original 494 patients 
was 84%. Of the 413 respondents, 47.2% was male. Mean age at epilepsy onset was 5.5 years 
(median 5.1, range 0.0–15.5) years. Mean follow-up was 14.8 years (median 14.8, range 11.6–17.5) 
years. 
 
Classifications 
All seizures and epilepsies were classified at enrollment and, if necessary, revised after 2 years 
using the seizure, etiology, and epilepsy classifications of the International League against Epilepsy 
(Gastaut, 1969; ILAE, 1981, 1989, 1993). Etiology at enrollment was idiopathic in 50.8%, 
cryptogenic in 21.3%, and remote symptomatic including mental retardation (intelligence quotient 
[IQ] < 70) in 27.8%. At the end of the present study, the etiologic classifications were checked 
again, as some patients proved to have neurologic brain-related morbidities. 
 
Definitions 
Intractability: no remission exceeding 3 months (at least one seizure per 3 month) during a 
minimum period of 1 year of observation despite adequate treatment (Arts et al., 2004). Adequate 
treatment: optimal choice and use of at least two AEDs, either alone or in combination. AED 
intolerance or allergy was not considered as failure. To make the analysis pragmatic, we calculated 
the duration of intractability as the interval between the first and last seizure of a period with at least 
one seizure per 3 month. Early onset of intractability: onset of intractability within the first 5 years 
of follow-up. Late onset of intractability: onset after the first 5 years of follow-up. Fast response to 
medication: 6 months of remission starting within 2 months after initiation of AED. Longest 
remission: maximum interval between seizures. Terminal remission: interval between the very last 
seizure and the end of follow-up. A 5-year terminal remission was reached by 71% of the cohort. 
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Statistics 
To investigate possible differences between groups, Chi-square statistics were used in case of 
categorical variables and one-way analysis of variance (ANOVA) in case of continuous variables. 
For the risk of intractability we used Kaplan-Meier survival statistics. Log rank (Mantel-Cox) was 
used to test for equality of the survival distributions for the different types of epilepsy. 
 
RESULTS 
 
Entire follow-up 
Figure 6.1 shows how many subjects were intractable during the 15-year follow-up and at which 
points in time. At least 50 patients had a period of intractability (12.1%): in 34 subjects it started 
during the first 5 years of follow-up (8.2% with early onset) and in 16 other subjects it started later 
and was present during the last year of follow-up (3.9% with late onset). In the last year of follow-
up a total of 35 patients were intractable (8.5% of 413). The mean follow-up of these 35 patients did 
not differ from those that were not intractable in the final year (14.6 vs. 14.8 years, ANOVA: 
F = 0.698, d.f. = 1, p = 0.40), neither did the median follow-up (14.5 [range 13.0–16.8] years versus 
14.9 [range 11.6–17.5] years), independent samples median test: p = 0.22). 
Another 31 patients with frequent seizures during the first 5 years were not considered intractable 
during that particular period despite their seizure pattern, because of insufficient compliance (n = 6), 
or inadequate treatment (n = 25), according to our definition of intractability (Figure 6.1). The same 
is true for four patients with inadequate treatment in the last year of follow-up and one patient with 
insufficient compliance in that year. For all the patients with inadequate treatment (no optimal 
choice and use of at least two AEDs) there was a plausible reason. 
Between the first 5 years and the last year of follow-up (intervening years: Figure 6.1), 283 patients 
(13 + 270) had definitely not been intractable during this period as could be derived from the date 
of their last seizure or AED discontinuation. The remaining 76 patients (15 + 61) may have had a 
period of intractability in these intervening years. This means that the proportion of patients with at 
least one period of intractability during the entire 15-year follow-up ranges from a minimum of 
12.1% definite intractable cases (34 + 3 + 13 = 50 of 413) to a possible maximum of 30.5%  
(34 + 3 + 13 + 15 + 61 = 126 of 413).  
 
Intractability during the first 5 years of follow-up 
During these years, the mean time to onset of intractability was 1.6 (95% confidence interval [CI] 
1.3–2.0, median 1.0) years, and its mean duration was 3.3 (95% CI 2.8–3.8, median 3.6) years.  
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Figure 6.1: Flowchart of patients with or without intractability during a mean follow-up of 15 
years (TR, terminal remission). 
The cumulative risk of intractability was 6.1% (95% CI 3.7–8.5) at 2 years of follow-up, and 8.2% 
(95% CI 5.4–11.0) at 5 years. Figure 6.2 (A, B) shows the Kaplan-Meier curves for several types of 
epilepsy according to the classifications of the ILAE and of Berg et al. (ILAE, 1989; Berg et al. 
2006). Using the ILAE classification, there was a significant difference between the curves in 
Figure 6.2A (Log rank [Mantel-Cox] χ2 = 33.78, d.f. = 6, p < 0.0001). Those with West syndrome 
or Lennox-Gastaut syndrome or epilepsy with myoclonic absences or myoclonic-astatic seizures 
(generalized cryptogenic and/or symptomatic epilepsies) had the highest risk of intractability in the 
first 5 years, whereas none of the patients with localization-related idiopathic etiology had a period 
of intractability. Using the Berg classification, the difference between the three curves in Figure 
6.2B was also significant (log rank [Mantel-Cox] χ2= 27.24, d.f. = 3, p < 0.0001). However, the 
difference between the focal (localization-related cryptogenic and symptomatic groups) and 
catastrophic (West syndrome or Lennox-Gastaut syndrome, epilepsy with myoclonic-astatic 
seizures or myoclonic absences, epilepsies and syndromes undetermined whether focal or 
generalized) curves was only marginally significant (log rank [Mantel-Cox] χ2= 3.44, d.f. = 1, p = 
0.064).  
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Figure 6.2: (A, B) Time course and cumulative risk of intractability during the first 5 years of 
follow-up for different types of epilepsy. 
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Figure 6.2: (A) Gen crypto/symp, generalized cryptogenic, and/or symptomatic epilepsies and syndromes 
(West syndrome; Lennox-Gastaut syndrome, epilepsy with myoclonic-astatic seizures or with myoclonic 
absences); loc rel symp, localization-related symptomatic epilepsies and syndromes; gen symp, generalized 
symptomatic epilepsies and syndromes; loc rel crypto, localization-related cryptogenic epilepsies and 
syndromes; gen idiop, generalized idiopathic epilepsies and syndromes; loc rel idiop, localization-related 
idiopathic epilepsies and syndromes. None of the rest group (n = 16) became intractable in these years (not in 
figure). (B) Catastrophic, all cryptogenic and symptomatic generalized epilepsies, and epilepsies with both 
focal and generalized features; focal, cryptogenic and symptomatic focal; idiopathic, partial, and generalized 
forms of idiopathic epilepsy. 
 
 
Of the focal group, 11.7% developed intractability during the first 5 years versus 21.7% of the 
catastrophic group. Time to onset of intractability during the first 5 years of follow-up did not differ 
between patients with focal epilepsy and those with catastrophic epilepsy (independent samples 
Mann-Whitney U-test: p = 0.149). 
 
Risk factors 
Of the patients with idiopathic etiology, 4.3% had a period of intractability either during the first 5 
years and/or last year of follow-up, whereas this was 17.0% for those with cryptogenic and 22.6% 
for those with remote symptomatic etiology (p < 0.001). Other risk factors at baseline were younger 
age at first seizure, type of epilepsy (generalized cryptogenic/symptomatic, localization-related 
symptomatic), mental retardation at enrollment, and febrile convulsions before enrollment (Table 
6.1). 
 
Three intractability groups 
We distinguished three groups of subjects with intractability: 15 subjects with intractability during 
the first 5 years only (group A), 19 subjects with intractability during both the first 5 years and the 
final year (group B), and 16 subjects with intractability during the final year but not during the first 
5 years (group C). The mean follow-up of group A, B, and C, and the group without intractability, 
showed no significant differences (14.8, 14.4, 14.9, and 14.8 years, respectively, ANOVA: F = 
0.648, d.f. = 3, p = 0.59); neither did the median follow-up (14.7 [range 13.3–16.8] years, 14.4 
[range 13.0–16.4] years, 14.9 [range 13.2–16.8] years, and 14.9 [range 11.6–17.5] years, 
independent samples median test: p = 0.33). A summary of the individual course of epilepsy and 
treatment effects on the 15 patients in group A is presented in Table S1 (Appendix 5). Eleven 
patients were seizure free in the last year of follow-up; seven of them even had a 5-year terminal 
remission. 
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For five patients of group A, we found a plausible explanation for the ending of their intractability, 
that is, seizures were abolished or the frequency was reduced after the introduction of a new AED in 
four patients and after a successful temporal lobectomy in one patient (Table 6.2). 
In group B (with intractability both during the first 5 years and the final year), 16 of the 19 patients 
used AEDs during the entire follow-up and had no substantial periods of remission and 50% had 
daily to monthly seizures. All patients in group B were considered to be drug resistant (Table 6.2). 
Table S2 (Appendix 5) describes the individual course of epilepsy for the 16 patients with late 
onset of intractability (group C). Seven had remissions in the first 5 years, ranging from 2.4 to 4.7 
years. Nine patients even discontinued AEDs after remission during the first 5 years of follow-up, 
but all had recurrences and restarted medication (Table 6.2); in four of them reinstitution of 
treatment failed to regain remission. This was the only possible explanation we found for the late 
onset of intractability in group C. At the end of follow-up, 8 of the 16 patients of group C were 
drug-resistant for about 3–8 years. 
 
Table 6.2. Possible explanations for temporary, continuing or late onset of intractability 
 
 Temporary 
Group A 
(n=15) 
Continuing 
Group B 
(n=19) 
Late onset 
Group C 
(n=16) 
Effect of a new AED 4   
Effect of a new AED, but not enough to be seizure free in 
the last year 
1   
Effect of temporal lobectomy 1   
No treatment effect 9 16  
3-year remission while on AEDs but relapsed  1  
Parietal arachnoid cyst: AED no effect. Five-year 
remission after drain removal. Relapse after 2 years 
without AEDs. Reinstitution of AEDs no effect. 
 1  
Stop AED after remission: AED failed after relapse  1 4 
Stop AED after remission: AED successful after relapse, 
but later on intractable 
  4 
Stop AED after remission: AED effect unknown after 
relapse and later on intractable 
  1 
Deteriorated without an obvious reason   7 
 
 
To unravel why there was such a large variation in time of onset and duration of intractability, we 
focused on differences between these three groups that might explain this variation. The three 
groups did not differ in baseline characteristics (Table 6.1), indicating that the risk for patients to 
fall into any of the three groups was similar. However, during follow-up, patients of group B had a 
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significantly longer time to intractability (Table 6.1, Figure 6.3) and, consequently, more were 
intractable in the fifth year of follow-up and had a shorter terminal remission; they also had a 
slightly shorter longest remission during the first 5 years compared with those of group A. 
Comparison of group A with the two groups that were intractable in the last year of follow-up 
(groups B + C) showed a tendency for a higher proportion of patients in the latter two groups to 
develop mental retardation during follow-up: one of 15 (6.7%) versus 9 of 35 (25.7%) (95% CI of 
difference 2.9–35.2, p <0.1). The significant differences found in the comparisons of group A and B 
with group C were all inherent to the poor results of groups A and B during the first 5 years. 
 
Figure 6.3: Time course and cumulative risk of intractability during the first 5 years of follow-
up for the group with temporary intractability and for the group both intractable during the 
first 5 years and the last year of follow-up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test of equality of survival distributions: log rank (Mantel-Cox) v2 = 6.06, d.f. = 1, p = 0.014. 
Group A: only intractable during first 5 years; group B: intractable during both the first 5 years and 
the last year.  
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DISCUSSION 
 
The present study was a pragmatic investigation. Our main interest was the time of onset of 
intractability, its course over time, and the variables that might influence it. The definition of 
intractability itself was not the issue; any other definition could have been used and probably would 
have yielded similar results.  
Unfortunately, our results and the resulting conclusions are limited by the lack of data on the onset 
of intractability in the period after the fifth year of follow-up. Nevertheless, we think that the data 
provide valuable insight into the onset and course of intractability during the long-term follow-up of 
our cohort, even though intractability in some years could not be established. However, in our 
opinion, the latter is not a significant drawback. In fact, if all subjects with possible intractability in 
the intervening years had been intractable, our conclusions about a fluctuating course and temporary 
intractability would have been strengthened. The main outcome of this prospective study is that at 
least 12% of our cohort with childhood-onset epilepsy experienced a period of intractability during 
a 15-year follow-up since diagnosis, and 8.5% were intractable in the final year. The majority 
became intractable within 5 years after epilepsy onset, but approximately 50% of the patients were 
no longer intractable at the last contact; some even reached a 5-year terminal remission. Other 
patients had a late onset of intractability after 5 years of follow-up, and in some, intractability was 
interrupted by long periods of remission. This has also been reported by others (Takenaka et al., 
2000; Sillanpää & Schmidt, 2006a). These findings show that time of onset, course, and duration of 
intractability vary considerably between subjects. According to the present study, these aspects of 
intractability are hardly predictable, even though intractability itself can be predicted to a certain 
extent. The risk factors for intractability found in the present study (younger age at onset, remote 
symptomatic etiology, type of epilepsy, and mental retardation) have also been reported by others 
(Huttenlocher & Hapke, 1990; Berg et al., 1996; Casetta et al., 1999; Kwong et al., 2003; 
Altunbasak et al., 2007). However, in the present study none of these risk factors were associated 
with a temporary, continuing, or late onset of intractability. In practice this means that a treating 
physician can only estimate the risk of intractability for an individual patient, but not the time of 
onset or duration of intractability, and the sustainability of remission following intractability. 
Especially for surgery candidates, it would have been valuable if these aspects of intractability 
could have been predicted. 
 
Intractability as a temporary phenomenon 
The finding that intractability can be followed by remission has also been reported by others (Berg 
et al., 2006, 2009; Callaghan et al., 2007, 2011; Choi et al., 2008, 2011), and some state that the 
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natural history of intractable seizures in children follows a gradual line of slow improvement, 
especially in patients with normal intelligence (Huttenlocher & Hapke, 1990). In our opinion this 
might particularly apply to children with a period of intractability early in the course of their 
epilepsy. 
In a prevalence cohort study of adults with intractable epilepsy no clear predictors for remission 
were found (Choi et al., 2008, 2011), whereas in a similar study, developmental delay, symptomatic 
generalized epilepsy, longer duration of intractability, and number of failed AEDs were negatively 
associated with remission, although in multivariate analysis only the number of failed AEDs 
remained significant (Callaghan et al., 2011). In a prospective childhood-onset study, idiopathic 
epilepsy and lower seizure frequency were positively associated with remission (Berg et al., 2009). 
In the present study no clear predictors were found for temporary intractability versus ongoing or 
repeating intractability. However, although the numbers were small, there were some significant 
differences between subjects with temporary intractability and those intractable again at the end, 
indicating that the epilepsy of the latter patients was probably more severe from the beginning and 
deteriorated further during follow-up.  
It has been shown that remission after intractability started after medication changes in 28–76% of 
adult subjects, although the relapse rate was high (Luciano & Shorvon, 2007; Callaghan et al., 
2011; Choi et al., 2011). In our cohort, we found a medication effect in 27% (4 of 15) of patients 
with temporary intractability, with 2 of the 4 subsequently entering terminal remission for at least 
10 years. In our cohort, apart from the patients with a positive effect of AEDs or surgery, and the 
patient not considered intractable in the final year, we think that the improvement resulted from the 
natural course of the patients’ epilepsy. 
  
Late-onset intractability 
More than 30% of our intractable patients had a late onset of intractability, starting 5 years or more 
after diagnosis; this has also been reported by others (Berg et al., 2003; Berg, 2004; Sillanpää & 
Schmidt, 2006a). Three years or more after diagnosis, Berg et al. (2006) found a late-onset 
intractability in 32% of children meeting their stringent definition of intractability. This occurred 
even after long periods of remission, a result that was confirmed in the present study. In line with 
this, Sillanpää et al. found a worsening course in 14% of their cohort, defined as a relapse occurring 
after a 5-year remission without regaining a final 5-year terminal remission (Sillanpää & Schmidt, 
2006a). So far, no clear explanation for the occurrence of late-onset intractability is available, 
although a poorer adherence to medication during follow-up might be one (Sabaté, 2003). In 
addition, AED failure after restart has been reported as a possible reason (Takenaka et al., 2000; 
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Schmidt & Loscher, 2005; Sillanpää & Schmidt, 2006b). Two studies found that reinstitution of 
medication that worked for years failed to achieve control in one of three or four relapsed patients 
(Bouma et al., 2002; Sillanpää & Schmidt, 2006b). In our study this occurred in five patients. 
During ongoing treatment, mechanisms such as developing drug tolerance or resistance might lead 
to deterioration or intractability. However, it remains uncertain whether late-onset intractability or a 
worsening course results from these mechanisms, or from the progressive nature of some types of 
epilepsy (Takenaka et al., 2000; Abou-Khalil, 2007). In view of this, we doubt that late-onset 
intractability is a temporary phenomenon, like part of the early-onset intractability, but rather that it 
might be severe and persistent. 
One study found evidence of a later onset of intractability in patients with focal epilepsy compared 
with those with catastrophic epilepsy (Berg et al., 2006). In our cohort, we found that slightly more 
patients with catastrophic epilepsy developed intractability during the first 5 years of follow-up 
(mostly during the first year) compared with those with focal epilepsy, but that there was no 
significant difference in the time to intractability. In addition, during the entire follow-up, the 
difference in intractability between these two groups was not significant (focal 18.2% vs. 
catastrophic 28.3%, Pearson’s χ2: 2.53, d.f. = 1, p = 0.112), unless they would have been 
temporarily intractable 5 years or more after enrollment. We conclude that our results do not 
convincingly support the findings of Berg et al., although the trend pointed in the same direction. In 
the study of Berg et al., more subjects with catastrophic epilepsy developed intractability during the 
first 5 years of follow-up than in our study (stringent definition: approximately 50.% vs. 21.7%, 
respectively), although for those with focal epilepsy the numbers were the same (approximately 
10% vs. 11.7%). In our cohort, the difference between the catastrophic and focal group was only 
marginally significant.  
 
Drug-resistant epilepsy according to the ILAE commission  
Recently the ILAE proposed the following definition for drug-resistant epilepsy (Kwan et al., 
2010): failure of adequate trials of two tolerated, appropriately chosen and used AED schedules to 
achieve sustained seizure freedom. In response to this, and to make our article as up-to-date as 
possible, we applied this definition to our cohort in addition to our definition at two points in time: 
at 5 years after enrollment and at last contact. 
A comparison of both definitions shows that there is very little difference (Table 6.3). The overall 
conclusion is more or less the same; in both cases intractability or drug-resistance can be temporary, 
continuing, or delayed. However, the ILAE definition labels more patients as being drug-resistant. 
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Certainly there is little doubt about treatment failure when a person still has seizures; however, we 
consider that in terms of severity of epilepsy, the ILAE definition may be too broad in labeling 
patients with only sporadic seizures as having intractable epilepsy. On the other hand, our definition 
may not label some highly refractory patients with brief remissions as intractable, when in fact they 
are. Having used the ILAE definition, we think that it is difficult to apply in a large cohort study, as 
the history of each individual patient has to be judged carefully, and the intra-observer and inter-
observer variability may be high. It should be stressed that it is not our intention to decide which 
definition is best or to promote our definition. We merely used our definition as a tool to study the 
course of intractability. In future cohort studies, we advocate the use of one worldwide accepted 
definition to make comparisons between studies easier. We consider the proposed definition of the 
ILAE as a good step forward. 
 
Considerations 
Considering the high proportion of patients with temporary intractability, one could argue that the 
time span used in our definition of intractability was too short, leading to the inclusion of too many 
subjects not fundamentally intractable. Table 6.4 shows our attempt to predict intractability in the 
final year of the 15-year follow-up with intractability in the first 5 years, while varying the period of 
continuous seizures. However, a longer period of continuous seizures in the first 5 years led to a 
decreased sensitivity of the prediction, whereas specificity remained almost the same. In this case, 
fewer subjects being intractable in the final year of follow-up would have been identified. 
Consequently, a longer period of continuous seizures as part of the definition of intractability does 
not solve the problem. Moreover, of the 14 patients with intractability lasting 4–5 years, two 
reached a 5-year and two a 1-year terminal remission. Therefore, determining how long a patient 
has to have frequent seizures to be labeled intractable remains arbitrary. 
Apart from the time span in our definition of intractability, using only two AEDs could be a matter 
of discussion. Other investigators use or recommend three AEDs (Camfield & Camfield, 1996; 
Kwong et al., 2003; Malik et al., 2008), although there is ample evidence that a third AED has little 
or no effect (Arts et al., 2004; Mohanraj & Brodie, 2006). Moreover, all patients who were 
intractable in the final year and 31 of the 34 patients with early onset had used at least three AEDs 
during follow-up. Considering this, we think that the number of AEDs in our definition is not an 
issue. 
Furthermore, there might be discussion about subjects in our study having an intractable seizure 
pattern in the last year of follow-up while using only one AED. After a long period of intractability, 
it may be best for a patient to stop medication or to reduce polytherapy in case none of the therapies 
is really effective. Many physicians would probably have labeled these subjects as being intractable; 
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however, in the present study we applied our definition strictly, and by doing so may have 
underreported the occurrence of intractability. 
The course of intractability was studied during a period of impressive maturation of the child’s 
brain. The fact that many patients had temporary intractability might be the result of these 
processes. On the other hand, the phenomenon of late-onset intractability might result from a 
continuing process of epileptogenesis. 
We studied the course of intractability using an objective approach and did not address the 
subjective severity of intractability, although we realize that this is also important, especially for 
patients just reaching adulthood.  
In this study, incorrect diagnoses of intractability may have been made as a result of 
noncompliance, incorrect medication, or incorrect diagnosis or classification of epilepsy. 
We attempted to exclude these errors to the best of our ability. During the first 5 years, regular 
plasma concentrations of AEDs were taken, giving us an impression of compliance. We did not 
have this information for the patients in the last year of follow-up, unless it was indicated in their 
medical records. The Dutch Study of Epilepsy in Children was a pragmatic study, conducted with 
experienced physicians working according to their usual clinical practice. 
To our knowledge, only a few cohort studies on childhood-onset epilepsy have aimed to identify 
possible reasons (other than clinical features) for the onset or ending of intractability, which makes 
the present study uncommon. Only a few studies reported that remission after intractability and 
relapse occurred in conjunction with changes in medication (Luciano & Shorvon, 2007; Callaghan 
et al., 2011; Choi et al., 2011). Although this is a delicate topic we think that the success or failure 
of treatment has to be considered at all times in future research investigating intractability. 
The fact that we found no risk factors for temporary, continuing, or late-onset intractability might 
be due to the small numbers, even though our cohort is one of the largest with childhood-onset 
epilepsy. Only meta-analyses using multiple cohorts might be able to detect these risk factors.  
 
CONCLUSIONS 
 
At least 12% of patients with childhood-onset epilepsy will have a period of intractability during a 
15-year follow-up. Onset, course, and duration of intractability can fluctuate to a great extent, and 
periods of remission and intractability can alternate with each other. Intractability can be temporary 
(especially in case of early onset), but can also begin many years after diagnosis, and in that case, is 
more likely to persist. These findings are in line with other investigations. 
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Apart from the risk factors for intractability, it is difficult to predict the time of onset of 
intractability and whether it will be temporary. Due to the relatively low frequency of intractability, 
meta-analyses are almost certainly needed for this. 
This study did not find a clear explanation for the variation in intractability. The most probable 
explanation is the natural course of the epilepsy itself, as intractability developed in some despite an 
early and successful start of treatment, and in only 16% could medication be held responsible for 
the termination or late onset of intractability. However, the effect of medication may be different in 
patients who did not have a period of intractability. More research is needed on the actual role of 
AEDs on the process of epileptogenesis; the question remains whether AEDs modify this process or 
merely refine it.  
Despite recent reports by the ILAE commission, a solid and all-encompassing definition of 
intractability, also taking into account the severity of sporadically occurring seizures, remains to be 
established. 
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Additional Supporting Information may be found in the online version of this article and in 
Appendix 5:  
Table S1. Course of epilepsy and effect of treatment for 15 patients with temporary intractability. 
Table S2. Course of 16 patients with late-onset intractability.  
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Chapter 7 General discussion 
 
The main objective of this thesis was to study the course and long-term outcome of childhood-onset 
epilepsy. Our hospital-based study with prospective follow-up since the time of diagnosis may not 
have been the most ideal approach. A population-based study would have been preferred to better 
describe the accurate incidence of childhood-onset epilepsy and all its different epilepsy types and 
syndromes, but such a study is very expensive and both time and labor consuming. Moreover, in 
practice, most patients contact their general practitioner after a seizure and are referred to the 
hospital for further medical examinations, or are brought to the ER of the nearest hospital right 
away. We might have missed subjects with minor seizures who were treated by their general 
practitioner and those that did not seek medical help at all. This might have biased our study to 
patients with more severe epilepsy. However, in view of the low proportion of remote symptomatic 
etiology in our cohort and the estimated 75% recruitment rate, this possible bias does not seem to be 
so bad. What is more, this study did have several advantages (most of them discussed in the former 
chapters) that must be taken into account, in particular the size of the cohort and the length of 
follow-up. We think that, despite several disadvantages, the present study did enhance the 
knowledge of childhood-onset epilepsy. 
Before discussing the main results, a remark has to be made about the terms ‘long-term’ and 
‘outcome’. The word outcome suggests a final condition. This is mostly not the case in epilepsy as 
there is enough evidence by now that a patient’s condition can alter as time goes on. Patients in 
remission for many years, for example, can get recurrent seizures and they even can become 
intractable. On the other hand, patients with monthly seizures for years can reach remission, 
sometimes even for a long time. Our study as well as some other studies demonstrated this [17, 83]. 
The word ‘long-term’ is rather arbitrary, but as there have been no studies so far with a life-long 
follow-up of patients with epilepsy, all studies with a follow-up exceeding the ones that have been 
published up to now give more insight into the course and ‘present state’ of patients at a further 
point in time. Our follow-up was on average 15 years since the time of diagnosis. Most other cohort 
studies had a shorter duration of follow-up. Only a few studies had a longer follow-up, however, all 
of them had fewer patients [21, 24, 28, 29, 96], and not all had a prospective follow-up from the 
time of diagnosis [21, 29]. With these remarks in mind the reader should realize that our results are 
only a snapshot at a certain point in time during the life of our patients.  
In the next paragraphs, I will discuss the various outcome measures that were used in the previous 
chapters and will put them into a broader perspective. 
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Outcome in terms of terminal remission and intractability. 
 
We studied the outcome of our cohort in terms of terminal remission at three points in time: at two, 
five and ~15 years after enrollment. At two years, 57% of the patients had a terminal remission of at 
least one year, at five years even a larger proportion (i.e. 64%) had a terminal remission of at least 
two years, and at 15 years the proportion of patients with a terminal remission of at least five years 
was as high as 71%. These results show a promising development of childhood-onset epilepsy over 
the years. Even more promising is the fact that of the 413 subjects with a 15-year follow-up, 24% 
had seizures only during the first year of follow-up and were in remission since then. This is 22% of 
the 466 patients of the original cohort we first published about.  
 
Another promising development is that the percentage of patients still having seizures in the ‘last’ 
year of follow-up declined from 43% at two years, to 24% at five years, and to 19% at ~15 years. 
However, a drawback was the increase in the number of patients with intractability, defined as 
having no remission exceeding three months during a minimum period of one year of observation 
despite adequate treatment. In the second year 4.5% (21/466) was intractable, in the fifth year 6% 
(27/453), and in the final year 8.5% (35/413). Based on these results, we conclude that with 
lengthier follow-up fewer patients will continue having seizures, but there is a small increasing 
group of patients whose epilepsy deteriorates and ends in intractability. Only 8 of the 35 patients 
being intractable in the final year of follow-up had probably been intractable since the early years of 
follow-up, which is 2% of the 413 subjects with an extended follow-up. 
 
In practice, what do these results mean for a physician and his patient with newly diagnosed 
epilepsy? Overall, chance of a good outcome is high as shown in the previous paragraph, but this 
will not be the case for every single patient. In this study and in many other studies, several 
variables proved to be associated with outcome. The most mentioned and strongest predictors were 
without doubt etiology and type of epilepsy as was demonstrated in our study as well (Figure 7.1 
and Figure 7.2). These two variables are highly correlated. Patients with idiopathic etiology have 
the best prospects, while those with remote symptomatic etiology have the worst. In more detail, all 
patients with idiopathic partial epilepsy eventually will reach a terminal remission of at least five 
years within 10 years of follow-up versus about 40% of the patients with cryptogenic and/or 
symptomatic generalized epilepsy (West syndrome, Lennox Gastaut syndrome, epilepsy with 
myoclonic-astatic seizures of myoclonic absences).  
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Figure 7.1: A 5-year terminal remission as a function of etiology and time.  
 
 
 
Figure 7.2: A 5-year terminal remission as a function of epilepsy type and time. 
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Although these two variables are each separately significant predictors of final outcome, a 
combination of variables should predict outcome even better. For this reason, we developed models 
to predict outcome based on intake information only or on a combination of this information with 
that of the first six months of follow-up. The models predicting a two-year outcome had a 
somewhat disappointing sensitivity and specificity (Table 7.1), with one of every three patients 
having an incorrect prediction. These two prognostic models have been tested in a newly recruited 
cohort of patients [93]. We concluded from that study that although both models predict outcome 
better than chance, they are insufficiently accurate to be of practical value. Both models performed 
less well with the validation cohort than with the original cohort, but in both instances the model 
based on intake and 6-month variables was more accurate.  
Compared with the models predicting a two-year outcome, those predicting a five-year outcome had 
similar sensitivities and specificities and did not predict outcome any better (Table 7.1).  
 
In addition to the previous chapters, we here present a model predicting the outcome of the 
extended follow-up (~15 years). A quick stepwise backward logistic regression analysis predicting 
a terminal remission of less than one year, showed that type of epilepsy in combination with febrile 
seizures before intake gave the best results, although specificity was very low in this model. Using 
intake and 6-month variables, which resulted in a model with a combination of age at onset, type of 
epilepsy, febrile seizures before intake and terminal remission at six months, hardly did result in a 
better predictive model. Sensitivity was higher but specificity was the same as in the model with 
only intake variables. 
  
Table 7.1 Results of stepwise backward logistic regression analyses predicting terminal 
remission 
 
Predicted 
outcome 
Based on Probability 
cutoff 
% 
Sensitivity 
 
% 
Specificity 
 
% 
Correct 
predict 
% 
Area under 
the ROC 
curve 
TR2 < 6 
months 
Intake variables only 38 62 69 67 0.69 (poor) 
 Intake & 6-month 
variables 
34 73 73 73 0.78 (fair) 
TR5 < 1 
year 
Intake variables only 25 65 64 64 0.70 (fair) 
 Intake & 6-month 
variables 
21 69 71 70 0.77 (fair) 
 
TRE < 1 
year 
Intake variables only  18 73 56 59 0.68 (poor) 
 Intake & 6-month 
variables 
16 85 55 61 0.74 (fair) 
TR2, TR5, TRE: terminal remission at two or five years after enrollment and after extended follow-up.  
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Studying these results, it is evident that the accuracy of the prediction models above is not perfect. 
The area under the ROC curve is a popular test to measure the accuracy of a model. However, this 
test may not be optimal in models that predict risk for a certain event or to classify subjects [97]. 
Nonetheless, the results we found were at best fair. It seems that outcome after a mean follow-up of 
about 15 years is not easier to predict on the basis of intake and 6-month variables than the earlier 
outcomes. This may be due to the fluctuating course of epilepsy during follow-up. Only subjects 
with idiopathic partial epilepsy had a steady course, with all having a terminal remission of at least 
five years. Further, information collected during a longer follow-up period probably better predicts 
long-term outcome. In a Finnish study, for instance, variables collected during the first year of 
follow-up were used to predict outcome after a 40-year median follow-up [20]. Having weekly 
seizures during the first year of follow-up was a strong predictor for drug resistant epilepsy in that 
study.  
 
The terminal remission at two years and five years after enrollment was measured at fixed points in 
time, whereas the terminal remission at the end of the extended follow-up was not: subjects had 
varying lengths of follow-up. Taking the time that passes until the outcome into account, shows that 
beside the two variables chosen in the logistic regression analysis one additional variable (age at 
onset) was selected using a Cox proportional hazard model based on only intake variables, with a 
higher chance of a terminal remission < 1 year at older age (Table 7.2). The model based on intake 
and 6-month variables (Table 7.3) also included one additional variable (type of seizure). For these 
two models no area under the ROC was calculated.  
 
Tables 7.2 Variables in the Cox proportional hazard model based on intake variables only 
predicting a 1-year terminal remission during a follow-up of about 15 years. 
  
 
B SE Wald df Sig. 
Exp(B) 
* 
95% CI Exp(B) 
Lower Upper 
Age at onset -,032 ,014 5,14 1 ,023 ,969 ,942 ,996 
Type of epilepsy:   56,64 6 ,000    
Symp gen / idiop gen -,266 ,220 1,46 1 ,227 ,766 ,497 1,180 
Crypto and symp gen / idiop gen -1,027 ,252 16,53 1 ,000 ,358 ,218 ,588 
Idiop part / idiop gen ,663 ,228 8,49 1 ,004 1,941 1,243 3,033 
Symp part / idiop gen -,796 ,182 19,08 1 ,000 ,451 ,316 ,645 
Crypto part / idiop gen -,435 ,154 8,00 1 ,005 ,647 ,479 ,875 
Other / idiop gen ,542 ,264 4,21 1 ,040 1,719 1,025 2,883 
Febrile seizures / no febrile seizures -,432 ,207 4,36 1 ,037 ,649 ,433 ,974 
* (Exp(B) < 1: higher chance of a terminal remission < 1 year).  
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Table 7.3 Variables in the Cox proportional hazard model based on intake & 6-month 
variables predicting a 1-year terminal remission during a follow-up of about 15 years. 
 
 
B SE Wald df Sig. 
Exp(B) 
* 
95% CI Exp(B) 
Lower Upper 
Age at onset -,045 ,015 8,95 1 ,003 ,956 ,929 ,985 
Type of seizures:   11,38 4 ,023    
CPS / mainly TCS -,254 ,213 1,42 1 ,233 ,776 ,511 1,177 
SPS / mainly TCS  -,351 ,298 1,39 1 ,238 ,704 ,393 1,261 
Absences / mainly TCS ,449 ,172 6,80 1 ,009 1,567 1,118 2,198 
Other / mainly TCS -,133 ,226 ,35 1 ,557 ,875 ,562 1,364 
Type of epilepsy:   37,91 6 ,000    
Symp gen / idiop gen -,148 ,222 ,45 1 ,504 ,862 ,558 1,332 
Crypto and symp gen / idiop gen -,611 ,301 4,14 1 ,042 ,543 ,301 ,978 
Idiop part / idiop gen ,940 ,258 13,27 1 ,000 2,559 1,543 4,243 
Symp part / idiop gen -,596 ,190 9,81 1 ,002 ,551 ,380 ,800 
Crypto part / idiop gen -,270 ,161 2,80 1 ,094 ,763 ,556 1,048 
Other / idiop gen ,404 ,274 2,18 1 ,140 1,498 ,875 2,564 
Febrile seizures / no feb seizures -,375 ,209 3,20 1 ,074 ,687 ,456 1,036 
Terminal remission 6-month follow-up ,005 ,001 31,81 1 ,000 1,005 1,003 1,006 
* (Exp(B) < 1: higher chance of a terminal remission < 1 year).  
 
Beside the modeling efforts above, we have evaluated the accuracy of two newly developed models 
predicting outcome in collaboration with the Dalhousie University and the IWK Health Centre of 
Halifax, Nova Scotia, Canada [50].  These two statistical models were based on stepwise logistic 
regression and on classification tree modeling techniques and were developed using the Canadian 
and Dutch cohort of children with epilepsy and were cross-validated. The conclusion from that 
study was that based on currently available clinical and EEG variables, predicting the outcome of 
childhood epilepsy is difficult and appears to be incorrect in about one of every three patients.     
 
Other prognostic models in epilepsy research were developed but all had moderate to fair results 
[13, 98-100]. Only one prognostic model constructed to predict the two-year outcome of temporal 
lobe epilepsy had good results with an accuracy of 0.93, but in a later study the accuracy levels 
were below 0.80, which the investigators regarded as not being clinically useful [98, 99].  
 
Based on the above findings we have to conclude that the modeling techniques above are not of 
sufficient quality to make accurate predictions. However, it might be that we and other investigators 
still have not been able to identify accurate predictors for the outcome of epilepsy. Perhaps, new or 
refined imaging techniques, the finding of biomarkers in blood or cerebrospinal fluid, or altered 
gene expressions might provide these. Nevertheless, the diversity of epilepsy types, syndromes and 
etiology and the fact that patients with the same phenotype or genotype often have different 
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outcomes makes it uncertain if prediction of outcome in patients with epilepsy using multivariate 
analysis techniques will be more accurate in future than it is at present.  
 
Other modeling techniques have been explored and developed. The need for these is obvious. In a 
review about computer modeling in epilepsy the following was stated: ‘Epilepsy is a complex set of 
disorders that can involve many areas of cortex as well as underlying deep brain systems. The 
myriad manifestations of seizures, as varied as déjà vu and olfactory hallucination, can thereby 
give researchers insights into regional functions and relations. Epilepsy is also complex genetically 
and pathophysiologically, involving microscopic (ion channels, synaptic proteins), macroscopic 
(brain trauma and rewiring) and intermediate changes in a complex interplay of causality. It has 
long been recognized that computer modeling will be required to disentangle causality, to better 
understand seizure spread and to understand and eventually predict treatment efficacy’ [101]. 
 
Artificial neural network models, for instance, are non-linear statistical data modeling or decision 
making tools that can be used to model complex relationships between inputs and outputs or to find 
patterns in data (Figure 7.3). 
 
Figure 7.3 Simplified view of a neural network 
 
 
 
One study had the objective to model successful outcomes after epilepsy surgery using this 
technique [102]. The investigators stated that standard multivariate techniques with the same goal 
had an accuracy of only 75-80%. With neural network models, they were able to predict seizure 
outcome with an accuracy of more than 95%. In an earlier study, accuracy results of 82% and 95% 
were found in an attempt to select patients for epilepsy surgery [103]. Using discriminant functions 
on the same patient sample gave much lower accuracies (55% and73%). Another study predicted 
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outcome of epilepsy with a 91% correct prediction rate [104]. Other applications of this technique 
in the field of epilepsy were the classification of subgroups of primary generalized epilepsy based 
on parameters obtained from EEG signals, and the outcome of drug treatment based on genetic 
markers [105, 106]. Berg et al. used Markov modeling to determine the probability that a patient 
with epilepsy will be in remission at a certain point in time during a median 7-year follow-up [71]. 
With this technique, which is a special application of the neural networks modeling technique, they 
were able to differentiate the fluctuating course of epilepsy for various epilepsy types to a certain 
extent. At present, more research in the field of epilepsy is being done using the above techniques. 
The Global Research in Pediatrics is a network of excellence (Grip) with the main aim to stimulate 
and facilitate the development and safe use of medicine in children, as drug development programs 
are usually only applicable to adults. One of the aims is to achieve a scientific consensus on: the 
role of pharmacokinetic/ pharmacodynamics (PK/PD) modeling in pediatric drug development to be 
proposed at the regulatory level, the use of simulation to reduce the number of children enrolled in 
trials and the number of samples for lab tests, and how the extrapolation methodology can be used 
in regulatory procedures. The data of the Dutch study of epilepsy in children will be used in this 
project.  
 
Although the artificial network modeling technique looks promising and has many advantages, 
there are also disadvantages (Table 7.4). It is for example difficult to understand the exact nature of 
the relationship between each single input variable and the predicted outcome, which makes it not 
possible to determine which variables are the strongest predictors of outcome. The output of neural 
network models is more difficult to interpret than that of the traditional multivariate techniques. 
With neural networks one can get an accurate prediction, while with the traditional techniques more 
insight into the problem can be obtained. Furthermore, there are no practical guidelines for how to 
select input variables, although in some studies the traditional techniques were used to select the 
input variables for neural network modeling [103, 104]. Finally, using a model in other datasets is 
not as easy as using logistic regression analysis: with logistic regression coefficients it is possible to 
calculate the probability of a certain outcome on a simple calculator, while one will need a copy of 
the trained software to do the same with the neural network model.  
Considering all points mentioned above, we think that models developed to predict course or 
outcome of epilepsy at present are still not sufficient and accurate enough to be used in daily 
clinical practice, at least not for a single person.  
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Table 7.4 Advantages and disadvantages of using neural networks for predicting medical 
outcomes [107] 
 
Advantages 
1. Neural network models require less formal statistical training to develop 
2. Neural network models can implicitly detect complex nonlinear relationships between 
independent and dependent variables 
3. Neural network models have the ability to detect all possible interactions between predictor 
variables 
4. Neural networks can be developed using multiple different training algorithms 
Disadvantages 
1. Neural networks are a “black box” and have limited ability to explicitly identify possible causal 
relationships 
2. Neural networks models may be more difficult to use in the field 
3. Neural network modeling requires greater computational resources 
4. Neural network models are prone to overfitting 
5. Neural network model development is empirical, and many methodological issues remain to be 
resolved 
 
Outcome in terms of mortality 
 
Beside the outcome in terms of terminal remission and intractability, we studied the mortality in our 
cohort. The results showed that mortality was significantly higher only in those with remote 
symptomatic etiology and was mainly caused by their underlying condition. This finding was 
demonstrated by others as well [15, 58, 66, 108, 109]. In this study none of the subjects with 
idiopathic etiology died. They had the same mortality rate as the Dutch population. A person with 
idiopathic etiology only has a higher risk of dying during a status epilepticus or as a result of 
drowning or severe trauma during an epileptic seizure. Further, some patients with epilepsy can get 
depressed and sometimes become suicidal. Other than this, there is a chance of sudden unexplained 
death (SUDEP) as a result of epilepsy. The frequency is very low, however, especially in children 
[110]. In our study the crude rate might have been 3/10,000 person-years of follow-up maximally. 
Yet, in the long-term follow-up study of Sillanpää much higher and disturbing rates were found: 18 
SUDEPs occurred on a total of 8692 years of follow-up, which leads to a crude SUDEP rate of 
20.7/10,000 persons-years of follow-up, which is 7 times higher than in our study [111]. Of all 
deaths in that study, 30% were due to SUDEP of which seven times in case of idiopathic etiology. 
In our study SUDEP did not occur in subjects with idiopathic etiology. One of the reasons might be 
that SUDEP in subjects with idiopathic etiology occurs at older age, as was suggested in the Finnish 
study mentioned above (median age at SUDEP: 27 years; range: 13-48). Regarding this finding and 
the fact that our cohort was younger at last contact (median age: 20.4; range 12.2–32.5 years), 
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SUDEP cases have to be expected in our idiopathic etiology group in the next years. Especially 
those with idiopathic generalized epilepsy using Lamotrigine might have a higher risk [112]. 
 
Outcome in case of fast response to medication 
 
In our cohort, about one third of the subjects had a fast response to medication. They had a 
remission of at least 6 months that began within two months after the start of treatment, and were 
subsequently randomized to stop treatment or continue treatment for another six months. At two 
years after randomization the recurrence rates of the 6-month and 12-month treatment groups were 
similar. Four years after randomization, there still was no significant difference in the recurrence 
rates, and neither in terminal remission. However, the group with 6-month treatment had relatively 
more late recurrences during follow-up and had a slightly worse terminal remission. We could not 
exclude that these findings might have been the result of the early withdrawal of treatment.  
Also at the end of the extended follow-up, the terminal remission in both groups was similar: 80% 
(71% without and 9% with AED at last contact) of the 6-month treatment group had a terminal 
remission of more than 5 years, versus 75% (64% without and 11% with AED at last contact) in the 
12-month group (95% CI of difference: -8.2; 17.7). In the 6-month group one subject with epilepsy 
as a result of a stroke died nine years later following cardiac arrest. Further, there were no 
differences in duration of epilepsy (interval between onset and last seizure), number of AEDs used 
during the first five years of follow-up, number of subjects still on AEDs at last contact, and 
number of subjects having seizures or being intractable in the last year of follow-up. 
Beside the randomized subjects with a fast response to medication, there were an additional 38 
subjects in our cohort with a fast response who were not randomized, mostly because parents 
refused or because of a language barrier. These subjects were treated according to the usual clinical 
practice, which means that most of them received medication much longer. During the first five 
years of follow-up all three groups had the same recurrence rate (6-month group: 59%, 12-month 
group: 51%; non-randomized group: 58%) and the mean number of AEDs used during these five 
years were similar. When we compare all randomized with the non-randomized fast responders, 
none of the variables mentioned above differed. Only the mean duration of medication during the 
first five years of follow-up was significantly longer in the group without randomization, as was to 
be expected (35.0 versus 25.5 months, ANOVA F=6.448, p=0.01).  
From the findings above we conclude that in children with a fast response to treatment, early 
withdrawal of medication after a short period of remission may not lead to negative long-term 
consequences. Several outcome measures at the end of follow-up were similar between randomized 
and non-randomized fast responders. Despite this, it is possible that there were differences in 
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seizure frequency or severity, or that recurrences occurred later in time (after more than four years 
of follow-up), but we did not study these in detail.   
The five variables that were predictive of an excellent terminal remission at four years after 
randomization in multivariate analyses (normal EEG, idiopathic etiology, having only absences, age 
at onset < 6 years, and no postictal signs) were not all predictive of a good outcome after extended 
follow-up. EEG and postictal signs did not matter anymore in univariate analysis, but the other 
variables did. Of the subjects with absences, more than 90% reached a 5-year terminal remission 
without medication during these years irrespective of age at onset. Subjects with other types of 
seizures, idiopathic etiology, and onset before the age of six had this outcome in 84% of the cases, 
and for those with later onset this was true for 61% of the cases (95% CI of difference: 4.2-41.3, 
p<0.05). For those of them with non-idiopathic etiology, these results were 71.4% with onset before 
six years of age versus 48.1% thereafter (95% CI of difference: 3.5; 43.2, p<0.1). Based on these 
results, subjects with absences are still good candidates for early withdrawal of medication, but 
subjects with other seizure types, non-idiopathic etiology, and onset after six years of age are not.  
 
Outcome in terms of social economic status 
 
Other than the outcomes described above, there were more aspects of epilepsy that needed attention. 
Besides the seizures, the AEDs with possible side effects, and the regular visits to hospitals, a 
patient has to deal with the effect of epilepsy on his or her social situation, educational and 
occupational achievement, and quality of life. Perhaps these aspects have more impact on subjects 
with an ordinary life having late onset of seizures than on young children with early onset. The most 
interesting finding of our study was that subjects with idiopathic etiology were comparable to their 
Dutch age peers in terms of living arrangements, having a partner or offspring and employment 
status, but not in terms of educational and occupational achievement. A lower educational 
attainment was reported by others as well [14, 15, 27, 29, 113] with a similar trend even for those 
with epilepsy only, normal intelligence and for those in remission and off AEDs. As described 
earlier, this could be a result of mild impairment of cognitive functions preceding the onset of 
epilepsy [81, 114-120].  
In chapter 5, we reported the age-adjusted standardized incidence rates for subjects with idiopathic 
etiology and for subjects in remission, but not specifically for subjects with idiopathic etiology 
having a 5-year terminal remission and in addition being off AEDs at last contact. To show that the 
lower educational and occupational levels were not a result of active epilepsy and/or ongoing 
treatment, we here present the standardized incidence rates for this latter group.  
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Table 7.5 Age-adjusted standardized incidence rates (SIR) for subjects with idiopathic 
etiology having a 5-year terminal remission and being off AEDs at last contact (* p<0.05). 
 
Present 
education 
(n= 68) 
SIR 
(95% CI) 
Highest 
attained 
education 
(n=67) 
SIR 
(95% CI) 
 Occupational 
level 
(n=61) 
 
SIR 
(95% CI) 
Lower 
vocational, 
general 
secondary, 
pre-university 
1.01 
(0.64-1.51) 
  Elementary: jobs 
with simple duties 
0.44 
(0.09-1.27) 
Intermediate 
vocational 
1.30 
(0.87-1.86) 
primary, lower 
vocational or 
lower general 
secondary 
1.27 
(0.83-1.86) 
Lower: jobs with 
duties at the level 
of preliminary 
vocational 
education 
1.26 
(0.83-1.85) 
Higher 
vocational 
0.99 
(0.54-1.67) 
higher general 
secondary or 
pre-university or 
intermediate 
vocational 
1.11 
(0.77-1.54) 
Intermediate: jobs 
with duties at the 
level of 
intermediate 
vocational 
education 
1.14 
(0.74-1.68) 
Scientific 0.25* 
(0.03-0.92) 
higher 
vocational or 
scientific 
0.43* 
(1.16-0.93) 
Higher/scientific: 
jobs with duties at 
the level of higher 
vocational or 
scientific education 
0.63 
(0.25-1.30) 
 
According to Table 7.5, fewer students followed a scientific education at last contact and fewer 
employees than expected attained a higher vocational or scientific education. These significant 
findings further strengthen the hypothesis that mild impairment of cognitive functions might be 
found in these subjects. This impairment might have been present before the onset of epilepsy, or 
developed later due to seizures or AEDs. However, it is possible that ‘having epilepsy’ was the 
reason for following education at a slower pace, or at a lower level, even though their cognitive 
abilities were not impaired. It is even possible that subjects with disorders like this are less 
ambitious in life, also because of the associated stigma, and are reserved to a certain extent by their 
fear of new seizures. More research is needed to confirm whether cognitive impairments or any of 
the above mentioned possible explanations are indeed the basis for the lower educational 
achievement.  
Beside the educational attainment, the marginally significant lower occupational level found in the 
whole group of subjects with idiopathic etiology was no longer present for those of them in 
remission and off AEDs, although the rate was still lower than expected. As mentioned before, 
more research is needed in this field, especially in under-employment. 
 Page | 129  
 
Course of epilepsy and treatment during follow-up 
 
During our study we did not only pay attention to the ‘final’ outcome of epilepsy, but to the course 
during follow-up as well. In three selected years of follow-up, we checked if seizures occurred or 
not (Figure 7.4).  
 
Figure 7.4 Course of epilepsy during follow-up 
 
 
 
Subjects with a favorable, varying or deteriorating course had a change of situation along the years 
of follow-up (Figure 7.5). In the other groups the course seemed to be steadier, at least for the three 
selected years. We concluded that the course of epilepsy can be inconsistent, and changes may 
occur after considerable periods of time. We also studied intractability during follow-up and 
showed a similar pattern: subjects can have early or late onset of intractability. It may be temporary, 
and sometimes it is interrupted by long periods of remission. Both the course of epilepsy and 
intractability are strongly dependent on etiology, age, and response to medication or early course 
during follow-up. One third of our cohort had their final seizure within the first year of treatment, 
but this group may have had a good outcome anyway, even without taking medication.  
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Figure 7.5 Course of epilepsy during follow-up for the cohort and for each etiological group 
 
 
On the other hand, one third of our subjects still used AEDs at last contact, showing the limitation 
of treatment. We also did not find a large role for treatment in preventing or terminating 
intractability as was discussed in chapter 6. Therefore, we agree with the statement that AEDs 
mostly suppress seizures but do not treat the epilepsy itself [121]. Juvenile myoclonic epilepsy may 
be the best example of this: medication is successful but once it is stopped new seizures mostly 
occur. In benign cases, childhood-onset epilepsy is a self-limiting disorder and the course is 
probably only marginally influenced by the treatment given. In other cases, epilepsy deteriorates 
despite the trials of numerous treatment strategies, and it is far from plausible that bad compliance, 
drug resistance or tolerance are the only causes for this. As a matter of fact, if drug resistance or 
tolerance would be autonomic mechanisms not related to the severity of epilepsy, these phenomena 
would be equal in all epilepsy types. In a recent study of subjects with juvenile myoclonic epilepsy 
true drug resistance was only found in those with a combination of three seizure types, but not in 
those with only myoclonic jerks with or without absences [122]. 
 
Recently, some investigators proposed a remission and relapse model for the temporal aspects of 
seizures in epilepsy based on their findings and that of others [123]. Remission was defined as two 
years without seizures, and with long-term remission they meant a terminal remission of at least two 
years, instead of the five years we used. They found that of adult subjects with refractory epilepsy 
(seizures in the past two years, at least five years after onset and who used at least two appropriate 
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AEDs during that time), 70% had a continuous seizure pattern with no periods of remission and 
30% had an intermittent pattern with 2-year remission periods (Figure 7.6).   
When we apply this model and the 2-year remission definition to our cohort, we found that 234 
(56.7%) of our subjects who had a 15-year follow-up (n=413) developed long-term remission 
within 5 years of onset, which was about similar to what was suggested in the above schedule 
(pathway a). However, 82 (19.9%) of our subjects reached a terminal remission of at least two years 
after the first five years of onset (pathway c), which was twice as high as was suggested above. 
 
Figure 7.6 Remission and relapse model of the temporal aspects of prognosis of epilepsy 
 
Further, at most 52 (12.6%) had a continuous pattern (pathway d) and at least 45 (10.9%) had an 
intermittent pattern (pathway e), whereas Neligan et al. found that 20% had a continuous and 10% 
an intermittent pattern, which means that the proposed model when applied to children is incorrect 
for the pathways c, d and e. Our continuous pattern group had no 2-year remission periods during 
the first five years of follow-up, but could have had remission periods after these years. However, 
accurate information about this later period was not available. In fact, in case of late remissions the 
continuous pattern group would become smaller than it was and the intermittent group would 
become larger, which makes the differences between the proposed model and our results even 
bigger than they are. 
Despite these differences in outcome, Neligan et al. concluded that there seems to be considerable 
heterogeneity in seizure patterns in people who do not enter long-term remission in the early years 
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after diagnosis. Like us, they found that some people who had a remission in the early years still 
developed refractory epilepsy, and some subjects with continuous seizures for at least five years 
entered terminal remission. Also they wondered to what extent the long-term remission developed 
within five years of onset represented the natural history of benign epilepsy or was a treatment 
effect. They believe both probably play a role and their clinical experience suggests that for those 
without remission treatment will often reduce the severity, timing or frequency of seizures in 
beneficial ways. With this, we fully agree. 
 
In line with the above remission and relapse model we would like to end with the following 
outcome schedule, in which a separation is made between the three etiological categories to make 
comparison with other cohorts easier (Figure 7.7).  
 
Figure 7.7 Outcome schedule based on the originally included subjects with epilepsy, with 
long-term remission meaning a terminal remission of at least five years and active epilepsy 
meaning having seizures in the last five years of follow-up 
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The results of our study suggest that there is a group of subjects with smooth sailing epilepsy, which 
we have added to this schedule: 82 subjects became seizure free within 2 months of AED-use and 
remained so during the rest of the 15-year follow-up and 4 subjects had a fast response but had a 
follow-up of only 5 years. Further, 42 subjects were seizure free within 2 months after enrollment 
without treatment and stayed free of seizures during follow-up. In total, 128 subjects had smooth 
sailing epilepsy which is 25.9% of the 494 subjects who were originally included in this study.  All 
percentages in the schedule refer to these subjects. By doing this we will get a more realistic view 
of the prognosis of newly diagnosed patients with epilepsy. For outcomes per epilepsy type or 
syndrome we refer to Chapter 4. The figure below shows that while in the remote symptomatic 
group more subjects died,  in the idiopathic etiology group more subjects did not respond to the 
‘extended follow-up’ questionnaire. They probably were in remission and did not wish to be 
bothered anymore: a reason we sometimes heard from subjects while doing this research. Smooth 
sailing epilepsy was significantly less often seen in the group with remote symptomatic etiology 
compared with the other groups and seizures in the last year of follow-up were significantly more 
frequent in the groups with non-idiopathic etiology. We did not use our intractability definition in 
this model, as there still is much debate about which definition best describes refractory, drug-
resistant, or intractable epilepsy.  
 
Final conclusion 
 
The overall conclusion of this 15-year follow-up study of childhood-onset epilepsy is favorable. 
Most children with epilepsy have a good or improving course during follow-up, and in one out of 
every four children it will be ‘smooth sailing’. Most also have a good outcome in terms of 
remission, intractability, and mortality, but with lengthier follow-up there is a small increasing 
group of patients whose epilepsy deteriorates and ends in intractability. 
Mortality was significantly higher only in those with remote symptomatic etiology and was mainly 
caused by their underlying condition. The frequency of sudden unexplained death as a result of 
epilepsy (SUDEP) was very low. 
The course of epilepsy can be dynamic, and changes may occur after considerable periods of time. 
This is also true for intractability. This finding might influence our interpretation of the results of 
prognostic studies, advice to patients, treatment strategies, and timing of referral for surgery.  
 
Multivariate modeling techniques developed to predict course or outcome of epilepsy are at present 
not accurate enough to be used in daily clinical practice, at least not for a single person, as one of 
every three patients will be misclassified. In future, neural network models may be a valuable 
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alternative by simulating the course and outcome of epilepsy and in that way may contribute to drug 
development programs for children. 
 
The influence of treatment on the course or outcome of epilepsy seems to be minor, especially for 
subjects having a benign type of epilepsy and who probably will do well even without treatment. At 
last contact, one third of all patients still used AEDs, although in most of them it was ineffective as 
they continued to have seizures or were intractable. The most important role of treatment is perhaps 
the reduction of the severity, timing or frequency of seizures, making life more comfortable for the 
patient. Further, it might be possible that treatment reduces the time to remission or prolongs the 
time to intractability, but this assumption is not based on facts. 
In children with a fast response to treatment, early withdrawal of medication after a short period of 
remission may not lead to negative long-term consequences. Especially subjects with absences are 
good candidates for early withdrawal of medication. 
 
Subjects with idiopathic etiology have the best results and resemble their Dutch age-peers in 
mortality, health perception, housing, having a partner, offspring, and employment status. Only 
educational and subsequent levels of occupation are a matter of concern. The disturbing finding that 
this group might have mild impairment of cognitive functions preceding the onset of epilepsy has to 
be examined in more detail. Also the presumption of underemployment is a matter of concern. 
Another point of interest is the possible occurrence of future SUDEPs in our cohort, if the high rates 
in the Finnish cohort of Sillanpää are accurate. Further, quality of life is an aspect that has not been 
highlighted in the current study. Beside this, neural networks analyses gain ground and need more 
data covering a longer follow-up to fine-tune predictive models. The Dutch Study of Epilepsy in 
Childhood is a solid basis for doing more research in these fields. The fact that there are only a few 
studies worldwide with prospective follow-up from the time of diagnosis with a considerable length 
of follow-up should be an important reason for prolonging the follow-up of the current cohort.  
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SUMMARY 
 
In this hospital-based study, 494 consecutive children with epilepsy (aged 1 month - 16 years) were 
prospectively followed up from the time of diagnosis. The main objective of this study was to 
investigate the course of childhood-onset epilepsy during a period of 15 years and the subsequent 
outcome in terms of remission, intractability, and mortality. Other points of interest were the early 
withdrawal of treatment in subjects with a fast response to AEDs, the development of models 
predicting outcome, and the health and socioeconomic status of subjects with epilepsy. During the 
first five years, regular visits or contacts were scheduled to ensure detailed gathering of data, such 
as type and frequency of seizures, etiology, use of antiepileptic drugs and dosage changes, possible 
side effects, and additional medical examinations. About 15 years after diagnosis a questionnaire 
was sent to all participants with items not only concerning seizures and medication, but also 
concerning health perception, restrictions due to epilepsy, other health problems, and in addition 
social, educational and occupational attainment. In the next section, the content of the chapters 
describing the results of some of the substudies will be summarized. 
 
Generally in subjects with epilepsy, antiepileptic drugs are withdrawn after a seizure-free period of 
at least two years. Some subjects have a fast response to treatment and in the past we examined if 
shorter treatment duration in this group would be possible without increasing the risk of recurrences 
[39]. In that study subjects with a fast response (having a 6-month remission starting within two 
months after the beginning of treatment) were randomized, either for a 6- or 12-month treatment. In 
Chapter 2 we describe the results of a 4-year follow-up after randomization. During these years, 
more than half of the 161 children had had one or more recurrent seizures: 59% of the 6-month and 
51% of the 12-month group. The difference was not significant. Also the recurrence rates at two 
years did not differ, but the 6-month group had relatively more late recurrences. After recurrence, 
55 children restarted medication of whom 25% without success. Adverse events or death did not 
occur, except for a status epilepticus after withdrawal in two subjects (one in each group).  
Beside the recurrence rate, we studied terminal remission (TR4) and found that 51% of the children 
had an excellent outcome (TR4 ≥ 2 years without AEDs), 21% had a TR4 ≥ 2 years with AEDs, and 
15% still had seizures in the last year. Differences between the two groups were not significant.  
We identified several variables that were predictive of an excellent outcome and based on some of 
these, we developed a model to identify children who may benefit from early withdrawal. The 
model correctly classified 73% of the children and was considered fair.  
We conclude that there was no significant difference in outcome between the two treatment groups, 
although the results of the 6-month group were not as good as that of the 12-month group. The 
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excellent outcome in half of all children meant that unnecessary treatment was prevented for more 
than one year. Conversely, in some children renewed medication failed, which may be a serious risk 
of early withdrawal. We cannot recommend early withdrawal in all fast responding children, but our 
predictive model might be of help. 
 
In Chapter 3 we described the course and prognosis of childhood-onset epilepsy during the first 
five years of follow-up. A 1-year terminal remission was found in 76% of the 453 subjects. It was 
remarkable that 14% of the cohort was completely seizure free since enrollment, and another 27% 
came into terminal remission within the first year of follow-up. On the other hand, 6% was 
intractable in the last year, of which half had been intractable in the second year as well. 
Treatment was used by 86% of the cohort, with half of them using only one AED during follow-up. 
The proportion of subjects with seizures in the fifth year depended strongly on the number of AEDs 
used, with an increase following more treatment regimens. However, 60% of the subjects using 
more than one AED did reach remission in the last year. At final contact, 36% of the cohort still 
used treatment. 
Half of the subjects had a good course with no seizures during the 2
nd
 and 5
th
 year. One quarter had 
an improving course, with seizures in the 2
nd
 year but not in the 5
th
 year, 6% had a deteriorating 
course with no seizures in the 2
nd
 year but seizures in the 5
th
 year and 17% had a poor course with 
seizures in both years. These four groups differed significantly in intake and 6-month variables. 
Rolandic epilepsy and idiopathic generalized epilepsy had the best course during follow-up and 
symptomatic or cryptogenic epilepsy the worst.  
Based on several significant predictors, two models predicting seizures in the last year were 
developed: one using intake variables only and one a combination of intake and 6-month variables. 
The prediction of both models was considered fair, but one of every three children was 
misclassified. 
Based on the results above, we concluded that most children with epilepsy had a good or improving 
course and a good outcome, and only a minority was intractable. This outcome is in line with other 
studies, despite differences in cohort composition and length of follow-up. Further, we concluded 
that intractability seems to have a fluctuating course and failure of one or more AEDs strongly 
predicts poor outcome, but despite this treatment can still be successful.  
 
In Chapter 4 the course and outcome of childhood-onset epilepsy during a 15-year follow-up was 
investigated. A questionnaire with items concerning epilepsy was completed by 413 subjects. Of 
these subjects, 71% had a 5-year terminal remission, most of them without medication at last 
contact. The others had active epilepsy, and 8.5% of the cohort ended with intractability.  
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Course was favorable in half of the cohort, and about 30% had an improving course. In both group, 
more than 80% had a 5-year terminal remission. About 12% had a varying or deteriorating, and 
10% a poor course. At least 60% of the subjects with a poor course were intractable in the final 
year, versus 28% of those with a deteriorating and 15% of those with a varying course.  
One third of the cohort had an early good course during the first five years of follow-up, with no or 
only seizures during the first 6 months. Part of them relapsed and ended with active epilepsy or 
intractability. For only a few relapses, we found a plausible explanation.  
The mean duration of seizure activity was 6.0 years, with 25% of the cohort having seizure activity 
for less than one year and 25% for more than 12 years.  
Treatment was or had been used by 86% of the subjects, with one third having their last seizure 
within the first year of treatment. Over 60% of the users stopped treatment (mean duration: 3 years), 
and 38% continued until last contact, with half of them still having seizures in the last year but one 
quarter having a terminal remission of at least five years. Most of these results were similar to those 
at five year follow-up.  
We found several significant predictors for active epilepsy and intractability. Based on these, we 
developed a model for final intractability, with an accuracy that was considered good. 
During 15-year follow-up, 18 subjects died of whom 9 during the first five years. The standardized 
mortality rate of subjects with idiopathic or cryptogenic etiology resembled that of Dutch age peers, 
but for those with remote symptomatic etiology it was 30 times higher. We found no definite cases 
of sudden unexplained death (SUDEP). 
We concluded that the 15-year outcome in childhood-onset epilepsy is favorable for most children, 
but 9% will end in intractability. Course of epilepsy can be inconsistent, sometimes with delayed 
improvement or deterioration. Mortality is higher only in case of remote symptomatic etiology, and 
is probably a consequence of the underlying severe disorder. The natural course of epilepsy 
probably best explains course and outcome, with some types of epilepsy being short-lived and 
others having an inherent poor outcome. Treatment probably has a minor role.  
 
Chapter 5 deals with other aspects of epilepsy. Half of the 413 subjects reported one or more 
neurologic brain-related morbidities (mostly the cause of their epilepsy) or other impairments and 
disabilities. One quarter of the cohort was mentally retarded, ranging from mild to severe. 
We compared our cohort with age peers of the Dutch population and calculated age-adjusted 
standardized incidence rates. The health perception of subjects with normal intelligence was worse 
for those with active epilepsy, especially for those still using medication. In addition, fewer subjects 
with a non-idiopathic etiology reported a very good health perception.  
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Restrictions were reported by 14% of the subjects with normal intelligence, mainly by those with 
active epilepsy. More subjects still using medication reported restrictions than those off medication. 
The most frequent restrictions were related to performing activities, or learning things because of 
concentration and memory problems. 
The living arrangements of subjects without remote symptomatic etiology and their Dutch age peers 
were comparable. Those with remote symptomatic etiology lived in an institution or living group 
for the disabled more often.  None of them had children, whereas the other etiology groups 
resembled their Dutch age peers in having offspring.  
Subjects with idiopathic or cryptogenic etiology following education at last contact resembled their 
Dutch age peers, although in the group with idiopathic etiology higher vocational or scientific 
education was slightly underrepresented. For those with remote symptomatic etiology the rate of 
special education was high. Employees in our cohort had a significantly lower educational 
attainment than expected, even those with idiopathic etiology. 
The employment status of subjects with idiopathic or cryptogenic etiology was similar to that of 
Dutch age peers, but those with remote symptomatic etiology more often depended on state welfare. 
When only subjects being part of the labor force were considered, similar employment rates were 
found for all three etiology groups. 
Fewer employees with idiopathic etiology had an occupation based on higher education. Subjects 
with remote symptomatic etiology had more often an elementary job level.  
Beside the comparison of the three etiology groups with the Dutch population, we also compared 
subjects in remission or not with the population. For many of the variables discussed above, the 
group in remission did worse than expected. This was mostly a result of subjects with remote 
symptomatic etiology in this group.  
Compared with other studies, our study showed better outcome in terms of marriage/cohabitation, 
or offspring for those with idiopathic etiology, but outcome in terms of health perception and 
education was similar.   
Based on the findings above, we conclude that even after long-term follow-up, childhood-onset 
epilepsy has a substantial impact on many aspects of life. However, the idiopathic and cryptogenic 
etiology groups resembled their Dutch age peers, but the educational and occupational achievement 
of those with idiopathic etiology were lower than expected. This might be due to the epilepsy and 
seizures, or to an assumed preexisting common cause for the epilepsy and other brain dysfunctions.   
 
In the past, many different words have been used to label patients with persistent seizures not 
responding to medication, such as intractability, drug-resistance or refractoriness. In our study we 
used intractability and defined it as having no remission exceeding 3 months during a minimum 
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period of one year of observation despite an optimal choice and use of at least two AEDs, either 
alone or in combination. In Chapter 6 we studied the course of intractability, in an attempt to find 
explanations for the development, discontinuation, or chronicity of intractability, and to distinguish 
the natural course of epilepsy from treatment effects. A comparison was made between 
intractability in the first five years and intractability in the final year. We also compared our 
definition with the recently proposed ILAE definition for drug resistant epilepsy.  
During the 15-year follow-up, at least 12% of the patients had a period of intractability: 8% with 
onset during the first 5 years of follow-up and 4% with later onset. In the last year of follow-up 
8.5% of the patients were intractable.  
Risk factors for intractability during the first five years or last year of follow-up were etiology, 
younger age at first seizure, epilepsy type, mental retardation at enrollment, and febrile convulsions.  
We distinguished three groups: 15 subjects with intractability during the first five years only (group 
A), 19 subjects with intractability during both the first five years and the final year (group B), and 
16 subjects with intractability during the final year (group C). 
In group A, the majority had no seizures in the last year of follow-up and many even had a 5-year 
terminal remission. For five patients the end of intractability could be explained by the introduction 
of new AEDs or by temporal lobectomy.  
The majority of group B used treatment during the entire follow-up. None had substantial periods of 
remission, 50% had daily to monthly seizures, and all were considered to be drug resistant. 
More than half of group C had remission during the first five years of follow-up and discontinued 
treatment, but all had recurrences and restarted treatment; in four of them without success. This was 
the only possible explanation we found for late onset of intractability. At the end of follow-up, half 
of group C were drug-resistant for about 3–8 years.  
The three groups did not differ in baseline characteristics, indicating that the risk for patients to fall 
into any of the three groups was similar. However, group B had shorter remission periods during the 
5-year follow-up and a significantly longer time to intractability, and thus more were intractable in 
the fifth year of follow-up. Comparison of group A with the other two groups showed a tendency 
for a higher proportion of patients developing mental retardation during follow-up. 
Both our definition and that of the ILAE showed that time of onset, course, and duration of 
intractability can differ between subjects with epilepsy. These aspects are hardly predictable, even 
though intractability itself can be predicted to a certain extent. A poor course during the first five 
years of follow-up probably increases the chance of final intractability. The natural course of 
epilepsy probably best explains the variability of intractability and the effect of medication seems to 
be minor.  
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SAMENVATTING 
 
Aan deze studie hebben in totaal 494 kinderen meegedaan nadat bij hen de diagnose epilepsie was 
gesteld. Hun leeftijd varieerde van 1 maand tot 16 jaar oud. Het belangrijkste doel van deze studie 
was het bestuderen van het beloop van kinderepilepsie gedurende een periode van 15 jaar en de 
uiteindelijke prognose. Er werd onder andere vastgesteld of een patiënt aan het einde van de follow-
up aanvalsvrij of medicamenteus onbehandelbaar was geworden. Ook werd nagegaan of de sterfte 
bij kinderen met epilepsie hoger was dan die van hun Nederlandse leeftijdsgenoten. Andere 
doelstellingen waren het korter behandelen van patiënten die snel aanvalsvrij werden na start van 
medicatie zonder toename van nadelige gevolgen, het ontwikkelen van modellen voor de 
voorspelling van de uiteindelijke uitkomst en het vaststellen van de gezondheidstoestand en sociaal 
economische status van personen met epilepsie. Tenslotte werd het beloop van ‘intractabiliteit’ 
bestudeerd met als doel meer inzicht te krijgen in diverse aspecten hiervan. Met intractabiliteit 
bedoelen we het hebben van aanvallen gedurende minimaal één jaar met aanvalsvrije periodes van 
hooguit drie maanden in dat jaar ondanks medicatie.  
Gedurende de eerste vijf jaar werden regelmatige visites of telefonische contacten gepland om 
uitgebreid gegevens te kunnen verzamelen, zoals het soort aanvallen en het aantal, de oorzaak van 
de epilepsie, het gebruik van medicatie (anti-epileptica) en mogelijke bijwerkingen daarvan en 
verder aanvullend medisch onderzoek. Na de eerste vijf jaar werd de follow-up beëindigd. 
Ongeveer 15 jaar na diagnose werd opnieuw contact gezocht met de patiënten en werd een 
vragenlijst verstuurd aan allen die oorspronkelijk vijf jaar lang werden gevolgd. Deze vragenlijst 
bevatte niet alleen vragen over hun aanvallen en medicatie, maar ook over hun 
gezondheidservaring, andere gezondheidsproblemen en ziektes, mogelijke beperkingen als gevolg 
van hun epilepsie en hun sociaal economische status. In de volgende paragrafen worden de 
resultaten van enkele deelstudies samengevat. 
 
Normaal gesproken wordt bij patiënten met epilepsie na minimaal twee jaar aanvalsvrijheid 
besloten tot het afbouwen van de gebruikte anti-epileptica. Sommige personen worden snel 
aanvalsvrij na de start van medicatie (snelle respons). In het verleden hebben we onderzocht of een 
kortere behandeling bij deze personen mogelijk is zonder een toename van de kans op nieuwe 
aanvallen [39]. In die studie kreeg de helft van de personen met een snelle respons medicatie 
gedurende zes maanden en de andere helft gedurende twaalf maanden. De indeling van de personen 
gebeurde door middel van loting. Met een snelle respons werd een aanvalsvrije periode bedoeld van 
minimaal zes maanden met een aanvang binnen twee maanden na de start van medicatie. In 
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Hoofdstuk 2 beschrijven we de resultaten na een follow-up van vier jaar na loting. Gedurende deze 
jaren heeft meer dan de helft van de 161 kinderen met een snelle respons één of meerdere nieuwe 
aanvallen gehad: 59% van de groep met een behandeling van zes maanden en 51% van de groep 
met een behandeling van twaalf maanden. Het verschil tussen beide groepen was niet significant. 
Ook de kans op nieuwe aanvallen twee jaar na loting verschilde niet, maar de groep met de kortere 
behandeling had relatief meer nieuwe aanvallen die later in de tijd optraden. Na een nieuwe aanval 
hebben 55 kinderen hun medicatie hervat waarvan een kwart met succes: zij werden opnieuw 
aanvalsvrij. In het cohort traden verder geen bijwerkingen en sterfte op, met uitzondering van twee 
personen die een aanval kregen die meer dan 30 minuten duurde (status epilepticus) na het stoppen 
van de medicatie in (één in elke groep).  
Naast de kans op nieuwe aanvallen, hebben we de terminale remissie (interval tussen allerlaatste 
aanval en laatste contact) berekend en vonden dat 51% van de kinderen een terminale remissie had 
van meer dan twee jaar zonder medicatie, 21% had ook een terminale remissie van meer dan twee 
jaar maar met medicatie en 15% had nog steeds aanvallen in het laatste jaar. Verschillen tussen de 
twee groepen waren niet significant. Op basis van enkele voorspellende variabelen hebben we een 
model ontwikkeld om kinderen te selecteren die voordeel zouden kunnen hebben van een korte 
behandeling. Het model deelde 73% van de kinderen goed in, wat betekent dat de accuraatheid van 
het model als redelijk wordt beschouwd. 
We concluderen dat er geen significant verschil in uitkomsten bestond tussen de twee groepen van 
behandeling, maar de resultaten van de groep met een kortere behandeling waren net iets minder 
goed dan die van de langere behandeling. Wel moet worden opgemerkt dat met de uitstekende 
uitkomst bij de helft van alle kinderen onnodige behandeling van meer dan één jaar werd 
voorkomen. Aan de andere kant werden sommige kinderen die na één of meerdere nieuwe 
aanvallen hun medicatie hervatten niet meer aanvalsvrij. Dit zou eventueel een risico kunnen zijn 
van een korte behandeling. We kunnen daarom een korte behandeling niet aanbevelen aan alle 
kinderen die snel reageren op medicatie, maar met behulp van ons voorspellende model kan een 
betere selectie van kinderen worden gemaakt die korter kunnen worden behandeld. 
 
In Hoofdstuk 3 is het beloop en de prognose van kinderepilepsie gedurende de eerste vijf jaar van 
follow-up beschreven. Van de 453 personen met een 5-jaar follow-up bleek 76% aan het eind 
minimaal één jaar aanvalsvrij te zijn. Het was opvallend dat 14% van de kinderen geen aanvallen 
meer heeft gehad sinds de diagnose en een andere 27% had alleen aanvallen in het eerste follow-up 
jaar en was daarna aanvalsvrij. Anderzijds had 6% in het laatste jaar van follow-up epilepsie die 
medicamenteus onbehandelbaar was. De helft van hen was ook al onbehandelbaar in het tweede 
jaar van follow-up. 
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Anti-epileptische medicatie (AEDs) werd gebruikt door 86% van de kinderen. De helft gebruikte 
slechts één soort anti-epilepticum gedurende de follow-up. Het aantal personen met aanvallen in het 
vijfde jaar was sterk afhankelijk van het aantal gebruikte AEDs, met een toename in geval van meer 
medicatie wisselingen. Desondanks had 60% van de personen die meer dan 1 AED gebruikten geen 
aanvallen meer in het laatste jaar van de 5-jaar follow-up. Bij het laatste contact gebruikte 36% van 
alle kinderen uit het cohort nog steeds medicatie. 
De helft van de kinderen had een goed beloop van hun epilepsie, zonder aanvallen gedurende het 
tweede en vijfde jaar. Bij een kwart van het cohort trad een verbetering op tijdens de follow-up met 
aanvallen gedurende het tweede jaar maar niet meer in het vijfde jaar, 6% had een verslechtering 
met geen aanvallen in het tweede jaar maar wel in het vijfde jaar en 17% had een slecht beloop met 
aanvallen in beide jaren. Deze vier groepen verschilden significant in variabelen die al bekend 
waren bij inclusie en in variabelen die gebaseerd waren op de eerste zes maanden follow-up. 
Rolandische epilepsie en idiopathisch gegeneraliseerde epilepsie hadden het beste beloop gedurende 
de follow-up en symptomatisch of cryptogene epilepsie het slechtste. 
Op basis van enkele significante variabelen werden twee modellen ontwikkeld met als doel 
aanvallen te voorspellen in het laatste jaar van follow-up: één gebaseerd op variabelen bekend bij 
aanvang van de studie en één op een combinatie van deze variabelen en variabelen verzameld 
tijdens de eerste zes maanden van follow-up. Het voorspellende vermogen van beide modellen werd 
als redelijk beschouwd, hoewel 1 op elke 3 kinderen een foutieve voorspelling kreeg. 
Op basis van de bovengenoemde resultaten concluderen we dat de meeste kinderen met epilepsie 
gedurende de eerste vijf jaar follow-up een goed beloop of een verbetering daarin hebben en een 
goede uitkomst zonder aanvallen in het laatste jaar. Slechts enkele kinderen eindigen met 
medicamenteus onbehandelbare epilepsie. Deze resultaten zijn in overeenstemming met andere 
studies, ondanks verschillen in de samenstelling van de cohorten en de duur van follow-up. Verder 
concluderen we dat onbehandelbare epilepsie een wisselend beloop kan hebben en dat falen van één 
of meerdere anti-epileptica een sterke voorspeller is van een slechte prognose, maar dat ondanks het 
gebruik van meer dan één anti-epilepticum uiteindelijk toch aanvalsvrijheid kan worden bereikt. 
   
In Hoofdstuk 4 werd het beloop van kinderepilepsie en de uiteindelijke uitkomst na 15 jaar follow-
up beschreven. Een vragenlijst over epilepsie werd ingevuld door 413 personen. Daarvan was 71% 
aan het einde van follow-up minimaal vijf jaar aanvalsvrij, de meesten zonder medicatie bij het 
laatste contact. De anderen hadden actieve epilepsie en 8.5% eindigde met medicamenteus 
onbehandelbare epilepsie. 
De helft van het cohort had een goed beloop van de epilepsie en ongeveer 30% had een beloop 
waarbij verbetering optrad tijdens de follow-up. In beide groepen was uiteindelijk meer dan 80% 
 Page | 152  
 
minimaal vijf jaar aanvalsvrij. Ongeveer 12% had een wisselend of verslechterend beloop en 10% 
een uitgesproken slecht beloop. Van de laatste groep had minimaal 60% in het laatste jaar van 
follow-up medicamenteus onbehandelbare epilepsie versus 28% van degenen met een 
verslechterend beloop en 15% van degenen met een wisselend beloop. 
Gedurende de eerste vijf jaren van follow-up had een derde van het cohort geen aanvallen of alleen 
gedurende de eerste zes maanden. Na die eerste vijf jaren kreeg een deel van hen opnieuw aanvallen 
en eindigde met actieve of onbehandelbare epilepsie. Voor slechts een aantal van hen vonden we 
een logische verklaring. 
Het gemiddelde interval tussen de eerste en laatste aanval was 6.0 jaar, maar bij 25% van het cohort 
was dit interval minder dan één jaar en bij nog eens 25% meer dan 12 jaar. 
Anti-epileptica werden gebruikt door 86% van alle personen. Een derde van deze personen had hun 
laatste aanval binnen een jaar na de aanvang van de medicatie. Meer dan 60% van alle gebruikers 
stopte uiteindelijk met medicatie gedurende de follow-up (gemiddeld na 3 jaar). Daarnaast 
gebruikte 38% bij het laatste contact nog steeds medicatie. De helft van deze laatste groep had nog 
steeds aanvallen in het laatste jaar, maar een kwart was al minimaal vijf jaar aanvalsvrij. De meeste 
van deze resultaten betreffende medicatie waren gelijk aan die na vijf jaar follow-up.  
We vonden verschillende significante voorspellers voor actieve epilepsie en onbehandelbare 
epilepsie. Uitgaande van deze variabelen werd een model gemaakt met als doel het voorspellen van 
onbehandelbare epilepsie. De accuraatheid van het model werd als goed beschouwd. 
Gedurende de 15 jaar follow-up zijn 18 personen overleden, van wie 9 gedurende de eerste vijf jaar. 
De gestandaardiseerde sterftecijfers van personen met epilepsie zonder een al langer bestaande 
hersenafwijking waren vergelijkbaar met die van Nederlandse leeftijdsgenoten, maar voor hen met 
een hersenafwijking waren deze 30 maal hoger. We vonden geen gevallen van ‘sudden unexplained 
death’ (SUDEP), waarbij iemand met epilepsie plotseling overlijdt en waar geen andere 
doodsoorzaak wordt vastgesteld. 
 Op basis van 15 jaar follow-up kan worden geconcludeerd dat kinderepilepsie een gunstig beloop 
en uitkomst heeft, maar uiteindelijk zal 9% van alle personen eindigen met medicamenteus 
onbehandelbare epilepsie. Het beloop van epilepsie kan wisselend zijn, vaak met een verbetering en 
soms een verslechtering op lange termijn. Sterfte is alleen hoger in geval men naast epilepsie een al 
langer bestaande hersenafwijking heeft (laat symptomatische epilepsie) en is vermoedelijk een 
gevolg van deze aandoening. Het natuurlijke beloop van epilepsie is waarschijnlijk de beste 
verklaring voor de gevonden resultaten, met sommige soorten van epilepsie die kort duren en 
andere soorten die een ‘ingebakken’ slechte prognose hebben. Anti-epileptica hebben waarschijnlijk 
maar een beperkte invloed op beloop en prognose. 
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Hoofdstuk 5 behandelt andere aspecten van epilepsie. De helft van de 413 personen met een 
follow-up van 15 jaar had te maken met één of meerdere neurologische hersenaandoeningen 
(meestal de oorzaak van hun epilepsie) of andere beperkingen en handicaps. Een kwart van het 
cohort was mentaal geretardeerd, variërend van mild tot ernstig. 
Het cohort is vergeleken met leeftijdsgenoten van de Nederlandse bevolking en er werden voor 
leeftijd gestandaardiseerde incidentiecijfers berekend. De algemene gezondheidstoestand van 
personen met een normale intelligentie werd als slechter ervaren door degenen met actieve 
epilepsie, vooral door hen die nog medicatie gebruikten. Ook vonden minder personen met een 
cryptogene of remote symptomatische etiologie (oorzaak van hun epilepsie) dat hun ervaren 
gezondheid ‘zeer goed’ was. Met cryptogeen bedoelen we hier dat er waarschijnlijk wel een 
onderliggende oorzaak voor de epilepsie bestaat maar deze nog niet bekend is en met ‘remote 
symptomatisch (ook wel laat symptomatisch genoemd) bedoelen we dat de epilepsie veroorzaakt is 
door een al langer bestaande onderliggende structurele hersenafwijking.  
Beperkingen werden gerapporteerd door 14% van de personen met een normale intelligentie, vooral 
door degenen met actieve epilepsie. Personen die nog medicatie gebruikten gaven vaker aan last te 
hebben van beperkingen dan personen die geen medicatie meer gebruikten. De meest genoemde 
beperkingen hadden te maken met het bezig zijn met activiteiten of het leervermogen door 
geheugenproblemen en verminderde concentratie.  
De woonsituatie van personen met idiopathische (voornamelijk genetisch bepaalde en 
leeftijdsafhankelijke epilepsie) of cryptogene etiologie was vergelijkbaar met hun Nederlandse 
leeftijdsgenoten, terwijl degenen met remote symptomatische etiologie vaker in een verpleeghuis of 
speciale woongroep woonden. Geen van deze laatste groep had kinderen, maar de idiopathische en 
cryptogene groep had even vaak kinderen als hun leeftijdsgenoten. Deze bevinding is in 
tegenspraak met andere studies waarin minder personen met idiopathische etiologie kinderen 
hadden. Ook bleek uit deze studies dat deze groep minder vaak een partner had, terwijl in onze 
studie er evenveel personen samenwoonden met een partner als bij hun leeftijdsgenoten. 
Personen met idiopathische of cryptogene etiologie die een opleiding volgden bij het laatste contact 
waren ook vergelijkbaar met hun leeftijdsgenoten, hoewel in de groep met idiopathische etiologie 
hoger beroepsonderwijs en een universitaire opleiding enigszins ondervertegenwoordigd waren.  
Voor degenen met remote symptomatische etiologie was het aantal personen dat speciaal onderwijs 
volgde hoog. Opvallend was dat de werkende personen in ons cohort een significant lager 
opleidingsniveau hadden dan hun werkende Nederlandse leeftijdsgenoten, zelfs wanneer ze een 
idiopathische etiologie hadden. Een zelfde resultaat werd ook in andere studies gevonden.  
De werksituatie van personen met idiopathische of cryptogene etiologie was vergelijkbaar met die 
van hun leeftijdsgenoten, maar degenen met remote symptomatische etiologie waren vaker 
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arbeidsongeschikt. Wanneer we ons beperken tot de beroepsbevolking, dan bleek het percentage dat 
werkte even groot te zijn in de drie etiologische groepen (idiopathisch, cryptogeen, remote 
symptomatisch).  
Minder werknemers met idiopathische etiologie hadden een beroep dat gebaseerd was op een 
hogere opleiding en werkenden met een remote symptomatische etiologie hadden vaker een beroep 
met eenvoudige taken.  
Naast de vergelijking van de drie etiologische groepen met de Nederlandse populatie hebben we 
ook personen die wel of niet in aanvalsvrij waren vergeleken met hun Nederlandse leeftijdsgenoten. 
Voor veel van de boven besproken variabelen deed de groep met aanvalsvrijheid het slechter dan 
verwacht. Dit was meestal het gevolg van het feit dat personen met remote symptomatische 
etiologie onderdeel uitmaakten van deze groep.  
Op basis van de gevonden resultaten concluderen we dat epilepsie begonnen in de kindertijd zelfs 
na vele jaren een substantiële invloed heeft op veel aspecten van het leven. De idiopathische en 
cryptogene etiologie groepen waren vergelijkbaar met hun Nederlandse leeftijdsgenoten, hoewel het 
opleidings- en beroepsniveau van hen met idiopathische etiologie lager was dan verwacht. Dit kan 
het gevolg zijn van de epilepsie en de aanvallen, of van al bestaande geringe onvolkomenheden in 
de hersenen die zowel tot epilepsie als tot bepaalde verminderde hersenfuncties hebben geleid. 
 
In het verleden zijn veel termen gebruikt voor het labelen van patiënten met aanhoudende aanvallen 
zonder reactie op medicatie, zoals ‘intractabiliteit’, medicatie-resistente of refractaire epilepsie. In 
onze studie hebben we de term intractabiliteit gebruikt, waarmee we bedoelen dat iemand ondanks 
optimaal gebruik van medicatie gedurende minimaal één jaar regelmatig aanvallen houdt zonder 
noemenswaardige aanvalsvrije periodes (korter dan 3 maanden). In Hoofdstuk 6 hebben we het 
beloop van intractabiliteit beschreven gedurende 15 jaar follow-up, in een poging verklaringen te 
vinden voor het ontstaan, de beëindiging of de aanhoudendheid van intractabiliteit en om 
onderscheid te maken tussen het natuurlijk beloop van de epilepsie en de invloed van medicatie. Er 
werd een vergelijking gemaakt tussen intractabiliteit in de eerste vijf jaar en intractabiliteit in het 
laatste jaar van follow-up. We hebben onze definitie ook vergeleken met de recentelijk voorgestelde 
ILAE definitie voor medicatie-resistente epilepsie. 
Gedurende de 15-jaar follow-up heeft tenminste 12% van de patiënten een periode van 
intractabiliteit gehad: 8% met een begin gedurende de eerste vijf jaar van follow-up en 4% met een 
later begin. In het laatste jaar van follow-up had 8.5% intractabiliteit en waarschijnlijk 4% is 
gedurende de gehele follow-up ‘intractable’ geweest. 
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Risicofactoren voor intractabiliteit gedurende de eerste vijf jaren of laatste jaar van follow-up waren 
etiologie, jonge leeftijd bij eerste aanval, epilepsie type, bestaande mentale retardatie en 
koortsstuipen.  
We onderscheidden 3 groepen: 15 personen met een periode van intractabiliteit alléén gedurende de 
eerste vijf jaar van follow-up (groep A), 19 personen met intractabiliteit gedurende zowel de eerste 
vijf jaar als in het laatste jaar van follow-up (groep B) en 16 personen met alléén intractabiliteit 
gedurende het laatste jaar van follow-up (groep C). 
De meerderheid van groep A had geen aanvallen in het laatste jaar van follow-up en velen waren 
uiteindelijk zelfs minimaal vijf jaar aanvalsvrij. Voor vijf personen kan het beëindigen van de 
intractabiliteit worden verklaard door de introductie van andere anti-epileptica of door een operatie 
(temporale lobectomie). 
De meeste personen uit groep B hebben gedurende de gehele follow-up medicatie gebruikt. Geen 
van hen had aanzienlijke periodes van aanvalsvrijheid. De helft had dagelijkse tot maandelijkse 
aanvallen en allen reageerden niet of onvoldoende op medicatie.  
Meer dan de helft van groep C had een periode van aanvalsvrijheid gedurende de eerste vijf jaar 
follow-up en stopte daarom met medicatie. Ze hadden allemaal één of meerdere nieuwe aanvallen 
en hervatten hun medicatie, maar bij 4 van hen was dit zonder succes: zij bleven aanvallen houden.  
Dit was de enige mogelijke verklaring die we hebben gevonden voor het late optreden van 
intractabiliteit. Aan het einde van de follow-up was de helft van groep C medicamenteus 
onbehandelbaar voor een duur van 3 tot 8 jaar. 
De drie groepen verschilden niet in variabelen die bekend waren bij de diagnose, wat aangeeft dat 
het risico voor patiënten om in één van de drie groepen terecht te komen gelijk was. Groep B had 
echter kortere aanvalsvrije periodes gedurende de eerste vijf jaar follow-up, maar het duurde 
significant langer voordat zij hun periode van intractabiliteit hadden. Daardoor waren er meer 
personen met intractabiliteit in het vijfde jaar van follow-up.  
In vergelijking met groep A ontwikkelden meer personen uit beide andere groepen mentale 
retardatie tijdens follow-up. Dit verschil was bijna significant. 
Zowel onze definitie van intractabiliteit als die van de ILAE toonde aan dat de tijd tot aanvang, 
beloop en duur van intractabiliteit kan verschillen tussen personen met epilepsie. Deze aspecten zijn 
nauwelijks te voorspellen, ondanks het feit dat het wel of niet krijgen van intractabiliteit wel tot op 
zekere hoogt kan worden voorspeld.  
Een slecht beloop tijdens de eerste vijf jaar van follow-up verhoogt waarschijnlijk de kans op 
uiteindelijke intractabiliteit. Het natuurlijke beloop van epilepsie verklaart waarschijnlijk het best de 
variabiliteit in intractabiliteit. Medicatie lijkt slechts een kleine rol te spelen in het voorkómen of 
beëindigen van intractabiliteit.  
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Direct na mijn studie las ik in de krant een advertentie van de Erasmus Universiteit van Rotterdam 
waarin men iemand zocht die de analyses zou willen doen van een tweetal onderzoeken. Eén 
daarvan was een epilepsieonderzoek bij volwassenen. Aangezien ik net een doctoraal-onderzoek 
had uitgevoerd bij patiënten met epilepsie in het kader van gezondheidsleer, als onderdeel van mijn 
studie Humane Voeding, trok deze studie mijn aandacht. Ik werd aangenomen en leerde Cees van 
Donselaar kennen voor wie ik jaren met heel veel plezier heb gewerkt. Cees is na enkele jaren cum 
laude op dit onderzoek gepromoveerd. Dankzij zijn enthousiasme is later het kinderepilepsie 
onderzoek opgezet, samen met de kinderneurologen Willem Frans Arts, Boudewijn Peters, Oebo 
Brouwer en Hans Stroink. Later kwam daar Els Peeters bij, die als neuroloog het stokje van Willem 
Frans overnam in de beide deelnemende ziekenhuizen van Den Haag. In de loop der jaren vertrok 
Cees en nam Willem Frans zijn plaats in als mijn ‘baas’. Ook met hem heb ik vele jaren met heel 
veel plezier gewerkt. Ons onderzoeksteam was zeer enthousiast en bruiste van de ideeën. We 
hebben jarenlang een hecht team gevormd, met regelmatige vergaderingen, lange discussies en af 
en toe interessante culturele en culinaire uitstapjes met onze partners. Ik kijk hier met heel veel 
plezier op terug.  
 
Tijdens mijn eerste sollicitatiegesprek op de Erasmus Universiteit werd mij gevraagd of ik zou 
willen promoveren. Ik heb toen geantwoord dat ik dat wel zou willen als het automatisch zou 
voortvloeien uit mijn werk, maar dat mijn kwaliteit van leven daar niet al teveel onder mocht lijden. 
Echter, van een promotie is al die jaren geen sprake geweest aangezien mijn taak juist was anderen 
ter zijde te staan tijdens hun promotie. Bovendien had ik die ambitie eigenlijk niet. Een aantal jaren 
geleden werd het idee geboren dat ik op het nog liggende materiaal van het Zuid-Hollands 
kinderepilepsie onderzoek zou kunnen promoveren. Ik kende de gegevens immers als mijn 
broekzak. Na enige aarzeling ben ik begonnen met het schrijven van het eerste artikel. En wie A 
zegt moet B zeggen! Na lang zwoegen, veel teleurstellingen en tegenslagen is het dan toch eindelijk 
gelukt dit boekje af te krijgen. Een hele inspanning, maar dat weten degenen die in het zelfde 
schuitje hebben gezeten als geen ander! Ik moet trouwens opmerken dat er geen grotere anticlimax 
bestaat dan de acceptatie van een artikel waaraan je zo hard hebt gewerkt. Je verwacht minimaal 
fanfares in de straat en knallende champagneflessen, maar er gebeurt niets…. 
 
Ik wil mijn hoogleraar Willem Frans Arts ontzettend bedanken, die ondanks zijn drukke agenda 
altijd tijd vond om mijn vele versies van de artikelen grondig door te lezen. We hebben elkaar al die 
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jaren weinig gezien, maar hadden wel wekelijks contact per e-mail. Wat een uitkomst is dat 
medium toch! Ook de anderen van het team, vooral Oebo, Cees en Hans, wil ik bedanken voor het 
becommentariëren van mijn artikelen. Ieder deed dat op zijn eigen manier: de één wilde alles in 
groter perspectief zien, de ander bekeek het tot in detail. Ook wil ik de leden van de leescommissie, 
Prof. dr. P. Sillevis Smitt, Prof. dr. H.A. Moll en Prof. dr . P. Boon hartelijk danken voor hun 
bijdrage aan deze promotie.  
In de loop der jaren zijn er meerdere medewerkers geweest die alle gegevens trouw hebben 
ingevoerd en uiteenlopende secretariële handelingen hebben verricht voor dit onderzoek. Ik wil 
vooral Mariette Westendorp en Joke Kuijpers bedanken die meerdere jaren altijd vol inzet voor ons 
in touw zijn geweest en een beetje gezelligheid brachten in die foeilelijke kamers van de medische 
faculteit. Ook Linda van Leeuwen wil ik hartelijk bedanken voor de laatste loodjes van invoeren 
nadat Joke is gestopt met werken. 
Uiteraard was dit onderzoek niet tot stand gekomen zonder alle kinderen die destijds in de studie 
werden geïncludeerd. Dank voor hen en hun ouders! 
Simone, jou wil ik hartelijk bedanken voor je onbaatzuchtige hulp bij het ontwerpen en 
vervaardigen van de omslag en bij het leggen van de eerste contacten met de drukker.  
Mijn trouwe Peter ben ik enorm dankbaar voor zijn steun en zijn bemoedigende woorden als het 
weer eens even tegen zat. En natuurlijk voor de glaasjes witte wijn die hij mij ’s avonds laat bracht 
wanneer ik weer achter mijn bureau zat te zwoegen, met daarbij af en toe een korte massage om 
mijn verkrampte schouders weer wat soepeler te maken.  
Mijn lieve dochter Charlotte wil ik bedanken voor het doorlezen van veel van mijn teksten. Zij kon 
hier als buitenstaander even een frisse blik op werpen. Wanneer zij het goed vond, durfde ik het met 
een gerust hart te versturen. Ik ben dan ook gerust en blij dat zij tijdens de verdediging van mijn 
proefschrift aan mijn zijde zal staan. 
Lieve Roderik, ook jij kent zo langzamerhand al heel wat tegenslagen. Maar het doet me goed om te 
horen en te zien dat je niet opgeeft. Doorzettingsvermogen is het sleutelwoord. Als je dat niet hebt 
kom je nergens. 
‘Mam, wanneer ga je nou promoveren?’ Hoe vaak heb je me die vraag wel niet gesteld. Ja, lieve 
Sebas, ik ga eindelijk promoveren! Het idee van de omslag is van jou afkomstig. Toen jij 9 jaar oud 
was heb je een kameleon geverfd die tot voor kort bij ons in de hal heeft gehangen en mij 
inspireerde, mede omdat jij rond die tijd na een éénmalige epileptische aanval in het ziekenhuis 
belandde. 
Lieve Jeanette, mijn andere paranimfje, ik ken geen trouwere vriendin dan jij. Ondanks het feit dat 
je in het buitenland woont, hebben we elkaar sinds we 16 jaar waren niet uit het oog verloren. Dank 
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APPENDIX 1 
 
Questionnaire Epilepsy Research 
 
 
 
 
Name:  
 
Date of birth:  
                                     
 
 
SEIZURES: 
 
1. When did you have your last epileptic seizure?  
 
 
                            
 
                                    Day         Month                Year 
 
If you don’t know the exact date of the seizure, please indicate below how long ago you 
had your last seizure.  
 
o  More than 5 years ago 
o 3 - 5 years ago 
o 2 - 3 years ago 
o 1 - 2 years ago 
o Less than 1 year ago 
 
 
 
MEDICATION: 
 
2. Do you currently use medication for your epilepsy?  
 
o No 
o Yes, please continue with question 4 
 
3. When did you stop your medication?  
 
                          
 
                              Day         Month                Year 
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If you don’t know the exact date, please indicate below how long ago you stopped your 
medication. 
 
o More than 5 years ago 
o 3 - 5 years ago 
o 2 - 3 years ago 
o 1 - 2 years ago 
o Less than 1 year ago 
 
 
4. Are you currently being treated by a specialist because of your epilepsy? 
 
o Yes Name specialist: ....................................................................................... 
 
Name hospital: ......................................................................................... 
 
o No When did you have your last appointment? 
 
                            
 
                                 Day         Month                Year 
 
Name doctor / specialist: ……………………………………………….. 
 
Name hospital: .…………………………………………………………. 
  
 
HEALTH: 
 
5. How is your general health perception?  
 
o Very good 
o Good 
o Moderate 
o Poor 
o Very poor 
o Don’t know, refuses answer 
 
6. Apart from your epilepsy, do you have one or more long-lasting illnesses, disorders or 
handicaps?  
 
o Yes 
o No 
o Don’t know, refuses answer  
 
If yes, please describe:      
 
..............................................................................................................................................
...................................................................................................................................... 
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7. To what extent does epilepsy restrict your daily activities at home?  
 
o Strongly restricted  
o Slightly restricted 
o Not restricted  
o Don’t know, refuses answer  
 
In case of restrictions, please describe:  
 
…………………………………………………………………………………..… 
…………………………………………………………………………………..… 
 
8. To what extent does epilepsy restrict your daily activities at school or work?  
 
o Strongly restricted  
o Slightly restricted 
o Not restricted  
o Don’t know, refuses answer  
 
In case of restrictions, please describe:  
 
……………………………. ……………………………………………………… 
…………………………………………………………………………………..… 
 
9. To what extent does epilepsy restrict your daily activities during sports or other leisure 
activities, and to what extent does epilepsy restrict commuting or traveling?  
 
o Strongly restricted  
o Slightly restricted 
o Not restricted  
o Don’t know, refuses answer  
 
In case of restrictions, please describe:  
 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
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SOCIAL ECONOMIC STATUS:   
 
 
We would like to know if persons with epilepsy accomplish the same things as persons without 
epilepsy. That is why we would like to ask some questions about education, occupation etc. 
 
 
10. What kind of living arrangement do you have? 
  
o Single 
o Single parent, with one or more kids 
o Cohabiting or married, no kids 
o Cohabiting or married, with one or more kids 
o Living with parents, but older than 18 years 
o Living with parents, but younger than 18 years 
o Part of other household 
 
11. What is your employment status?  
 
o Employed 
o Unemployed 
o Volunteer 
o Disabled (with welfare pension) 
o Student 
o Housewife / houseman 
o Unknown  
 
12. What was the highest education that you attained? 
 
o  Primary school 
o  Lower general secondary education 
o  Lower vocational education 
o  Higher general secondary or pre-university education 
o  Intermediate vocational education 
o  Higher vocational education 
o  Scientific education (university) 
o  Unknown  
o  Other, please describe: ……………………………………………………………… 
 
13. At present, do you follow education?  
 
o Yes, please describe: ………………………………………………………………… 
o No 
 
14. In case of no education, what is your profession?  
 
 
………………………………………………………………………………. 
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15. Remarks:  
 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………… 
 
 
 
 
 
 
Date of completion: 
 
                                    Day         Month                Year 
 
 
Residence: ………………………………………………   
 
 
 
Signature: ……………………………………… 
 
 
 
 
 
Thank you very much for completing this questionnaire! 
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APPENDIX 2 
 
Additional Supporting Information belonging to Chapter 2 
 
Table E-1: Patient and disease characteristics of 154 children with newly diagnosed epilepsy 
 
 
6-month 
group 
N=77 
12-month 
group 
n=77 
Total 
 
n=154 
OR for 
excellent 
outcome 
95% CI of 
OR 
Gender: 
     Boys 
     Girls 
 
36 (47%) 
41 (53%) 
 
40 (52%) 
37 (48%) 
 
76 
78 
 
1.00 
0.56 
 
 
0.29-1.07 
Age at onset (y) (mean): 
     Less than 6 years 
     6 years or more   
6.3 (se 0.4) 
32 (42%) 
45 (58%) 
6.8 (se 0.5) 
33 (43%) 
44 (57%) 
6.5 (se 0.3) 
65 
89 
 
1.00 
0.47* 
 
 
0.24- 0.91 
Number of fits before AED: 
     1 or 2 
     3, 4 or 5 
     6 thu 10 
     >10 
 
24 (31%) 
17 (22%) 
6 (8%) 
30 (39%) 
 
17 (22%) 
24 (31%) 
8 (10%) 
28 (36%) 
 
41 
41 
14 
58 
 
1.00 
2.21 
0.96 
2.64* 
 
 
0.89-5.49 
0.27-3.45 
1.12-6.19 
Positive family history: 10 (13%) 9 (12%) 19 0.86 0.33-2.26 
Febrile convulsions : 12 (16%) 9 (12%) 21 1.35 0.53-3.44 
Seizure type before  
randomization:   
     Generalized Tonic Clonic  
     Simple/complex partial 
     Absence seizures      
 
 
52 (68%) 
13 (17%) 
12 (16%) 
 
 
57 (74%) 
7 (9%) 
13 (17%) 
 
 
      109 
20 
25 
 
 
1.00 
0.61 
4.55** 
 
 
 
0.23-1.66 
1.53-13.54 
Epilepsy type: 
     Generalized  
     Localization related 
     Mixed 
 
41 (53%) 
31 (40%) 
5 (6%) 
 
48 (62%) 
26 (34%) 
3 (4%) 
 
89 
57 
8 
 
1.00 
0.21*** 
0.53 
 
 
0.10-0.45 
0.12-2.31 
Etiology:  
     Idiopathic  
     Remote symptomatic  
     Cryptogenic 
 
47 (61%) 
13 (17%) 
17 (22%) 
 
45 (58%) 
14 (18%) 
18 (23%) 
 
92 
27 
35 
 
1.00 
0.34* 
0.23*** 
 
 
0.14-0.86 
0.10-0.57 
EEG1 (at intake) 
     Normal 
     Epileptic 
     otherwise abnormal 
 
13 (17%) 
48 (62%) 
16 (21%) 
 
21 (27%) 
43 (56%) 
13 (17%) 
 
34 
91 
29 
 
1.00 
0.33** 
0.39 
 
 
0.14-0.78 
0.13-1.14 
EEGs at intake (combined): 
     Normal 
     Epileptic 
     otherwise abnormal 
 
10 (13%) 
54 (70%) 
13 (17%) 
 
14 (18%) 
53 (69%) 
10 (13%) 
 
24 
107 
23 
 
1.00 
0.29* 
0.26* 
 
 
0.10-0.82 
0.07-0.96 
EEG3 (before randomization):      
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     Normal 
     Epileptic 
     otherwise abnormal 
39 (51%) 
21 (27%) 
17 (22%) 
46 (60%) 
18 (23%) 
13 (17%) 
85 
39 
30 
1.00 
0.30** 
0.67 
 
0.13-0.69 
0.29-1.55 
Mental retardation: 7 (9%) 11 (14%) 18 0.58 0.21-1.60 
Pre-existing neurological signs: 3 (4%) 7 (9%) 10 0.39 0.10-1.61 
Post-ictal signs: 9 (12%) 6 (8%) 15 0.13** 0.03-0.62 
Odds ratios (OR) for excellent outcome (TR4 of at least two years without medication).  
*p < 0.05, **p < 0.01, ***p < 0.001 
 
 
 
 
Table E-2: Multivariate analysis: Odds ratios (OR) and their 95% CI’s and derived regression 
coefficients (RC) after shrinkage (0.89) for the model predicting an excellent outcome in 
childhood epilepsy 
  
 OR 95% CI RC 
Age at onset:  
0 = less than 6 years 
1 = 6 years or more  
 
 
0.50* 
 
 
0.24-1.05 
 
 
-0.61 
Etiology: 
0 = idiopathic 
1 = non-idiopathic 
 
 
0.51* 
 
 
0.23-1.10 
 
 
-0.60 
Absence Seizures:  
0 = no 
1 = yes 
 
 
4.52*** 
 
 
1.47-13.93 
 
 
1.34 
Postictal signs:  
0 = no 
1 = yes 
 
 
0.19** 
 
 
0.04-0.99 
 
 
-1.48 
EEGs at intake (combined): 
0 = normal 
1 = abnormal 
 
 
0.22*** 
 
 
0.08-0.66 
 
 
-1.33 
Constant   1.87 
Number of observations = 154, number of covariate patterns = 16.  
Goodness of fit test: Pearson 2 (10) = 7.92, Prob. >2 = 0.6362.  
Area under ROC curve = 0.7730.  
Risk score Z: (-0.61 age -0.60 etiology +1.34 absences -1.48 postictal signs -1.33 EEGs + 1.87).  
*p < 0.1; **p < 0.05; ***p < 0.01. 
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 r
em
is
si
o
n
, 
fo
ll
o
w
ed
 b
y
 9
 
m
o
n
th
s 
o
f 
w
ee
k
ly
 S
P
S
. 
T
h
en
 1
.5
-y
ea
r 
re
m
is
si
o
n
. 
S
to
p
 C
L
B
, 
C
B
Z
 c
o
n
ti
n
u
ed
. 
S
o
m
et
im
es
 S
P
S
 c
au
se
d
 b
y
 e
m
o
ti
o
n
. 
A
ls
o
 
n
o
ct
u
rn
al
 d
o
u
b
tf
u
l 
se
iz
u
re
s.
 R
ec
u
rr
en
ce
 a
ft
er
 s
to
p
 A
E
D
. 
 
<
1
  
A
E
D
s 
sl
ig
h
t 
ef
fe
ct
?
 (
1
 A
E
D
 
at
 e
n
d
) 
1
  
S
P
S
, 
C
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
sp
as
ti
c 
te
tr
ap
ar
es
is
, 
tu
b
er
o
u
s 
sc
le
ro
si
s)
 
5
 
N
o
 e
ff
ec
t 
o
f 
A
E
D
 i
n
 f
ir
st
 5
-y
ea
r 
fo
ll
o
w
-u
p
. 
In
te
n
si
ty
 o
f 
se
iz
u
re
s 
re
d
u
ce
d
 d
u
ri
n
g
 t
h
e 
la
st
 y
ea
rs
 o
f 
ex
te
n
d
ed
 f
o
ll
o
w
-u
p
, 
b
u
t 
st
il
l 
m
o
n
th
ly
 C
P
S
. 
N
o
t 
in
tr
ac
ta
b
le
: 
T
R
E
 =
 4
 m
o
n
th
s.
 
<
1
  
A
E
D
s 
n
o
 
ap
p
ar
en
t 
ef
fe
ct
. 
(2
 A
E
D
s 
at
 e
n
d
) 
1
1
b
 
ab
se
n
ce
s,
 a
n
d
 s
o
m
e 
T
C
 a
ft
er
 9
 y
ea
rs
 
(I
d
io
p
at
h
ic
 g
en
er
al
iz
ed
 e
p
il
ep
sy
) 
2
 
5
 w
ee
k
s 
o
f 
d
ai
ly
 a
b
se
n
ce
s:
 A
E
D
. 
N
o
 e
ff
ec
t 
o
f 
A
E
D
 d
u
ri
n
g
 5
 
y
ea
rs
 o
f 
fo
ll
o
w
-u
p
, 
d
es
p
it
e 
se
v
er
al
 i
n
cr
ea
se
s 
o
f 
d
o
sa
g
e.
 
<
1
 
N
o
t 
co
n
si
d
er
ed
 
in
tr
ac
ta
b
le
b
. 
A
E
D
s 
n
o
 e
ff
ec
t.
 
(1
 A
E
D
 a
t 
en
d
) 
1
3
  
C
P
S
, 
T
C
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
m
en
ta
ll
y
  
re
ta
rd
ed
, 
m
il
d
 s
p
as
ti
c 
te
tr
ap
ar
es
is
) 
3
 
A
ft
er
 2
 P
S
G
: 
A
E
D
. 
M
o
n
th
ly
 s
ei
zu
re
s 
d
u
ri
n
g
 4
.5
 y
ea
rs
 
d
es
p
it
e 
C
B
Z
 &
 V
IG
. 
C
B
Z
 r
ep
la
ce
d
 b
y
 O
C
B
Z
. 
A
ft
er
 a
d
d
-o
n
 
o
f 
C
L
B
: 
re
d
u
ct
io
n
 o
f 
se
iz
u
re
s.
 
=
1
 
A
E
D
s 
sl
ig
h
t 
ef
fe
ct
?
 (
2
 A
E
D
s 
at
 e
n
d
) 
8
  
m
y
o
cl
o
n
ic
, 
to
n
ic
 &
 T
C
 s
ei
zu
re
s,
 C
P
S
 
sp
as
m
s,
 a
b
se
n
ce
s 
(W
es
t 
sy
n
d
ro
m
e,
 
tu
b
er
o
u
s 
sc
le
ro
si
s,
 l
at
er
 l
o
ca
li
za
ti
o
n
 
re
la
te
d
 s
y
m
p
to
m
at
ic
 e
p
il
ep
sy
) 
3
 
A
ft
er
 5
.5
 y
ea
rs
 o
f 
d
ai
ly
 s
ei
zu
re
s,
 r
em
is
si
o
n
 a
ft
er
 c
h
an
g
e 
to
 
L
T
G
. 
A
b
o
u
t 
1
 y
ea
r 
b
ef
o
re
 t
h
e 
en
d
 o
f 
fo
ll
o
w
-u
p
 
tr
an
sp
la
n
ta
ti
o
n
 o
f 
k
id
n
e
y
 f
o
ll
o
w
ed
 b
y
 5
 s
ev
er
e 
se
iz
u
re
s 
as
 a
 
re
su
lt
 o
f 
o
p
er
at
io
n
. 
>
1
  
E
ff
ec
t 
o
f 
L
T
G
. 
(1
 A
E
D
 a
t 
en
d
) 
 P
ag
e 
| 1
8
3
  
 
 
S
u
b
je
ct
 
  
  
 S
ei
zu
re
 a
n
d
 e
p
il
ep
sy
 t
y
p
e 
  
  
  
  
  
 A
E
D
a  
C
o
u
rs
e 
o
f 
ep
il
ep
sy
 
T
R
E
 
E
ff
ec
t 
A
E
D
 
1
2
  
T
C
, 
at
o
n
ic
 a
n
d
 m
y
o
cl
o
n
ic
 s
ei
zu
re
s,
 
ab
se
n
ce
s 
 (
Ju
v
en
il
e 
m
y
o
cl
o
n
ic
 
ep
il
ep
sy
) 
4
 
A
to
n
ic
 s
ei
zu
re
s 
d
u
e 
to
 i
n
co
rr
ec
t 
A
E
D
. 
C
h
an
g
e 
to
 V
P
A
: 
af
te
r 
3
 m
o
n
th
s 
a 
4
-m
o
n
th
 r
em
is
si
o
n
, 
fo
ll
o
w
ed
 b
y
 1
 y
ea
r 
o
f 
w
ee
k
ly
 
ab
se
n
ce
s 
&
 m
y
o
cl
o
n
ic
 j
er
k
s.
 A
d
d
-o
n
 E
S
M
: 
3
.5
-y
ea
r 
re
m
is
si
o
n
. 
L
at
er
, 
u
n
su
cc
es
sf
u
l 
to
 s
to
p
 o
r 
re
d
u
ce
 A
E
D
. 
>
1
  
E
ff
ec
t 
o
f 
E
S
M
. 
(1
 A
E
D
 a
t 
en
d
) 
1
4
  
ab
se
n
ce
s,
 C
P
S
, 
T
C
 &
 a
to
n
ic
 s
ei
zu
re
s 
(L
o
ca
li
za
ti
o
n
 r
el
at
ed
 s
y
m
p
to
m
at
ic
 
ep
il
ep
sy
, 
m
en
ta
ll
y
 r
et
ar
d
ed
, 
sp
as
ti
c 
d
ip
le
g
ia
) 
9
 
A
E
D
s 
d
u
ri
n
g
 1
st
 5
 y
ea
rs
 w
it
h
o
u
t 
ef
fe
ct
. 
A
ft
er
 7
 y
e
ar
s,
 
sp
o
ra
d
ic
 C
P
S
; 
4
 m
o
n
th
s 
la
te
r:
 e
p
il
ep
sy
 i
s 
re
g
u
la
te
d
 w
el
l,
 
al
th
o
u
g
h
 t
h
e 
sa
m
e 
3
 A
E
D
s 
ar
e 
u
se
d
 a
s 
in
 t
h
e 
1
st
 5
 y
ea
rs
. 
>
2
  
A
E
D
s 
n
o
 
ap
p
ar
en
t 
ef
fe
ct
. 
(2
 A
E
D
s 
at
 e
n
d
) 
7
  
T
C
, 
m
y
o
cl
o
n
ic
 &
 a
to
n
ic
 s
ei
zu
re
s,
 
S
P
S
, 
C
P
S
, 
S
E
, 
ab
se
n
ce
s 
(S
y
m
p
to
m
at
ic
 
g
en
er
al
iz
ed
 e
p
il
ep
sy
, 
p
ro
b
ab
ly
 R
et
t 
sy
n
d
ro
m
e)
 
7
 
3
 y
ea
rs
 o
f 
d
ai
ly
 s
ei
zu
re
s 
w
it
h
o
u
t 
ef
fe
ct
 A
E
D
, 
fo
ll
o
w
ed
 b
y
 3
 
y
ea
rs
 o
f 
sp
o
ra
d
ic
 C
P
S
. 
T
h
en
, 
1
 y
ea
r 
o
f 
d
ai
ly
 a
b
se
n
ce
s.
 A
ft
er
 
th
at
, 
sp
o
ra
d
ic
 a
b
se
n
ce
s 
&
 p
er
io
d
s 
w
it
h
 d
ai
ly
 s
ei
zu
re
s.
 F
ew
er
 
se
iz
u
re
s 
af
te
r 
in
cr
ea
se
 P
H
B
. 
 
>
5
  
A
E
D
s 
sl
ig
h
t 
ef
fe
ct
?
 (
1
 A
E
D
 
at
 e
n
d
) 
5
  
ab
se
n
ce
s,
 T
C
 (
Id
io
p
at
h
ic
 g
en
er
al
iz
ed
 
ep
il
ep
sy
) 
2
 
N
o
 e
ff
ec
t 
A
E
D
 o
n
 d
ai
ly
 a
b
se
n
ce
s.
 I
n
 5
th
 a
n
d
 6
th
 y
ea
r 
o
f 
fo
ll
o
w
-u
p
 s
p
o
ra
d
ic
 a
b
se
n
ce
s.
 I
n
cr
ea
se
 o
f 
ab
se
n
ce
s 
af
te
r 
w
it
h
d
ra
w
al
 o
f 
o
n
e 
o
f 
th
e 
A
E
D
s.
  
>
8
  
A
E
D
s 
sl
ig
h
t 
ef
fe
ct
?
 (
N
o
 
A
E
D
 a
t 
en
d
) 
9
  
C
P
S
, 
T
C
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
ar
g
in
in
o
-
su
cc
in
ic
 a
ci
d
u
ri
a)
 
7
 
In
tr
ac
ta
b
le
 f
o
r 
4
.5
 y
ea
rs
 d
es
p
it
e 
A
E
D
s.
 D
u
ri
n
g
 5
th
 y
ea
r 
o
f 
fo
ll
o
w
-u
p
 s
ta
rt
 O
C
B
Z
. 
A
ft
er
 5
 m
o
n
th
s:
 7
-m
o
n
th
 r
em
is
si
o
n
 
fo
ll
o
w
ed
 b
y
 2
 m
o
n
th
s 
o
f 
se
iz
u
re
s.
 A
d
d
-o
n
 L
T
G
 n
o
 e
ff
ec
t:
 
st
o
p
. 
T
h
en
 T
R
E
 u
si
n
g
 O
C
B
Z
. 
>
9
  
E
ff
ec
t 
o
f 
O
C
B
Z
?
 (
1
 A
E
D
 
at
 e
n
d
) 
1
0
  
S
P
S
, 
C
P
S
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
lo
w
-g
ra
d
e 
g
an
g
li
o
g
li
o
m
a)
 
5
 
In
tr
ac
ta
b
le
 f
o
r 
al
m
o
st
 5
 y
ea
rs
, 
fo
ll
o
w
ed
 b
y
 a
n
te
ri
o
r 
te
m
p
o
ra
l 
lo
b
ec
to
m
y
. 
T
R
E
 a
ft
er
 o
p
er
at
io
n
. 
>
9
  
A
E
D
s 
n
o
 e
ff
ec
t.
 
(N
o
 A
E
D
 a
t 
en
d
) 
1
5
c  
 
S
P
S
, 
C
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
m
es
ia
l 
te
m
p
o
ra
l 
g
li
o
si
s)
 
3
 
A
E
D
 f
o
ll
o
w
ed
 b
y
 6
-m
o
n
th
 r
em
is
si
o
n
: 
st
o
p
 A
E
D
 
(r
an
d
o
m
iz
ed
) 
fo
ll
o
w
ed
 b
y
 s
ei
zu
re
s:
 r
es
ta
rt
. 
In
cr
ea
si
n
g
 
am
o
u
n
t 
o
f 
se
iz
u
re
s:
  
in
tr
ac
ta
b
le
 (
ca
n
d
id
at
e 
su
rg
er
y
).
 A
d
d
-o
n
 
V
G
B
: 
af
te
r 
6
 m
o
n
th
s 
T
R
E
. 
>
1
0
  
E
ff
ec
t 
o
f 
V
G
B
. 
(1
 A
E
D
 a
t 
en
d
: 
fe
ar
 o
f 
se
iz
u
re
s)
 
2
  
ab
se
n
ce
s,
 T
C
 &
 a
ft
er
 o
n
e 
y
ea
r 
d
ai
ly
 
m
y
o
cl
o
n
ic
 j
er
k
s 
(C
ry
p
to
g
en
ic
 
g
en
er
al
iz
ed
 e
p
il
ep
sy
 w
it
h
 m
y
o
cl
o
n
ic
 
ab
se
n
ce
s)
 
6
 
D
u
ri
n
g
 t
h
e 
4
th
 a
n
d
 5
th
 y
ea
r 
o
f 
fo
ll
o
w
-u
p
 a
 g
ra
d
u
al
 r
ed
u
ct
io
n
 
o
f 
se
iz
u
re
 f
re
q
u
en
c
y
 f
o
ll
o
w
ed
 b
y
 T
R
E
 (
n
o
t 
ca
u
se
d
 b
y
 A
E
D
 
ch
an
g
es
).
 P
ro
b
ab
ly
 b
en
ig
n
 t
y
p
e 
o
f 
ep
il
ep
sy
. 
>
1
0
  
A
E
D
s 
n
o
 
ap
p
ar
en
t 
ef
fe
ct
. 
(N
o
 A
E
D
 a
t 
en
d
) 
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e 
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8
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S
u
b
je
ct
 
  
  
 S
ei
zu
re
 a
n
d
 e
p
il
ep
sy
 t
y
p
e 
  
  
  
  
  
 A
E
D
a  
C
o
u
rs
e 
o
f 
ep
il
ep
sy
 
T
R
E
 
E
ff
ec
t 
A
E
D
 
6
  
T
C
, 
m
y
o
cl
o
n
ic
 a
n
d
 a
to
n
ic
 s
ei
zu
re
s,
 
ab
se
n
ce
s 
(S
y
m
p
to
m
at
ic
 g
en
er
al
iz
ed
 
ep
il
ep
sy
, 
A
n
g
el
m
an
 s
y
n
d
ro
m
e)
 
8
 
N
o
 e
ff
ec
t 
o
f 
A
E
D
 f
o
r 
2
.5
 y
ea
rs
. 
A
ft
er
 a
d
d
it
io
n
 o
f 
E
S
M
: 
tw
o
 
m
o
n
th
s 
la
te
r 
T
R
E
. 
>
1
2
  
E
ff
ec
t 
o
f 
E
S
M
. 
(3
 A
E
D
s 
at
 e
n
d
) 
a :
  A
E
D
: 
an
ti
-e
p
il
ep
ti
c 
d
ru
g
s 
u
se
d
 d
u
ri
n
g
 t
h
e 
fi
rs
t 
fi
v
e 
y
ea
rs
 o
f 
fo
ll
o
w
-u
p
. 
b
: 
S
u
b
je
ct
 w
as
 p
ro
b
ab
ly
 i
n
tr
ac
ta
b
le
 i
n
 l
as
t 
y
ea
r 
o
f 
fo
ll
o
w
-u
p
 b
as
ed
 o
n
 s
ei
zu
re
 
p
at
te
rn
 b
u
t 
w
as
 n
o
t 
co
n
si
d
er
ed
 i
n
tr
ac
ta
b
le
 i
n
 f
in
al
 y
ea
r 
b
ec
au
se
 o
f 
in
ad
eq
u
at
e 
A
E
D
. 
c :
 S
u
b
je
ct
 t
ak
in
g
 p
ar
t 
o
f 
o
u
r 
ra
n
d
o
m
iz
ed
 p
ro
sp
ec
ti
v
e 
st
u
d
y
 o
f 
ea
rl
y
 
d
is
co
n
ti
n
u
at
io
n
 o
f 
A
E
D
s 
[3
9
].
 S
P
S
: 
si
m
p
le
 p
ar
ti
al
 s
ei
zu
re
s,
 C
P
S
: 
co
m
p
le
x
 p
ar
ti
al
 s
ei
zu
re
s,
 S
E
: 
st
at
u
s 
ep
il
ep
ti
cu
s,
 P
S
G
: 
p
ar
ti
al
 s
ei
zu
re
s 
w
it
h
 
g
en
er
al
iz
at
io
n
, 
T
C
: 
to
n
ic
 c
lo
n
ic
 s
ei
zu
re
s.
 T
R
E
: 
te
rm
in
al
 r
em
is
si
o
n
 a
t 
en
d
 o
f 
fo
ll
o
w
-u
p
 i
n
 y
ea
rs
. 
C
L
B
: 
cl
o
b
az
am
, 
C
B
Z
: 
ca
rb
am
az
ep
in
e,
 O
C
B
Z
: 
o
x
ca
rb
az
ep
in
e,
 E
S
M
: 
et
h
o
su
x
im
id
e,
 V
G
B
: 
v
ig
ab
at
ri
n
, 
V
P
A
: 
v
al
p
ro
ic
 a
ci
d
, 
P
H
B
: 
p
h
en
o
b
ar
b
it
o
n
e,
 L
T
G
: 
la
m
o
tr
ig
in
e.
 
  
 
 P
ag
e 
| 1
8
5
  
 
 
 
 
 P
ag
e 
| 1
8
6
  
 
 
S
u
p
p
le
m
en
ta
ry
 T
a
b
le
 S
2
. 
C
o
u
rs
e 
o
f 
1
6
 s
u
b
je
ct
s 
w
it
h
 l
at
e-
o
n
se
t 
in
tr
ac
ta
b
il
it
y
 
  S
u
b
je
ct
  
S
ei
zu
re
 a
n
d
 e
p
il
ep
sy
 t
y
p
e
 
A
E
D
 a
 
C
o
u
rs
e 
o
f 
ep
il
ep
sy
 
F
in
a
l 
y
ea
r 
fo
ll
o
w
-u
p
 
p
at
 1
  
S
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
cr
y
p
to
g
en
ic
 e
p
il
ep
sy
) 
3
 
A
E
D
 f
o
ll
o
w
ed
 b
y
 6
-m
o
n
th
 r
em
is
si
o
n
: 
st
o
p
 A
E
D
 
(r
an
d
o
m
iz
ed
)b
. 
A
ft
er
 3
.5
 y
ea
rs
: 
2
 P
S
G
: 
re
st
ar
t 
A
E
D
 
fo
ll
o
w
ed
 b
y
 S
P
S
 &
 T
C
 w
it
h
 i
n
cr
ea
si
n
g
 f
re
q
u
en
cy
: 
fa
il
u
re
 o
f 
A
E
D
. 
 
O
n
e 
se
iz
u
re
 /
 m
o
n
th
. 
U
n
k
n
o
w
n
 s
in
ce
 w
h
en
 d
ru
g
-
re
si
st
an
t 
(3
 A
E
D
s 
at
 e
n
d
).
  
p
at
 2
  
A
b
se
n
ce
s 
(I
d
io
p
at
h
ic
 j
u
v
en
il
e 
ab
se
n
ce
 e
p
il
ep
sy
 c
h
an
g
in
g
 t
o
 
lo
ca
li
za
ti
o
n
 r
el
at
ed
 c
ry
p
to
g
en
ic
 
ep
il
ep
sy
) 
3
 
A
b
se
n
ce
s:
 A
E
D
. 
O
n
e 
y
ea
r 
o
f 
sp
o
ra
d
ic
 a
b
se
n
ce
s,
 
fo
ll
o
w
ed
 b
y
 a
 1
.5
-y
ea
r 
re
m
is
si
o
n
. 
S
to
p
 A
E
D
: 
sp
o
ra
d
ic
 
ab
se
n
ce
s 
so
m
e 
o
f 
lo
n
g
 d
u
ra
ti
o
n
. 
S
ei
zu
re
s 
ch
an
g
in
g
 t
o
 
m
o
re
 c
o
m
p
le
x
 p
ar
ti
al
 t
y
p
e.
 R
es
ta
rt
 A
E
D
: 
se
v
er
al
 t
ri
al
s 
n
o
 e
ff
ec
t:
 f
a
il
u
re
 o
f 
A
E
D
. 
 
1
-2
 l
o
n
g
 l
as
ti
n
g
 a
b
se
n
ce
-l
ik
e 
an
d
 o
th
er
 s
ei
zu
re
s 
/ 
w
ee
k
. 
P
ro
b
ab
ly
 d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 
5
 y
ea
rs
 (
2
 A
E
D
s 
at
 e
n
d
) 
p
at
 3
  
C
P
S
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
cr
y
p
to
g
en
ic
 e
p
il
ep
sy
 w
it
h
 
tu
b
er
o
u
s 
sc
le
ro
si
s 
co
m
p
le
x
 
d
ia
g
n
o
se
d
 a
ft
er
 y
ea
rs
).
 T
u
rn
ed
 
o
u
t 
to
 b
e 
m
en
ta
ll
y
 r
et
ar
d
ed
 
d
u
ri
n
g
 f
o
ll
o
w
-u
p
. 
2
 
A
ft
er
 9
 C
P
S
 a
 1
-y
ea
r 
re
m
is
si
o
n
 f
o
ll
o
w
ed
 b
y
 2
 m
o
n
th
s 
o
f 
d
ai
ly
 C
P
S
: 
A
E
D
. 
A
ft
er
 3
 m
o
n
th
s 
p
ar
en
ts
 s
to
p
 A
E
D
. 
A
ft
er
 3
 m
o
n
th
s:
 1
.5
 m
o
n
th
s 
o
f 
d
ai
ly
 C
P
S
: 
re
st
ar
t 
A
E
D
 →
 
2
-y
ea
r 
re
m
is
si
o
n
. 
T
h
en
: 
2
 m
o
n
th
s 
o
f 
C
P
S
 f
o
ll
o
w
ed
 b
y
 1
-
y
ea
r 
re
m
is
si
o
n
 a
ft
er
 i
n
cr
ea
se
 o
f 
A
E
D
. 
T
h
is
 w
as
 r
ep
ea
te
d
 
se
v
er
al
 t
im
es
. 
M
R
I 
at
 a
g
e 
8
 y
ea
rs
: 
n
o
rm
al
. 
 
D
ai
ly
 c
lu
st
er
ed
 C
P
S
. 
P
ro
b
ab
ly
 d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 
5
 y
ea
rs
 (
3
 A
E
D
s 
at
 e
n
d
) 
p
at
 4
  
F
C
, 
T
C
, 
C
P
S
, 
ab
se
n
ce
s 
(A
t 
en
ro
ll
m
en
t 
la
b
el
ed
 a
s 
id
io
p
at
h
ic
, 
la
te
r 
sy
m
p
to
m
at
ic
 g
en
er
al
iz
ed
 
ep
il
ep
sy
, 
p
re
m
at
u
re
 b
ir
th
: 
tw
in
s)
 
4
 
~
1
4
 F
C
 i
n
 1
st
 y
ea
r 
o
f 
ag
e.
 A
t 
ag
e 
1
: 
cl
u
st
er
 o
f 
6
 T
C
. 
A
ft
er
 
in
ta
k
e 
2
 T
C
: 
A
E
D
. 
C
lu
st
er
s 
o
f 
1
-2
 T
C
 /
 m
o
n
th
, 
so
m
e 
w
it
h
 f
ev
er
, 
w
it
h
 r
em
is
si
o
n
s 
o
f 
3
-1
1
 m
o
n
th
s.
 T
C
 &
 
ab
se
n
ce
s 
in
 3
rd
 y
ea
r 
o
f 
fo
ll
o
w
-u
p
: 
N
ea
rl
y
 i
n
tr
a
ct
a
b
le
. 
In
 
5
th
 y
ea
r:
 r
em
is
si
o
n
, 
b
u
t 
C
P
S
 i
n
 l
as
t 
m
o
n
th
. 
 
L
ig
h
t 
re
ta
rd
at
io
n
, 
b
eh
av
io
ra
l 
p
ro
b
le
m
s,
 a
n
d
 a
u
ti
sm
. 
D
ai
ly
 
cl
u
st
er
ed
 s
ei
zu
re
s.
 P
ro
b
ab
ly
 
d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 3
 y
ea
rs
  
 
(2
 A
E
D
s 
at
 e
n
d
) 
p
at
 5
  
S
E
, 
C
P
S
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
cr
y
p
to
g
en
ic
 e
p
il
ep
si
es
) 
1
 
P
ar
ti
al
 S
E
, 
af
te
r 
4
 m
o
n
th
s 
1
 C
P
S
: 
st
ar
t 
A
E
D
. 
D
u
ri
n
g
 ~
2
 
y
ea
rs
 C
P
S
 e
v
er
y
 1
-2
 m
o
n
th
s,
 w
it
h
 2
 r
em
is
si
o
n
s 
o
f 
at
 
le
as
t 
3
 m
o
n
th
s.
 T
h
en
: 
1
 C
P
S
 /
 y
ea
r 
u
n
ti
l 
fi
v
e 
y
ea
rs
 o
f 
fo
ll
o
w
-u
p
. 
 
C
P
S
 e
v
er
y
 1
-2
 m
o
n
th
s.
 
M
u
lt
i-
fo
ca
l 
ep
il
ep
sy
. 
U
n
k
n
o
w
n
 s
in
ce
 w
h
en
 d
ru
g
-
re
si
st
an
t 
(3
 A
E
D
s 
at
 e
n
d
) 
p
at
 6
  
T
C
, 
C
P
S
, 
at
o
n
ic
/ 
as
ta
ti
c 
se
iz
u
re
s,
 
sl
ee
p
 a
tt
ac
k
s 
(S
y
m
p
to
m
at
ic
 
g
en
er
al
iz
ed
 e
p
il
ep
sy
 w
it
h
 
m
y
cl
o
n
ic
-a
st
at
ic
 s
ei
zu
re
s,
 
m
en
ta
ll
y
 r
et
ar
d
ed
) 
3
 
~
1
0
 s
ei
zu
re
s 
w
it
h
in
 2
 w
ee
k
s 
fo
ll
o
w
ed
 b
y
 1
-y
ea
r 
re
m
is
si
o
n
. 
T
C
 &
 C
P
S
: 
A
E
D
. 
A
ls
o
 a
to
n
ic
/a
st
at
ic
 s
ei
zu
re
s 
&
 s
le
ep
 a
tt
ac
k
s.
 A
ft
er
 1
0
 m
o
n
th
s 
a 
3
-y
ea
r 
re
m
is
si
o
n
: 
st
o
p
 A
E
D
. 
A
ft
er
 1
.5
 y
ea
rs
: 
8
 m
o
n
th
s 
o
f 
C
P
S
. 
S
u
cc
es
sf
u
l 
re
st
ar
t 
o
f 
A
E
D
. 
 
S
y
m
p
to
m
at
ic
 m
u
lt
i-
fo
ca
l 
ep
il
ep
sy
: 
1
-2
 T
C
 &
 o
th
er
 
se
iz
u
re
s 
d
ai
ly
. 
S
o
m
e 
m
a
y
 b
e 
re
la
te
d
 t
o
 b
eh
av
io
r.
 P
ro
b
ab
ly
 
d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 5
 y
ea
rs
. 
(2
 A
E
D
s 
at
 e
n
d
) 
 P
ag
e 
| 1
8
7
  
 
 
 S
u
b
je
ct
  
S
ei
zu
re
 a
n
d
 e
p
il
ep
sy
 t
y
p
e
 
A
E
D
 a
 
C
o
u
rs
e 
o
f 
ep
il
ep
sy
 
F
in
a
l 
y
ea
r 
fo
ll
o
w
-u
p
 
p
at
 7
  
C
P
S
, 
T
C
, 
ab
se
n
ce
s 
(L
en
n
o
x
 
G
as
ta
u
t 
sy
n
d
ro
m
e,
 m
en
ta
ll
y
 
re
ta
rd
ed
) 
2
 
D
u
ri
n
g
 2
.5
 m
o
n
th
s 
C
P
S
 b
ef
o
re
 i
n
ta
k
e:
 A
E
D
. 
A
ft
er
 4
.5
 
m
o
n
th
s 
o
f 
se
iz
u
re
s,
 r
em
is
si
o
n
 u
n
ti
l 
5
 y
ea
rs
 o
f 
fo
ll
o
w
-u
p
. 
U
se
d
 A
E
D
 f
o
r 
2
.5
 y
ea
rs
. 
R
ec
u
rr
en
ce
s 
8
 y
ea
rs
 a
ft
er
 s
to
p
 
A
E
D
: 
re
st
ar
t 
A
E
D
 n
o
 e
ff
ec
t,
 h
o
w
ev
er
 E
E
G
 d
if
fe
re
d
 f
ro
m
 
ea
rl
ie
r 
E
E
G
s 
as
 w
el
l 
as
 t
h
e 
se
iz
u
re
s.
 F
a
il
u
re
 o
f 
A
E
D
s?
?
 
~
 2
 T
C
 /
 m
o
n
th
 &
 a
b
se
n
ce
s.
 
P
ro
b
ab
ly
 d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 
5
 y
ea
rs
 (
4
 A
E
D
s 
at
 e
n
d
) 
p
at
 8
  
in
fa
n
ti
le
 s
p
as
m
s,
 P
S
G
, 
S
P
S
 &
 
C
P
S
 (
W
es
t 
sy
n
d
ro
m
e,
  
m
en
ta
ll
y
 
re
ta
rd
ed
) 
4
 
D
u
ri
n
g
 1
.5
 m
o
n
th
s 
in
fa
n
ti
le
 s
p
as
m
s 
&
 P
S
G
: 
A
E
D
. 
R
em
is
si
o
n
 o
f 
1
 y
ea
r:
 s
to
p
 A
E
D
. 
A
ft
er
 6
 m
o
n
th
s:
 2
-
m
o
n
th
 p
er
io
d
 o
f 
P
S
G
, 
S
P
S
 &
 C
P
S
: 
re
st
ar
t 
A
E
D
. 
A
ft
er
 7
 
m
o
n
th
s 
o
f 
se
iz
u
re
s:
 2
-y
ea
r 
re
m
is
si
o
n
 f
o
ll
o
w
ed
 b
y
 2
 P
S
G
. 
F
re
q
u
en
t 
ab
se
n
ce
s 
&
 a
to
n
ic
 
se
iz
u
re
s.
 U
n
k
n
o
w
n
 s
in
ce
 
w
h
en
 d
ru
g
-r
es
is
ta
n
t 
(1
 A
E
D
 
at
 e
n
d
) 
p
at
 9
  
S
P
S
, 
C
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 
re
la
te
d
 c
ry
p
to
g
en
ic
 e
p
il
ep
sy
, 
m
u
lt
if
o
ca
l)
. 
T
u
rn
ed
 o
u
t 
to
 b
e 
m
en
ta
ll
y
 r
et
ar
d
ed
 d
u
ri
n
g
 f
o
ll
o
w
-
u
p
. 
3
 
2
 P
S
G
 w
it
h
in
 3
 w
ee
k
s:
 A
E
D
. 
W
it
h
in
 2
 m
o
n
th
s 
2
 C
P
S
. 
A
 
9
-m
o
n
th
 r
em
is
si
o
n
. 
P
S
G
 a
n
d
 a
ft
er
 1
 m
o
n
th
 S
P
S
. 
T
h
en
 9
-
m
o
n
th
 r
em
is
si
o
n
: 
2
 u
n
cl
ea
r 
ev
en
ts
 w
it
h
in
 1
 m
o
n
th
. 
T
h
en
 
8
-m
o
n
th
 r
em
is
si
o
n
: 
in
 n
ex
t 
8
 m
o
n
th
s 
1
1
 S
P
S
, 
C
P
S
, 
an
d
 
P
S
G
. 
E
x
tr
a 
A
E
D
: 
1
 s
ei
zu
re
 /
 y
ea
r.
  
D
es
p
it
e 
se
v
er
al
 t
ri
al
s 
o
f 
A
E
D
s 
1
 s
ei
zu
re
 /
 w
ee
k
. 
U
n
k
n
o
w
n
 s
in
ce
 w
h
en
 d
ru
g
-
re
si
st
an
t.
 (
2
 A
E
D
s 
at
 e
n
d
) 
p
at
 1
0
  
A
ty
p
ic
al
 a
b
se
n
ce
s,
 T
C
 
(S
y
m
p
to
m
at
ic
 g
en
er
al
iz
ed
 
ep
il
ep
sy
, 
 m
il
d
 p
h
y
si
ca
l 
h
an
d
ic
ap
, 
 m
en
ta
ll
y
 r
et
ar
d
ed
) 
2
 
3
 y
ea
rs
 o
f 
ab
se
n
ce
s:
 A
E
D
. 
A
ft
er
 6
 m
o
n
th
s:
 1
-y
ea
r 
re
m
is
si
o
n
. 
D
u
ri
n
g
 1
 m
o
n
th
: 
d
ai
ly
 s
ta
ri
n
g
. 
A
ft
er
 4
 
m
o
n
th
s:
 T
C
 w
it
h
 f
ev
er
. 
T
h
en
 2
.5
-y
ea
r 
re
m
is
si
o
n
 
fo
ll
o
w
ed
 b
y
 a
b
se
n
ce
s 
d
u
ri
n
g
 3
 m
o
n
th
s.
  
D
ai
ly
 s
ei
zu
re
s.
 U
n
k
n
o
w
n
 
si
n
ce
 w
h
en
 d
ru
g
-r
es
is
ta
n
t 
(1
 
A
E
D
 a
t 
en
d
) 
p
at
 1
1
  
C
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
m
ic
ro
ce
p
h
al
y
, 
m
en
ta
ll
y
 r
et
ar
d
ed
) 
3
 
1
 m
o
n
th
 o
f 
w
ee
k
ly
 C
P
S
: 
A
E
D
. 
D
u
ri
n
g
 8
 m
o
n
th
s 
C
P
S
 i
n
 
re
d
u
ci
n
g
 n
u
m
b
er
s.
 A
 7
-m
o
n
th
 r
em
is
si
o
n
. 
T
h
en
 3
 C
P
S
 
w
it
h
in
 6
 w
ee
k
s 
fo
ll
o
w
ed
 b
y
 1
-y
ea
r 
re
m
is
si
o
n
. 
1
 u
n
cl
ea
r 
ev
en
t 
an
d
 a
 2
n
d
 a
ft
er
 2
 m
o
n
th
. 
A
ft
er
 1
.5
-y
ea
r 
re
m
is
si
o
n
: 
P
S
G
. 
 
O
n
e 
se
iz
u
re
 /
 m
o
n
th
. 
F
o
u
r 
y
ea
rs
 b
ef
o
re
: 
sp
o
ra
d
ic
 
se
iz
u
re
s.
 U
n
k
n
o
w
n
 s
in
ce
 
w
h
en
 d
ru
g
-r
es
is
ta
n
t 
(1
 A
E
D
 
at
 e
n
d
) 
p
at
 1
2
  
S
E
 w
it
h
 f
ev
er
, 
m
y
o
cl
o
n
ic
 j
er
k
s,
 
C
P
S
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
m
u
lt
if
o
ca
l,
 s
ev
er
e 
en
ce
p
h
al
o
p
at
h
y
 a
ft
er
 S
E
, 
m
en
ta
ll
y
 r
et
ar
d
ed
) 
2
 
S
E
. 
A
ft
er
 8
 y
ea
rs
: 
1
0
 m
o
n
th
s 
o
f 
d
ai
ly
 m
y
o
cl
o
n
ic
 j
er
k
s 
&
 
C
P
S
: 
A
E
D
→
1
-y
ea
r 
re
m
is
si
o
n
: 
st
o
p
 A
E
D
 (
ra
n
d
o
m
iz
ed
)b
. 
A
 3
-m
o
n
th
 r
em
is
si
o
n
 f
o
ll
o
w
ed
 b
y
 3
 m
o
n
th
s 
o
f 
m
y
o
cl
o
n
ic
 j
er
k
s.
 A
ft
er
 2
-y
ea
r 
re
m
is
si
o
n
: 
6
 m
o
n
th
s 
o
f 
m
y
o
cl
o
n
ic
 j
er
k
s:
 n
o
t 
re
g
ar
d
ed
 a
s 
ep
il
ep
sy
: 
n
o
rm
al
 E
E
G
. 
R
es
ta
rt
 A
E
D
 a
ft
er
 i
n
cr
ea
se
 o
f 
se
iz
u
re
s 
9
 y
ea
rs
 a
ft
er
 
in
ta
k
e 
(n
o
 i
n
fo
 o
f 
ef
fe
ct
).
 A
ft
er
 3
 y
ea
rs
 a
b
n
o
rm
al
 E
E
G
: 
ad
d
-o
n
 L
T
G
 (
n
o
 i
n
fo
 o
f 
ef
fe
ct
).
 
M
o
n
th
ly
 m
y
o
cl
o
n
ic
 j
er
k
s.
 
P
ro
b
ab
ly
 d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 
8
 y
ea
rs
 (
2
 A
E
D
s 
at
 e
n
d
) 
 P
ag
e 
| 1
8
8
  
 
 
  S
u
b
je
ct
  
S
ei
zu
re
 a
n
d
 e
p
il
ep
sy
 t
y
p
e
 
A
E
D
 a
 
C
o
u
rs
e 
o
f 
ep
il
ep
sy
 
F
in
a
l 
y
ea
r 
fo
ll
o
w
-u
p
 
1
3
 
F
C
, 
S
E
, 
C
P
S
, 
P
S
G
 (
L
o
ca
li
za
ti
o
n
 
re
la
te
d
 s
y
m
p
to
m
at
ic
 e
p
il
ep
sy
, 
sp
as
ti
c 
te
tr
ap
ar
es
is
).
 T
u
rn
ed
 o
u
t 
to
 b
e 
m
en
ta
ll
y
 r
et
ar
d
ed
 d
u
ri
n
g
 
fo
ll
o
w
-u
p
. 
2
 
F
C
 a
t 
ag
e 
fi
v
e.
 A
ft
er
 4
 m
o
n
th
s 
S
E
: 
A
E
D
. 
A
ft
er
 6
-m
o
n
th
 
re
m
is
si
o
n
: 
6
 m
o
n
th
s 
o
f 
sp
o
ra
d
ic
 C
P
S
 &
 P
S
G
. 
A
E
D
 
ch
an
g
e:
 C
P
S
 a
ft
er
 3
 m
o
n
th
s,
 C
P
S
 a
ft
er
 1
 m
o
n
th
. 
A
ft
er
 a
 
1
-y
ea
r 
re
m
is
si
o
n
: 
C
P
S
. 
A
 2
-y
ea
r 
re
m
is
si
o
n
 u
n
ti
l 
5
 y
ea
rs
 
af
te
r 
in
ta
k
e.
  
A
ft
er
 a
t 
le
as
t 
7
 y
ea
rs
 o
f 
re
m
is
si
o
n
 r
el
ap
se
. 
A
t 
en
d
 
m
o
n
th
ly
 i
n
cr
ea
se
 o
f 
C
P
S
 a
n
d
 
sp
o
ra
d
ic
 P
S
G
. 
P
ro
b
ab
ly
 
d
ru
g
-r
es
is
ta
n
t 
si
n
ce
 4
 y
ea
rs
 
(2
 A
E
D
s 
at
 e
n
d
) 
1
4
c  
A
ty
p
ic
al
 a
b
se
n
ce
s 
(G
en
er
al
iz
ed
 
id
io
p
at
h
ic
 e
p
il
ep
sy
 c
h
an
g
in
g
 t
o
 
sy
m
p
to
m
at
ic
 g
en
er
al
iz
ed
 
ep
il
ep
sy
).
 T
u
rn
ed
 o
u
t 
to
 b
e 
m
en
ta
ll
y
 r
et
ar
d
ed
 d
u
ri
n
g
 f
o
ll
o
w
-
u
p
. 
2
 
~
3
 m
o
n
th
s 
o
f 
ab
se
n
ce
s:
 A
E
D
. 
A
ft
er
 5
 m
o
n
th
s 
o
f 
sp
o
ra
d
ic
 
ab
se
n
ce
s 
1
-y
ea
r 
re
m
is
si
o
n
: 
st
o
p
 A
E
D
. 
A
ft
er
 5
 m
o
n
th
s:
 
ab
se
n
ce
s 
d
u
ri
n
g
 3
 m
o
n
th
s.
 R
es
ta
rt
 o
f 
A
E
D
: 
1
9
 m
o
n
th
s 
o
f 
re
m
is
si
o
n
 f
o
ll
o
w
ed
 b
y
 d
ai
ly
 a
b
se
n
ce
s 
u
n
ti
l 
en
d
 o
f 
5
-y
ea
r 
fo
ll
o
w
-u
p
: 
2
n
d
 A
E
D
 n
o
 e
ff
ec
t.
  
2
0
 a
b
se
n
ce
s/
d
a
y
. 
S
o
m
et
im
es
 
fa
ll
s 
d
o
w
n
 o
r 
is
 
p
h
o
to
se
n
si
ti
v
e.
 D
ru
g
-
re
si
st
an
t 
si
n
ce
 ~
8
 y
ea
rs
 (
2
 
A
E
D
s 
at
 e
n
d
) 
1
5
c  
C
P
S
, 
P
S
G
, 
S
E
 (
L
o
ca
li
za
ti
o
n
 
re
la
te
d
 c
ry
p
to
g
en
ic
 e
p
il
ep
sy
) 
1
 
3
 P
G
S
 &
 1
 S
E
 w
it
h
in
 3
.5
 m
o
n
th
s:
 A
E
D
. 
D
u
ri
n
g
 p
er
io
d
 
o
f 
3
 y
ea
rs
: 
3
-6
 s
ei
zu
re
s/
y
ea
r.
 N
ex
t:
 2
 y
ea
rs
 w
it
h
 n
o
 
re
m
is
si
o
n
s 
o
f 
m
o
re
 t
h
an
 3
 m
o
n
th
s.
 D
u
ri
n
g
 f
u
rt
h
er
 
fo
ll
o
w
-u
p
 s
p
o
ra
d
ic
 p
er
io
d
s 
o
f 
re
m
is
si
o
n
 (
≤
 1
 y
ea
r,
 
so
m
et
im
es
 w
it
h
o
u
t 
A
E
D
).
  
2
-3
 s
ei
zu
re
s/
m
o
n
th
. 
U
n
k
n
o
w
n
 s
in
ce
 w
h
en
 d
ru
g
-
re
si
st
an
t 
(2
 A
E
D
s 
at
 e
n
d
) 
1
6
c  
C
P
S
 (
L
o
ca
li
za
ti
o
n
 r
el
at
ed
 
sy
m
p
to
m
at
ic
 e
p
il
ep
sy
) 
T
u
b
er
o
u
s 
sc
le
ro
si
s 
w
it
h
 n
o
rm
al
 
in
te
ll
ig
en
ce
 
1
 
D
u
ri
n
g
 5
 w
ee
k
s 
1
 C
P
S
/d
ay
: 
A
E
D
→
6
-m
o
n
th
 r
em
is
si
o
n
: 
st
o
p
 A
E
D
 (
ra
n
d
o
m
iz
ed
)b
. 
A
ft
er
 4
 m
o
n
th
s 
C
P
S
: 
re
st
ar
t 
A
E
D
 w
it
h
o
u
t 
ef
fe
ct
: 
fa
il
u
re
 o
f 
A
E
D
. 
D
u
ri
n
g
 4
 y
e
ar
s 
o
n
ly
 2
 r
em
is
si
o
n
 p
er
io
d
s 
o
f 
3
 m
o
n
th
s.
 
1
-2
 C
P
S
 /
m
o
n
th
 U
n
k
n
o
w
n
 
si
n
ce
 w
h
en
 d
ru
g
-r
es
is
ta
n
t 
(1
 
A
E
D
 a
t 
en
d
) 
a :
 a
n
ti
-e
p
il
ep
ti
c 
d
ru
g
s 
u
se
d
 d
u
ri
n
g
 t
h
e 
fi
rs
t 
fi
v
e 
y
ea
rs
 o
f 
fo
ll
o
w
-u
p
. 
b
: 
su
b
je
ct
s 
ta
k
in
g
 p
ar
t 
o
f 
o
u
r 
ra
n
d
o
m
iz
ed
 p
ro
sp
ec
ti
v
e 
st
u
d
y
 o
f 
ea
rl
y
 d
is
co
n
ti
n
u
at
io
n
 
o
f 
A
E
D
s 
[3
9
].
 c
: 
in
tr
ac
ta
b
le
 s
ei
zu
re
 p
at
te
rn
 d
u
ri
n
g
 f
ir
st
 f
iv
e 
y
ea
rs
 o
f 
fo
ll
o
w
-u
p
, 
b
u
t 
h
ad
 n
o
t 
en
o
u
g
h
 A
E
D
s 
o
r 
to
o
 s
h
o
rt
ly
 t
o
 b
e 
co
n
si
d
er
ed
 i
n
tr
ac
ta
b
le
 i
n
 
th
es
e 
y
ea
rs
. 
S
P
S
: 
si
m
p
le
 p
ar
ti
al
 s
ei
zu
re
s,
 C
P
S
: 
co
m
p
le
x
 p
ar
ti
al
 s
ei
zu
re
s,
 T
C
: 
to
n
ic
 c
lo
n
ic
 s
ei
zu
re
, 
P
S
G
: 
p
ar
ti
al
 s
ei
z
u
re
 w
it
h
 g
en
er
al
iz
at
io
n
, 
S
E
: 
st
at
u
s 
ep
il
ep
ti
cu
s,
 F
C
: 
fe
b
ri
le
 c
o
n
v
u
ls
io
n
. 
L
T
G
: 
la
m
o
tr
ig
in
e.
 
 
